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INTRODUCTION
People with epilepsy usually appear to be physically well but they often suffer 
social and psychological handicaps impairing their quality of life (QOL). Living 
with epilepsy necessitates paying attention to more than seizures and the 
antiepileptic drug (AED) treatment. It is now widely acknowledged that people 
with epilepsy are as likely to be distressed by social and cultural problems as 
they are by continuing seizures and also that epilepsy has profound physical, 
psychological, and social consequences (Scambler and Hopkins, 1980). 
Although current seizure frequency is one of the most important predictors 
showing the efficacy of treatment, it is not the only measure, especially from the 
patient’s viewpoint, commonly used in clinical studies of new AEDs (Smith et 
al., 1993). The effect of any disease is determined by several factors, including 
underlying biology, as well as host factors and available medical interventions, 
but also the attitudes and reactions of the surrounding society (Eisenberg, 1997). 
Assessment of health-related quality of life (HRQOL) is a relatively new 
concept within the epilepsy area that meshes traditional medical care with 
psychosocial concerns. Several studies have used HRQOL in epilepsy as an 
outcome measure and have also used it to give a broader measure of the burden 
of the disease (Nortvedt et al., 2000). The purposes of addressing the QOL 
include the improvement of the quality of patient care, differentiating among 
treatment options, and evaluating the allocation of health care resources. 
Because of the emphasis on the phenomenological experience of the individual, 
it is necessary that QOL be determined from the patients’ subjective viewpoint, 
the physicians’ viewpoint being deliberately excluded, as the individual 
patient’s perspective has become an integral aspect of health care assessment 
(Cramer, 1994).
In recent years there have been a number of initiatives to develop QOL 
outcome measures for epilepsy. Although proven useful in their country of 
origin, standard scales are not directly applicable across nations due to cultural 
diversity. In order to use such instruments in a new national context, a thorough 
translation and testing phase, preceding the inclusion of an instrument in a 
study, is necessary. Measures also need to be psychometrically tested in a 
specific cultural context to assure their psychometric soundness (Bullinger, 
1995; Mathias et al., 1994; Hunt, 1993). It is generally agreed from the work on 
QOL to date that the best approach is to use a standard generic instrument with 
disease-specific additions and much of the work in QOL of adults having 
epilepsy has followed this approach (Baker, 2001; Chadwick, 1996).
There is a growing awareness of the psychosocial implication of epilepsy. 
People with epilepsy face social disadvantages not shared by those suffering 
from other chronic diseases. Psychiatric problems, particularly anxiety, dep­
ression, and loss of self-esteem are common among people with epilepsy (Col-
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lings, 1994; Baker et al., 1996; Collings, 1990b; Trostle et al., 1989; Dodrill et 
al., 1984a; Britten et al., 1986). Most patients feel that a prospective employer’s 
knowledge of a diagnosis of epilepsy will make it more difficult for them to get 
a job (Chaplin et a l 1992). A number of studies have addressed the stigmati­
sing nature of epilepsy and its associated psychological distress (Baker et al., 
1997a; Baker et al., 1996; Jacoby, 1994; Baker et al., 1997b; Austin, 1996; 
Levin et al., 1988). Information on these issues has come mainly from deve­
loped countries (Baker et al., 1997a; Jacoby et al., 1996; Levin et al., 1988; 
Boshes and Kienast, 1970; Bagley, 1972; Rodin, 1972; Zielinski, 1972; Ryan et 
al., 1980b). Very few studies originate from developing countries (Placencia et 
al., 1995; Danesi, 1984; Virmani et al., 1977; Aziz et al., 1997) and there is 
clearly a lack of documented evidence regarding the impact of epilepsy in 
Eastern Europe (Mimics et al., 1998; Bielen et al., 2000; Lam et al., 2001).
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REVIEW OF THE LITERATURE
1. The problem of epilepsy
Epilepsy is an example of a medical diagnosis that is retained even when signs 
and symptoms (i.e., seizures) are well controlled and all laboratory tests are 
normal (Cramer et al., 1996). Jacoby (1992) has described epilepsy as both a 
medical diagnosis and a social label, which means that there are several psycho­
social problems accompanying the disease, therefore, its impact on a person’s 
everyday-life can be significant.
Throughout history, myths and mystery have surrounded epilepsy and 
people suffering from this disease have been seen as possessing “an undesired 
differentness” (Goffman, 1963). Though known as “the sacred disease” to the 
ancient Greeks (Temkin, 1971), epilepsy has more often been associated with 
negative and pejorative imagery. Across time and different cultures, it has been 
variously viewed as the outcome of sin, as the product of demonic possession or 
a form of madness and consequently, as a condition to be feared and rejected 
(Jacoby and Baker, 2000). When in some societies the seizures are still viewed 
as contagious or demonic (Rwiza et al., 1993) in western culture the traces of 
such beliefs are mirrored in reactions of fear toward persons with epilepsy, as 
well as in discrimination by employers (Krauss et al., 2000). Scambler (1988) 
hypothesises three dimensions regarding this ambiguity relating to the unpredic­
tability of epilepsy, the dramatic nature of the attacks, and the fear on the part of 
others of having to cope with a person’s seizures.
The possibility of recurrent seizures is a silent but ever-present component of 
daily life for most patients who carry the diagnosis of epilepsy, creating uncer­
tainty regarding diagnosis, occurrence of seizures, nature of seizures and 
effectiveness of medication and over the remittance of seizures another defining 
quality of the disease (Jacoby and Baker, 2000). Thus, epilepsy has sometimes 
been termed a “silent disability” because for many individuals the QOL limi­
tations, caused by the unpredictable occurrence of seizures with altered 
awareness or altered sensation and by the side-effects of antiepileptic medica­
tions, are underestimated by society (Vickrey, 1995).
At the same time, epilepsy is one of the most common neurological condi­
tions, with an age-adjusted incidence of between 20 and 70 per 100,000 and an 
estimated prevalence of 0.4 to 1% (Jacoby and Baker, 2000; Bharucha and 
Shorvon, 1997; Forsgren, 1992; Joensen, 1986; Keränen et al., 1989). World 
wide, there are around 50 million people with epilepsy (Bharucha and Shorvon, 
1997). According to the present available data, originating from Tartu, the 
estimated prevalence ratio of active epilepsy is 5.3 per 1,000. This means, in 
Estonia, with a population of approximately 1.4 million people, epilepsy
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roughly affects 7950 adults with approximately 530 new cases yearly (Õun 
et al., accepted for publication-a; Õun et al., accepted for publication-b).
Epidemiological studies have shown that seizures in 70-80% of people deve­
loping epilepsy will be well controlled by AED treatment (Sander, 1993) and 
the disease should not profoundly diminish the quality of everyday life in this 
group (Jacoby, 1992; Baker e ta i,  1997a).
Epilepsy is not a single disorder, but a group of disorders in which seizures 
recur. According to the classification of epileptic syndromes by the Commission 
of the International League against Epilepsy (ILAE) (1989), there must be taken 
into account a range of factors including seizure type, neurological history, 
family history, age of seizure onset and aetiology. The most important subdi­
vision of the epileptic syndromes is between those with a recognisable cause, 
the “symptomatic” epilepsies and those without, the so-called cryptogenic and 
idiopathic epilepsies. Also, there are many different types of epileptic seizure. 
In everyday use, however, clinicians still use one of the simplest solutions. This 
is the classification by the ILAE Commission (1981) (ILAE, 1981), which divi­
des seizures into those originating from a localised abnormality in the cortex 
(partial or localisation-related seizures), and those arising from some innate 
abnormality in the neuronal function (primary or idiopathic generalised sei­
zures) (Leach et al., 2000). Seizures can also be differentiated according to 
whether or not they involve any alteration or impairment of consciousness. 
Because different seizures manifest themselves differently, they also vary in the 
degree to which they present a risk to physical safety, their predictability, 
response to treatment and the potential to interfere in the everyday-life of the 
individual (Jacoby and Baker, 2000).
Epilepsy remains a “stigmatising disease”. The social stigma is apparent 
when people speak openly about having cancer, but do not about having 
epilepsy, even when the seizures are well-controlled (Cramer, 1993). At the 
same time, an epileptic seizure, unlike hypertension, diabetes, and most forms 
of heart disease, usually cannot be hidden (Morrell and Pedley, 2000).
Epilepsy is an episodic disorder rather than a condition. The disabling effects 
of seizures are short-lived, and for much of the time a person’s ability to 
function physically is unimpaired. Regardless of that, it has been found that 
people with epilepsy are more dysfunctional compared to those in the general 
population and also even to ones who suffer from some other long-standing 
illness (Baker et al., 1997a). Adolescents with epilepsy have a higher frequency 
of behavioural problems than do healthy or chronically ill control groups (Aus­
tin et al., 1996; Wirrell et al., 1997; Clement and Wallace, 1990). They also 
express more worries: adolescents with epilepsy are less interested in 
competitive sports; others are concerned that epilepsy will prevent them from 
becoming parents or successfully employed (Rossi et al., 1997). Epilepsy 
appears to globally affect emotional status (Collings, 1990c; Collings, 1994; 
Baker et al., 1996). When a group of people with epilepsy was compared to a 
group of people with diabetes, a chronic but non-neurological disease, and a
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group of people with multiple sclerosis that may have an early impact on 
mobility with some patients becoming wheel chair bound as the disease prog­
resses, the epilepsy and multiple sclerosis groups scored significantly worse 
than the diabetes group on the criteria describing well-being and emotional 
status. Despite this the epilepsy group reported better health perceptions 
compared to the other two groupings (Hermann et al., 1996). When comparing 
QOL among young people, with inactive or active epilepsy, with that of a 
similar sample of youths with asthma, which is also an episodic condition that 
requires daily medication during active treatment, the evaluation showed that 
the epilepsy group had more problems in the psychological and social domain 
and, in addition, the youths with epilepsy had more problems at school (Austin 
et al., 1996).
In addition to the physical impact of seizures and their medication, people 
have to cop>e with the limitations imposed by statute, which embrace impli­
cations for social functioning, the prejudice, fear and lack of understanding by 
other people and with impact on the psyche due to these factors. People with 
epilepsy find themselves in a condition to which they must somehow adapt and 
adjust (Jacoby and Baker, 2000).
2. The concept and purposes for research into 
health-related quality of life
Assessment of HRQOL is a relatively new concept within the epilepsy area that 
meshes traditional medical care with psychosocial concerns. The modem 
concept of QOL arose in England during the Industrial Revolution in the 19th 
century. This sociologic concept has been applied to the medical field and 
called HRQOL, which reflects the degree of satisfaction of patients as the end 
users of medicine. The therapeutic outcome needs to be judged from two 
aspects (i.e., QOL and quantity of life). QOL must be determined from the 
patients’ subjective viewpoint with the physicians’ objective viewpoint being 
deliberately excluded (Kugoh, 1996).
The concept of QOL has not yet been defined in a uniform way. It is a multi­
dimensional term describing a field of interest rather than a single variable 
(Hunt, 1997). The concept of QOL may be defined as “a complex amalgam of 
satisfactory functioning in terms of physical, social, psychological and voca­
tional well-being” (Scambler, 1993). Devinsky and Cramer (1993) stated that 
the essence of QOL is the balance between patients’ perceived and desired sta­
tus. It is also defined by how well one is able to function and how he/she feels 
about daily life (Cramer, 1994), on the assumption that aspects of functional 
health status have an impact on QOL. It is a uniquely personal perception 
comprising health status and/or non-medical aspects of life that can be
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measured by determining opinions of subjects (patients) and by using an 
“expert” instrument (Gill and Feinstein, 1994). Caiman (1984) discussed the 
concept of QOL as the difference between a person’s expectations and actual 
experience. The definition is known as Caiman’s Gap. When the gap between 
actual achievements and desired status is wide, the dissonance can lead to a 
conceived low QOL. When the gap is small, QOL often is perceived as high. 
Schipper et al. (1990) have described it as the functional effect of an illness and 
consequent therapy on a patient as perceived by the patient. The concept is 
broader than the sum of individual components because it represents a synergy 
among multiple domains and differs from status or the patient’s outcome 
(Spilker, 1990). Another definition of HRQOL is the degree of subjective well­
being, attributable to or associated with lack of symptoms, psychological state 
and activities pursued (Bulpitt, 1997). Compared to the World Health 
Organization’s definition of 1948 (WHO, 1948), which stated that “Health is a 
state of complete physical, mental, and social well-being and not merely the 
absence of disease or infirmity”, the concept of QOL covers a much larger field 
of human necessities, although a clear definition is still missing (Zeitlhofer 
et al., 2000).
The main components that determine QOL are subjective well-being and 
satisfaction with different aspects of life, objective functioning in social roles 
and environmental living conditions. With the increase of wealth, indicators of 
QOL have expanded from the material terms of income or possessions to 
include also more spiritual rewards such as satisfaction, personal development, 
and participation within the community (McDowell and Newell, 1996). 
Although there are certain basic facts, which obviously influence life quality 
such as age, health, social status, etc., the final assessment of QOL has to be 
made by the individual through his own estimation. Notwithstanding the risk of 
arbitrary self-misinterpretation, the QOL concept emphasises the value of self- 
determination, placing the personal dimension of man in the foreground 
(Zeitlhofer et al., 2000).
QOL issues are most relevant to disorders that are chronic and associated 
with problems beyond the experience of the obvious disease symptoms. 
Epilepsy is the paradigm of such a disorder. Seizures are usually infrequent, and 
AED therapy, side effects, and attendant psychosocial problems are usually 
chronic (Devinsky, 1993). In the field of epilepsy, the formal assessment of 
QOL is a relatively recent science. The QOL studies in epilepsy focus on 
dimensions that are specific or very closely connected to health and medical 
care, for which reason we should talk about HRQOL (Patrick and Erickson, 
1993), the reason being that it is often impossible to separate out health-related 
and non-health-related aspects of QOL (Hunt, 1997).
Use of the term “quality of life in epilepsy” was first documented in the title 
of the proceedings of a UK Royal Society of Medicine Round Table in 1990 
(Chadwick, 1990). QOL became a main conference topic for the first time in 
1991 and results of the first randomised trial of epilepsy treatment to incorpo­
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rate a comprehensive and systematic QOL assessment were published in 1992 
(Jacoby, 2000). Several studies have used HRQOL in epilepsy as an outcome 
measure and these give a broader measure of the burden of the disease 
(Nortvedt et al., 2000). In the 1990’s, there has been a significant number of 
publications of QOL assessment tools for epilepsy, including the Epilepsy Sur­
gery Inventory (ESI-55) (Vickrey et al., 1992), the Liverpool QOL Battery 
(Baker et al., 1993; Baker et al., 1994a), and the QOLIE scales (Devinsky et al.,
1995) and their application in a range of descriptive studies and clinical trials of 
treatment for epilepsy.
Advances in the assessment of HRQOL in epilepsy are needed for clinical 
effectiveness research and for quality of care research in epilepsy. Monitoring 
HRQOL in epilepsy enables patients to express their concerns about a variety of 
issues affected by the diagnosis that often are not brought to the attention of the 
physician. There are growing numbers of pharmacological treatment options for 
epilepsy, with new antiepileptic medications recently released in the USA and 
Europe, and more under evaluation (Wieser, 1994). Comparison of the effects 
of different antiepileptic medications on HRQOL is desirable to enable infor­
med clinical decision-making about the optimal medical management in epi­
lepsy (Testa and Nackley, 1994). There is also a need to include assessment of 
HRQOL outcomes in studies of treatment discontinuation for epilepsy (Jacoby 
et al., 1992).
In addition to medical management, the impact of surgical treatment of 
epilepsy on HRQOL is not well established (Vickrey, 1995). It has been sugges­
ted that the HRQOL may actually decrease over time among epilepsy surgery 
patients who have less than a 90% reduction in seizure frequency post-opera- 
tively (McLachlan et al., 1997), although a 50% reduction in seizures has 
become a traditional endpoint for add-on AED therapy (Perucca, 1997). The 
National Institute of Health (NIH) consensus conference on surgery for epilepsy 
has called for the incorporation of HRQOL measures into future studies of 
surgery (NIH, 1990). There is also a nascent recognition of the need to investi­
gate HRQOL outcomes of rehabilitative therapies (Vickrey, 1995).
Universally, there are increasing efforts to control health care costs. In this 
setting, there are many unanswered questions about the optimal mechanisms for 
management of epilepsy (Begley et al., 2000). Thus, there is a great need for 
research in quality of care assessment for epilepsy. Because HRQOL is a central 
outcome for these kinds of studies, advances in measurement of HRQOL in epi­
lepsy are also needed for quality of care research (Greenfield et al., 1992; 
Kravitz et al., 1992).
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3. The stigma of epilepsy
Much of the literature on the social consequences of epilepsy assumes that the 
disorder bears a universal and devastating stigma (Baker et al., 1996; Placencia 
et al., 1995; Baker et al., 1999; Jacoby, 1994; Baker et al., 1997b). Used in the 
past to indicate a mark or brand to identify slaves and criminals, the word stig­
ma in modern times has come to refer to what Goffman (1963) has described as 
“any attribute that is deeply discrediting”. The stigma of epilepsy consists of 
deeply discrediting attributes such as propensity to crime and violence, sexual 
deviance, heritability and mental illness, restrictions or denials of common 
benefits (such as a drivers’ license or life insurance) and limitations on opportu­
nities that lead to independence (such as housing or employment discrimi­
nation) (Livneh and Antonak, 1997).
Several authors have argued (Schneider and Conrad, 1981; Dell, 1986) that 
stigma is not solely the outcome of societal devaluation of differentness, but in 
order for stigma to exist, individuals possessing such differentness must also 
accept this devaluation. Given that its physical manifestations are transient, 
individuals with epilepsy may be seen as possessing a characteristic, which is, 
in Goffman’s (1963) terminology, potentially discreditable. Those people must 
continually decide what, when and to whom to disclose. For some people with 
epilepsy, managing information about their condition can be a potent source of 
stress and anxiety (Jacoby, 1994).
The aetiology of stigma is complex, with multiple origins. A number of 
authors cited the importance of parental reaction to the diagnosis (e.g., shame 
and concealment (Austin, 1996), or alternatively, over protection of the child 
(Scambler and Hopkins, 1986)). Feelings of stigma may arise as a direct conse­
quence of experiencing the fear of others or the worry about having to commu­
nicate with someone having a seizure, also the problem may be exacerbated by 
lack of accurate information about epilepsy (Baker et al., 1999; Hills and Baker, 
1992).
The severity of the condition, as defined by seizure type and frequency and 
the personality of the individual (Ryan et al., 1980a) may affect the responses to 
any direct or indirect experiences of discrimination (Schneider and Conrad, 
1981). Scambler (1988) hypothesises that epilepsy is a stigmatising illness be­
cause people with epilepsy threaten the social order by failing to conform to 
cultural norms and by causing ambiguity in social interactions. Dell (1986) 
argues that stigma is serious and real, limiting the QOL of people with epilepsy. 
Social function is often impaired because of the stigma associated with a diag­
nosis of epilepsy. Perception of stigma can reduce motivation for work and 
social activity, relationships of the patient with family, friends and co-workers 
may change.
Danesi (1984), in a study evaluating how people with epilepsy perceive their 
condition, found some evidence of non-acceptance. Persons with epilepsy rated
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themselves lower than people without epilepsy with respect to employability 
and higher with respect to emotional problems and tendencies toward violence.
Studies in the area of adjustment to seizures concern evaluation of the accep­
tance of the seizure disorder and feelings of not being accepted because of the 
disorder. Masland (1985) believes that the person’s own reaction to having the 
seizure disorder is the most significant factor in adjustment. Schneider and 
Conrad (1980) reported that perception of stigma was related to direct exposure 
to rejection and disapproval from others. Persons with epilepsy maintained 
selective coping mechanisms to manage their reactions to stigma.
Amston et al. (1986) have reported significant relationships between 
patients’ feelings of stigma and a number of measures of psychopathology. The 
stigma of epilepsy and its psychosocial repercussions can best be understood by 
drawing a distinction between “felt” and “enacted” stigma. In this dichotomy, 
enacted stigma refers to episodes of discrimination against people with epilepsy, 
solely on the grounds of their social unacceptability. Whereas felt stigma refers 
to the feeling of shame associated with being epileptic or what might be called 
an “ontological deficit”, a sense of “being imperfect” and the fear of enacted 
stigma or, in other words, a fear of meeting with discrimination consequent 
upon an epileptic identity (Scambler, 1993).
In their article, Ryan et a l  (1980a) provided evidence that felt stigma may 
not be as all-embracing as suggested and that persons with epilepsy do not uni­
versally feel stigmatised by the disorder. Among the subjects they studied, the 
majority felt neither unreasonably limited nor treated differently because of 
their epilepsy.
The relationship between the severity of seizures and the perception of 
stigma due to the disorder is found to be highly dependent on other characte­
ristics, such as the perception of employment discrimination, the perception of 
limitations imposed by the disorder and the years of school education attained 
by the individual.
Also, Jacoby in her study (1992), reported that for people whose epilepsy 
was well controlled (who had been seizure-free for at least two years) the 
psychosocial functioning and adjustment appeared high, with low levels of 
distress.
Felt stigma can be assessed by using a scale developed originally to measure 
patient perceptions of the stigma of another neurological condition — stroke 
(Hyman, 1971) and this is reworded for epilepsy. The scale consists of three 
questions each of them requiring a yes/no response. Respondents with epilepsy 
have to state whether they have felt that other people (a) are uncomfortable with 
them, (b) treat them as inferior, or (c) prefer to avoid them. An individual’s 
score is the sum of the “yes” responses, and the higher the score the greater is 
the perception of stigma (Jacoby, 1994).
Stigmatisation seems to vary from region to region, and it tends to be more 
severe outside the developed world (Theodore, 2000; Jallon, 1997; Shorvon and 
Farmer, 1988; Van Ree, 1972; Walker, 1972; Senanayake and Abeykoon,
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1984). However, despite its changed manner, it is still a difficult problem in 
Western countries. According to the results from the European quality of life 
study that included patients from 15 countries, the highest proportions of stig­
matised persons were found among the respondents from France and Germany. 
Respondents were more likely to feel stigmatised if they had a combination of 
seizure types or if they had frequent seizures (Baker et al., 1997a).
4. Epilepsy and employment
Employment is a crucial topic for people with epilepsy because working, being 
an employee and earning a living are outward signs of the psychosocial 
integration and of acceptability by others (Chaplin, 2000; Dodrill, 1983).
There are a number of ways in which epilepsy appears to have an impact on 
employment. Firstly, the person with epilepsy is barred by law from certain 
occupations because of the potential hazards to him and others if a seizure 
occurs in the workplace. Secondly, the stigma attached to epilepsy and the 
resulting prejudice on the part of employers and co-workers limits employment 
opportunities for individuals with epilepsy. The employment problems of 
people with epilepsy may be further compounded by the effects of AEDs on 
cognitive functions, which can reduce educational and work performance and 
by poor self image, which may limit attempts to seek employment and affect 
interpersonal relationships at work (Fraser et al., 1983; Rodin et al., 1972).
Because people with epilepsy have high rates of under- and unemployment 
they are often dependent on others for financial security (Dodrill et al., 1984b). 
Clemmons (1983) reported that 50% of a sample of persons with epilepsy were 
dependent on family or federal subsidy. Although several reports in the relevant 
literature have maintained that people with epilepsy generally have lower than 
average income (Fraser et al., 1983; Dodrill et al., 1984b; Batzel et al., 1980; 
Fraser and Clemmons, 1983; Laaksonen, 1983), few statistical studies have 
investigated the relationship between epilepsy and lower socio-economic status.
Persons with epilepsy frequently experience psychosocial difficulties 
especially in terms of employment (Baker et al., 1997a). Difficulties are 
experienced in all aspects of employment such as job application, promotion 
and dismissal (Cooper, 1995), and also in interpersonal relationships (Baker 
et al., 1997a). A number of studies have highlighted the employment difficulties 
encountered by individuals with epilepsy (Fraser et al., 1983; Rodin et al., 
1972), and under- and unemployment have been identified as two of the most 
serious problems they face (Collings, 1990c; Masland, 1983; Elwes et al.,
1991). Among people with epilepsy, it has been reported that unemployment is 
a major source of stress and that having full-time employment is a major factor 
in the prediction of overall well-being (Collings, 1990c).
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There is general agreement about the fact that the unemployment rate of 
people with epilepsy is higher than in the general population (Fraser et al., 
1989; Chaplin et al., 1998; Elwes et al., 1991). Studies in the UK (Collings, 
1990c; Scambler and Hopkins, 1980) have reported that employment rates 
among people with epilepsy are lower than in the general UK population. In the 
US labour market, the unemployment rate among people with epilepsy, who are 
maintaining an active job search is reported to be 13-25% (Thorbecke and 
Fraser, 1997). The generally accepted rate of unemployment in people with 
epilepsy has been calculated to even be between 15-50%, although this is a high 
figure it is lower than is found in other disability groups (Fraser et al., 1989). 
But, in some studies (Chaplin et al., 1998; Collings and Chappell, 1994), this 
rate has been questioned and lower rates ranging between 9-11% have been 
suggested.
In studies by Elwes et al. (1991) and Jacoby (1995), higher rates of unem­
ployment were found among persons with active epilepsy compared to people 
whose epilepsy was in remission or well-controlled. Scambler and Hopkins 
(1980), in their study of a community sample of adults with epilepsy, found that 
less than half of those who had worked full-time after the onset of their seizures 
could recall that their careers had been inhibited by their epilepsy. Yet most felt 
“at risk” and chose to conceal their condition from their employers or potential 
employers. Employment disadvantage was found to be related both to a wor­
king class status and to a high rate of epileptic activity. The conductors of the 
study suggested that epileptics were prone to deny themselves career opportu­
nities.
Collings (1990c) found full-time employment to be a predictor of psycho­
logical well-being, and less adequate financial status has also been found to be a 
predictor of depression (Hermann et al., 1992). Hermann et al. (1990) have 
reported that vocational difficulties were among the factors contributing to 
increased psychopathology in people with epilepsy.
Epilepsy has a negative impact in several aspects of employment. Scambler 
and Hopkins (1980) stated that among the respondents in their survey, almost 
all of those with full-time employment experience, after the onset of seizures, 
believed epilepsy to be stigmatising despite the fact that less than a quarter 
could recall instances of discrimination. In the Jacoby (1995) study, only 2% of 
those asked recalled an occasion over the preceding two years when they had 
been treated unfairly at work because of their epilepsy and only 3%, of those 
asked, said that during the same time they had failed to get a job they applied 
for because of the condition. But, nearly a third of the patients (32%) felt that 
their epilepsy made it more difficult for them than for others to get a job. 
Among those who felt that having epilepsy made getting a job more difficult, 
39% felt this was because employers preferred not to employ people with 
disabilities of any kind. A third felt it was because of fear and lack of under­
standing about epilepsy on the part of employers; and a fifth attributed these 
difficulties to the potential dangers of seizures in the workplace. Although no
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specific question about disclosure was asked, a number of respondents com­
mented that they had not disclosed their epilepsy out of fear of discrimination.
In a study from Tunis, Gouider et al. (2000) found that 19.2% of people with 
epilepsy from the group had changed jobs because of epilepsy. Kokkonen et al. 
(1997) found that the epileptic patients even with the same condition of 
employment had more frequently a less secure job.
A number of authors have emphasised the importance of good seizure cont­
rol. Seizure frequency has shown to be related to the likelihood of being in 
employment (Rodin et al., 1972; Scambler and Hopkins, 1980; Jones, 1965), 
which is to be expected. Collings (1990c), Elwes et al. (1991), and Jacoby 
(1995) all have reported lower rates of employment among people with active 
epilepsy than among those who were seizure-free. But, Jacoby (1995) specifies 
that where seizures are well controlled and uncomplicated by other handicaps, 
people with epilepsy do not generally experience problems with employment.
Chaplin (2000) stated that many people with epilepsy were unnecessarily 
restricted in their choice of employment due to, ignorance about epilepsy, the 
stigma associated with epilepsy or the expectations of stigma. Because employ­
ment is a major factor in the calculation of QOL, any anticipated QOL improve­
ments from; for example, new medical treatments are reduced or invisible if the 
individual is still not able to work.
Although a higher rate than among the general population might be expected 
due to the nature of the condition, it has been found that the frequency of seizu­
res is not the most important factor influencing the employment of people with 
epilepsy. In areas with high general employment figures, a comparison between 
a group of people with epilepsy in remission and a group with uncontrolled 
seizures shows only a slight increase in employment problems in the second 
group (8% to 10%) (Chaplin et al., 1998).
In Western countries, the main problem for working-people with epilepsy is 
not unemployment, but integration in the workplace. Many problems are 
reported by people with epilepsy at work: stigma as already mentioned, limi­
tations for career prospects, a lower salary, an unpleasant atmosphere and loss 
of job due to the discovery of epilepsy at work (Chaplin et al., 1998; Lassouw 
et al., 1997). The type of jobs open to people with epilepsy may reflect diffe­
rences in their medical condition. In a study conducted in the Netherlands 
(Lassouw et al., 1997), it was found that none, of the group of working-people 
with epilepsy, were self-employed.
Gouider et al. (2000) stated that one third of the patients considered that 
epilepsy reduced their productivity or awareness. However, Gloag (1985) revea­
led that the quality of work of epileptic persons was equal to that of the general 
population.
The lack of declaration of the disease in the workplace was found to be 
19.5% by Gouider et al. (2000). It was outlined with higher frequency (37%) in 
a study by McIntyre (1979). Scambler and Hopkins (1980) reported that 80% of 
patients did not voluntarily declare their disease. Worsening of relationships in
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the workplace, especially with employers, was outlined by Jacoby (1995) in 
34% of patients. 27% considered that epilepsy was a cause of discrimination at 
work (Scambler and Hopkins, 1980).
Gouider et al. (2000) reported that in the sample of predominantly manual 
workers (90%) with disrupted or primary education, epilepsy induced frequent 
changes of job and deterioration of relationships with employers in the sample 
where persons had mostly generalised epilepsy and 18% of the patients were 
having more than one seizure per month. The study investigators concluded that 
manual workers with epilepsy, especially workers over 40 years, constituted a 
vulnerable group in terms of employment problems.
5. Impact of epilepsy and its therapy with regard 
to social adjustment
Limited independence
Epilepsy often begins in childhood. Coping with seizures precludes many nor­
mal activities (e.g., work and sport). Parents may become overly protective be­
cause of the possibility that a seizure might result in an accident or cause self- 
harm and limit the child’s, and often the young adult’s, self-esteem and inde­
pendence. Most epilepsy patients must take antiepileptic medications daily, 
often for the duration of their lives. The sense of dependence on medication is 
fostered by physicians and reinforced when seizures occur after missed doses. A 
sense of independence can be limited further by the need to report the diagnosis 
of epilepsy on applications for work and insurance. Restrictions are imposed 
either by law (e.g., the patient is prevented from driving) or by self-imposed 
concerns (e.g., social embarrassment). Similar restrictions also affect patients 
who have infrequent seizures (Cramer, 1993; Cramer, 1994).
Limitations on driving
Driving is often restricted for people with seizure disorders, particularly among 
those individuals with inadequately controlled epilepsy. Both licensing laws and 
insurance accessibility (and cost) delay resumption of normal activity after the 
diagnosis of epilepsy. If the patient does not have alternative modes of transpor­
tation (i.e. public transport, assistance from friends or relatives), limitations on 
driving can further restrict independence and ability to work and he/she can be 
quite socially isolated (Schwartz et al., 1995). Inability to drive to work or to 
drive as a job requirement could, in addition, result in demotion to a position 
with less responsibility or to dismissal (Cramer, 1994). The health risk associa­
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ted with social isolation is considerable, so preventing one of the reasons for 
this isolation would be salutogenic (Berkman and Syme, 1979).
Sexual behaviour and marriage
A large number of indirect relationships exist between epilepsy and problems of 
sexual behaviour. The existing data suggest that people with epilepsy appear to 
have lower rates of sexual activity and more sexual disturbance than those not 
having epilepsy (Max, 1980; Fenwick et al., 1985). Hyposexuality is the most 
prominent problem. Although it has been specifically associated with temporal 
lobe epilepsy, this is presumably only one of several factors that may contri­
bute. The individual’s overall mental health is an important consideration; 
depressed or anxious people often have little interest in sex. The chronic use of 
AEDs may also produce alterations in sex hormone levels and thus affect sexual 
functioning and fertility (Hermann and Whitman, 1984; Strauss, 1989; Cramer 
and Jones, 1991). Data from the VA (Veterans Affairs) Co-operative Studies 
(Mattson et al., 1985; Mattson et al., 1992) clarified the differential effects of 
AED on sexual function in men. Primidone was associated with decreased 
libido or impotence significantly more often (22%) than carbamazepine (13%), 
phenobarbital (16%), or phenytoin (11%).
Adolescents with epilepsy may have limited opportunities for social activi­
ties and thus sexual contact because of their isolated position in peer groups 
(Hermann and Whitman, 1984).
There is evidence that people with epilepsy are less likely to marry and have 
children (Jacoby, 1992; Collings, 1990b; Dansky et al., 1980; Batzel and Dod­
rill, 1984; Jacoby et al., 1996). This is an important social issue that has many 
possible reasons. These include low levels of confidence and self-esteem and 
over-protection on the part of their family may render people with epilepsy 
socially more inept. The social isolation because of fear of seizures or restric­
tions on activities may limit their chances of meeting a prospective partner 
(Jacoby, 1992).
Dansky et al. (1980) reported that the marriage rate for both men and women 
was significantly reduced when seizures had begun in the first decade of life. 
Also Jacoby et al. (1996) showed that the earlier age at onset was associated 
with reduced likelihood of being married.
AED therapy and compliance
Evaluations conducted by physicians have mostly concentrated on seizure 
management, assessing strategies for AED prescribing and for surgery. It is as if 
seizure control is primary and everything else secondary. It seems that seizure 
control is equated with “normality” (often restoration of the status quo ante) 
and therefore a person’s well-being. Allowing for the undoubted importance of 
seizure control, research has accumulated to show that epilepsy often does have
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a marked, deleterious effect on QOL quite independently of seizure frequency 
(Scambler, 1993).
Seizures and AED therapy have a major impact on patients’ lives that often 
linger after long-term remission is achieved. AED therapy, by decreasing sei­
zure frequency and possible severity, has the potential to ameliorate the psycho­
social consequences of the disease. However, therapy may itself cause new 
problems in daily living because of adverse effects, interactions with other 
drugs, frequent blood sampling, feelings of dependency on a potential life-long 
medication regimen, and financial cost associated with long-term therapy 
(Wagner etal., 1995).
Low self-esteem, lack of independence, need for AEDs, restrictions on 
alcohol use and driving, reporting of epilepsy on job and insurance applications, 
and presence of AEDs in urine tests are chronic problems frequently faced by 
patients with epilepsy (Ryan et al., 1980a; Hermann, 1991; Hayden et al., 
1992).
It has been suggested that patients who successfully discontinue from AEDs 
are able to think that they not only are free from recurrent seizures, but also 
from a diagnostic label that many believe to be stigmatising and may derive 
considerable psychosocial benefits (Jacoby et al., 1992).
For any epilepsy patient, the ideal outcome would be seizure freedom while 
on no drug therapy. For some patients this may be a realistic goal, others should 
be controlled on the lowest possible number of drugs at the lowest possible 
dosage (Reynolds and Shorvon, 1981; Brodie, 1992).
Most patients, with epilepsy of recent onset, will achieve a long-lasting 
remission soon after the start of therapy, with minimal side effects. Annegers et 
al. (1979) showed that 61% of patients were in 5-year remission ten years after 
presentation, rising to 70% after 20 years and these rates have remained 
essentially unchanged until now, despite the introduction of modem AEDs. The 
patients with an idiopathic generalised seizure disorder usually respond very 
well to treatment. It would appear that over 80% of those with a clinical and 
electro-encephalographic (EEG) picture of an idiopathic generalised seizure 
disorder will be rendered seizure-free on treatment with sodium valproate. In 
those patients with symptomatic or cryptogenic epilepsy, the response rates are 
lower. Patients experiencing partial seizures are less likely to get remission than 
those with only tonic-clonic seizures. The worst prognosis would appear to be 
in those who have both partial and secondary generalised seizures (Chadwick,
1992).
When an AED, “correct” for the specific syndrome, has been used 
unsuccessfully, it is reasonable to turn to a second drug, most usually as mono­
therapy. In some instances a trial of a two-drug combination may be considered. 
The second drug will be withdrawn in the absence of a satisfactory sustained 
response. Realistically once patients are demonstrably refactory to two different 
monotherapies, it is unlikely that they will fully respond to a third or even 
fourth monotherapy (Leach et al., 2000). The careful use of combination
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treatment may be the only option for patients refactory to monotherapy. It has 
been estimated that some 20% of patients developing epilepsy have a chronic 
disorder that cannot be controlled by drugs (Jacoby, 1992; Baker et al., 1993; 
Chadwick, 1998).
In recent years, considerable emphasis has been placed on the desirability of 
monotherapy (Reynolds and Shorvon, 1981; Brodie, 1992). In general, therapy 
should be initiated with monotherapy, using an AED that is specific for the 
epilepsy syndrome being treated and that has the most favourable side effect 
profile. However, if monotherapy is not effective in controlling seizures without 
side effects, a rational approach, using more than one AED, or combined AEDs 
with multiple mechanisms of action, should be used (Leppik, 2000). Combining 
older AEDs has traditionally been seen as helping few patients while hindering 
many by causing a multitude of side effects. The truth is probably less dramatic, 
especially with the newer AEDs (Leach and Brodie, 1995).
When the likelihood of seizure freedom is low. it may be more prudent not 
to pursue freedom from seizures, but instead to achieve a balance between redu­
cing seizures and inducing side effects, with the minimum number of AEDs. 
This acknowledges the fact that drug-related adverse effects, especially with 
AED polypharmacy, can themselves be disabling and worrying (Leach et al., 
2000).
AEDs have been shown to have a number of undesirable side effects, both 
physical and cognitive. The negative effects of AED treatment consist of side 
effects from the drugs and the intrusion of regular pill taking into daily life. 
Most patients with epilepsy will have seizures much less often than the times 
they need to take their medication and the latter serves as a frequent reminder to 
the patient that not all is well with them. This, in addition, may give rise to 
embarrassment and stigmatisation at work or school, if dosing is more frequent 
than once or twice a day. A more common negative effect of AEDs is the side 
effects. Acute dose-related side effects are generally predictable, such as seda­
tion, dizziness, nausea and impairment of concentration and cognition. Some 
side effects are more drug specific, such as blurring of vision and diplopia from 
carbamazepine, hair loss and weight gain from valproate, and oscillopsia and 
ataxia from phenytoin. Acute dose-related side effects may not result in a 
patient complaining vociferously and so they should be specifically enquired 
about, as their occurrence will undoubtedly have a deleterious effect on QOL 
and on compliance, with subsequent difficulties in making rational drug 
changes. Chronic cognitive side effects may develop insidiously and not be 
perceived unless they are looked for, or recognised until a drug is withdrawn, 
but may have a profound effect on QOL. Most of the AEDs have the potential 
to cause slowing down, and more widespread cognitive side effects have been 
associated with barbiturates and phenytoin, and with the use of polytherapy 
(Thompson and Trimble, 1982; Duncan et al., 1990; Duncan, 1990).
A function of the patient-physician relationship is compliance or non- 
compliance with treatment regimens (Stanaway et al., 1985; Sadler, 1986). For
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patients with epilepsy who become seizure-free after starting AED treatment, 
the question arises of whether they could then discontinue AEDs.
Lack of control of one’s health and resentment of the need to take medica­
tion may be major factors leading to non-compliance with a medication regi­
men. The arguments in favour of discontinuation of AEDs include concerns 
about side effects or possible long-term effects, sense of disillusionment be­
cause therapy can only control, not cure, epilepsy and to some people conti­
nuing therapy implies continuing epilepsy, even though they are seizure-free 
(Jacoby et al., 1992). Compliance with AED therapy is known to be poor 
(Gibberd et al., 1970; Dawson and Jamieson, 1971). In a study of adults with 
epilepsy by Scambler (1989), 25% admitted that they had, at some stage, 
deliberately experimented with or stopped medication without consulting a 
physician. Stanaway et al. (1985) reported that 37% of people with epilepsy, 
from within their study, were not taking medication as prescribed and that 31% 
of seizures were estimated to occur as a result of failure to comply. The positive 
feedback gained by the patient who discontinues or reduces medication intake 
without immediate reoccurrence of seizures may have an important negative 
influence on later ability to readjust to a medication schedule if seizures recur 
(Meador ef al., 1990).
Persons who relapse after discontinuation may risk the loss of employment. 
Their driving-license may be forfeited. And all this may have a considerable 
impact on the quality of daily life. The uncertainty associated with a possible 
relapse may affect confidence, self-esteem, and sense of control and, as a result, 
relationships with others (Jacoby et al., 1992). Although clinical consensus now 
is that patients should be considered for discontinuation of AEDs after being 
seizure-free for two years, many continue therapy for prolonged periods be­
cause of uncertainty about the outcome of discontinuation (Guberman and 
Bruni, 1999).
The social and psychological effects
It has been suggested that the psychosocial problems, observed among patients 
with epilepsy, are more handicapping than the seizures themselves (Livingston, 
1981). Baker et al. (1996) consider the burden of epilepsy to be so variable that 
merely the fact of having epilepsy can result in psychosocial problems, indepen­
dent of the frequency or severity of seizures.
Earlier studies in this field have highlighted several areas of particular 
concern for people with epilepsy (Collings, 1990c; Cramer, 1994; Chaplin et 
al., 1992; Hermann, 1992). Fear of physical injuries or social embarrassment, 
cognitive impairment (due to underlying brain dysfunction and/or anticonvul­
sant medication) and the stigma historically attached to being “epileptic” are 
potent factors which lead to self-imposed and societally imposed restrictions on 
many pleasurable and productive activities (Hermann and Whitman, 1991).
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Anxiety, depression, anger, low self-esteem, social isolation and withdrawal, 
familial maladjustment and low marriage rates are common (Collings, 1990b; 
Hermann, 1992; Thompson and Oxley, 1988).
Patients commonly experience anxiety and depression when epilepsy is diag­
nosed. Fear of seizure disorder exposure can become overwhelming when coup­
led with a sense of loss of control over their body (Cramer, 1994). The effects 
of medication and seizures also impinge on the psychological condition, 
particularly if cognition is impaired or memory loss becomes apparent to the 
patient (Meador et al., 1990). Standage and Fenton (1975) compared the mental 
status of patients with epilepsy and patients with musculoskeletal disorders, fin­
ding similar symptom profiles. Anxiety and depression were twice as high in 
the epilepsy group.
People with epilepsy are generally considered to be at greater risk of psycho­
pathology and more likely to be socially dysfunctional than people without epi­
lepsy, but the reasons for this continue to be a focus for debate (Jacoby et al.,
1996). Hermann and Whitman (1991) argue that there are three main groups of 
variables that may contribute to the development of psychopathology in epi­
lepsy: clinical factors related to the natural history of epilepsy, including age at 
onset, duration of epilepsy, seizure type, aetiology and seizure control; 
medication factors, including type of AED, number of AEDs, and serum levels; 
and psychosocial factors, including perceived stigma and discrimination, locus 
of control, adjustment to epilepsy, social support, and socio-economic status. 
Previous research into modelling the psychopathology of epilepsy in a hospital- 
based population highlighted that the number of stressful life events in the past 
year, poor adjustment to epilepsy and financial stress were the most significant 
independent predictors of psychopathology (Hermann et al., 1990). The only 
clinical factor that correlated significantly with psychiatric status was earlier age 
of onset, although this proved not to be predictive of psychopathology in the 
population of people with epilepsy studied by Baker et al. (1996). A study of 
people with resistant epilepsy found that perception of seizure severity was a 
significant predictor of anxiety, self-esteem and locus of control, with seizure 
frequency only making a negligible contribution (Smith et al., 1991).
Epilepsy has shown to be associated with higher than average rates of 
psychiatric morbidity (Kogeorgos et al., 1982; Trimble, 1985). Anxiety and 
depression are the commonest forms of psychiatric morbidity in people with 
epilepsy and often coexist (Jacoby et al., 1996; Robertson et al., 1987). Amtson 
et al. (1986) and Collings (1990c) too, cite anxiety as the problem most 
commonly elicited from patients themselves. Smith et al. (1991) reported that in 
a group of patients with intractable epilepsy, 33% were classified as clinically 
anxious and 15% as clinically depressed by the Hospital Anxiety and Depres­
sion (HAD) Scale (Zigmond and Snaith, 1983). At the same time, some authors 
think that the findings showing that anxiety and depression are the commonest 
forms of psychiatric morbidity among people with epilepsy, reflect the view that
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anxiety and depression are also the commonest forms of psychiatric morbidity 
in the general population (Goldberg and Blackwell, 1970; Regier, 1988).
In epilepsy, medical outcomes are usually defined by seizure severity (e.g., 
frequency, type, intensity, postictal symptoms, etc.) and medication side effects. 
Devinsky (1993) argues that in all this, we are missing the patient’s perspective. 
Although one might believe in the physician’s ability to assess the patient’s 
QOL accurately, there is often a poor correlation between the patient’s and the 
physician’s assessments (Slevin et al., 1988).
The individual patient’s perspective has become an integral aspect of health 
care assessment (Cramer, 1994). Several authors have drawn attention to the 
importance of considering the social aspects of epilepsy (Burden, 1981; Scamb­
ler, 1987), which have been recognised as crucial to a comprehensive under­
standing of the condition (Chaplin et al., 1990).
Severe social problems are most frequently found in those patients having 
poor seizure control and multiple seizure types or with associated handicaps 
(Thompson and Oxley, 1988; Dodrill, 1986; Beran and Flanagan, 1987). Col­
lings (1990a) found that the most significant discriminator of well-being was 
the correspondence between current self-perceptions and the anticipated self 
without epilepsy, with other predictors consisting of employment status, seizure 
control, certainty of diagnosis and age. Rodin et al. (1977) discovered that more 
than half the persons with epilepsy, which they sampled, had some sort of 
psychological or social problem with behavioural manifestations. Interpersonal 
adjustment refers to a person’s ability to relate to other people; i.e., having close 
personal friends, being able to deal appropriately with the opposite sex, etc. 
Relationships with other people are viewed as being among the most important 
variables in psychosocial adjustment (Dodrill et.al., 1980).
Social isolation and withdrawal are also commonly reported in the psycho­
social adjustment of the people with epilepsy (Max, 1980; Heisler and Fried­
man, 1981; Fraser and Smith, 1982; Ziegler, 1982) and are related to marriage 
and sexual behaviour. Fear, anxiety, and the attitudes of others toward the 
person with epilepsy contribute to withdrawal (Laaksonen, 1983). Lack of self­
esteem reinforces this pattern, reducing the person’s opportunity to learn 
appropriate social interaction skills (Woodward, 1982). Withdrawal and social 
isolation may also occur within families, increasing the tensions between per­
sons with epilepsy and their families and contributing to the overall pattern of 
social isolation (Ritchie, 1981).
The person’s view of treatment received or medical management signi­
ficantly affects psychosocial adjustment (Dodrill et al., 1980). Reactions to the 
physician involved and to having medications administered, as well as the 
degree of treatment compliance, are considered significant factors.
Psychosocially oriented explanations have emphasised the various psycho­
logical and social stress factors associated with having seizures. Seizures are 
essentially unpredictable traumatic events over which the individual has little or 
no control. The nature of epilepsy may thus be conducive to “learned helpless­
27
ness”; and it has been suggested that this may be one way of understanding 
some of the inter-ictal behavioural concomitants of epilepsy, particularly the 
apparent high rates of depression and anxiety (Hermann, 1979). Medical misin­
formation, fear of seizures and fear of death from seizures is widespread among 
patients and this may affect behaviour in adverse ways. Patients may have con­
cerns about what they think are the potentially destructive effects of epilepsy, 
such as progressive brain damage, mental deterioration, mental illness and loss 
of intelligence. A common approach to dealing with such fears and concerns is 
social and emotional withdrawal. Depression and anxiety in epilepsy may in 
part be due to such mechanisms (Aldenkamp and Hendriks, 2000).
Baker et al. (1997a), in their European study of people with epilepsy, found 
that when asked to what extent they felt epilepsy and its treatment affected 
several aspects of daily living, high percentages of respondents reported that it 
substantially affected their plans and ambitions for the future (47% reported “a 
lot/some”), feelings about themselves (40% reported “a lot/some”), and their 
social life (41% reported “a lot/some”). Conversely, there were high percen­
tages who felt that relationships with significant others were unaffected (48% 
describing relationships with close family members as not affected). More than 
one third (38%) of respondents believed that epilepsy affected their ability to 
work and their standard of living (36%) “a lot/some”, but there were also sub­
stantial proportions who believed that employment (47%) and standard of living 
(43%) were not affected by epilepsy. Respondents with frequent seizures were 
more likely than the rest to believe that epilepsy affected the various aspects of 
their daily lives a lot or some. Similarly, respondents with mixed seizure types 
were more likely to believe this than those who had only tonic-clonic seizures 
or only some other types of seizure.
Jacoby et al. (1996), in their findings from a U.K. community study, repor­
ted that there was a clear relationship between current level of seizure activity 
and subjects’ psychological well-being, as measured by their scores on the HAD 
Scale. Overall, 25% of subjects were classified as anxious and 9% as depressed, 
but the percentages increased, from 13 and 4%, respectively, among individuals 
who were seizure-free to 44 and 21%, respectively, among those reporting fre­
quent seizures, defined as one or more seizures a month. Subjects currently 
experiencing frequent seizures were two to three times as likely as those 
currently seizure-free to believe that epilepsy affected the various aspects of 
their daily lives “a lot” or “some”. Current seizure activity thus appeared to be 
important factor in determining the psychosocial status of this population.
But the investigations, which are based on community populations, suggest 
that although significant social difficulties may be experienced, many people 
with epilepsy cope well in society (Zielinski, 1986).
28
6. Quality of life measures in epilepsy
Review
There is no consensus on which instruments are most suitable for measuring 
QOL. Commonly, HRQOL instruments are questionnaires made up of a number 
of items or questions. These items are added up in a number of domains (also 
sometimes called dimensions). A domain or dimension refers to the area of 
behaviour or experience that we are trying to measure. Domains might include 
mobility and self-care (which could be further aggregated into physical func­
tion), or depression, anxiety, and well-being (which could be aggregated to form 
an emotioned function domain). For some instruments, investigators do rigorous 
valuation exercises in which the importance of each item is rated in relation to 
the others. More often, items are equally weighted, which assumes that their 
value is equal (Guyatt et al., 1993).
There are two principal types of QOL instruments: generic and specific. The 
generic instruments assess a variety of general functions (e.g., ability to perform 
activities of daily life, overall feelings of well-being, limitations of the medical 
disorder on social functions, etc.) and have the advantage of being useful for a 
large number of disorders as well as in general population. Most of the instru­
ments are well validated and the result of extensive development. They are 
relatively brief and efficient and facilitate comparisons between different 
groups. However, generic instruments are limited because many of the general 
questions they include (such as how many city blocks can you walk or the 
severity of pain) may be useful for cardiac and oncological disorders but may 
not be relevant for less physically disabling disorders such as epilepsy. Further, 
generic instruments may be insensitive to the most important aspects of specific 
disorders. Indeed, generic instruments are not sensitive to many of the important 
medical, medication, cognitive, social, and psychological disorders associated 
with epilepsy. Disease-targeted instruments concentrate on issues of particular 
relevance to a specific disease or disorder and therefore may be more sensitive 
than generic measures to differences within the targeted condition but do not 
permit comparison of results between disorders or populations (Devinsky,
1993).
In recent years there have been a number of initiatives to develop QOL out­
come measures for epilepsy (Table 1): those which have concentrated on the 
development of a novel measure (e.g., Washington Psychosocial Seizure 
Inventory (WPSI) (Dodrill et al., 1980) and the Social Effects Scale (Chaplin et 
al., 1990)); those that involve a single previously developed generic measure 
with epilepsy-specific additions (e.g., Epilepsy Surgery Inventory (ESI-55) 
(Vickrey et al., 1992) and the Quality of Life in Epilepsy Inventory (QOLIE) 
(Devinsky et al., 1995)); those that make use of previously validated scales 
addressing specific QOL domains together with additional disease-specific
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questions (e.g., Liverpool QOL Battery (Baker et al., 1993; Jacoby et al., 
1992)); and finally the patient-generated approach adopted by Kendrick and 
Trimble (1994). It is generally agreed from the work on QOL to date that the 
best approach is to use a standard generic instrument with disease-specific 
additions, and much of the work in QOL of adults with epilepsy has followed 
this approach (Baker, 2001; Chadwick, 1996).
Table 1. QOL measures used in the studies of epilepsy or AEDs.
Physical measures
Liverpool Seizure Severity Scale (Baker et a l,  1991)
Chalfont Seizure Severity Scale (Duncan and Sander, 1990)
Veterans Seizure Severity Scale (Cramer et al., 1983)
Social functioning
Social Effects Scale (Chaplin et al., 1990)
Impact of Epilepsy Scale (Jacoby et al., 1993)
Life Fulfilment Scale (Baker et al., 1994b)
Seals Inventor (Brown and Thomlinson, 1984)
Stigma Scale (Jacoby, 1994)
Psychological well-being_____________________________________________
Hospital Anxiety and Depression Scale (HAD) (Zigmond and Snaith, 1983) 
Profile of Mood Scale (McNair et al., 1981)
Affect Balance Scale (Bradburn, 1969)
Mastery Scale (Pearlin and Schooler, 1978)
Self-Esteem Scale (Demo, 1985)_______________________________________
Disease-specific measures____________________________________________
Washington Psychosocial Seizure Inventory (WPSI) (Dodrill et al., 1980) 
Quality of Life Inventories for Epilepsy (QOLIE-89, QOLIE-31, QOLIE-IO) 
(Cramer, 1994; Devinsky et al., 1995)
The Liverpool Initiative (Baker et al., 1993)
The Queens Square Initiative (Kendrick and Trimble, 1994)
The Epilepsy Surgery Inventory (ESI-55) (Vickrey et al., 1992)_____________
General health status measures_____ ___ _____________________________ _
Nottingham Health Profile (Hunt et al., 1985)
The Medical Outcomes Study 36-Item Short Form Health Survey (MOS SF-36) 
(Ware and Sherboume, 1992)
The RAND 36-Item Health Survey (RAND-36) (Hays et al., 1993)___________
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Although proven useful in their country of origin, standard scales are not 
directly applicable across nations due to cultural diversity. In order to use such 
instruments in a new national context, a thorough translation and testing phase 
preceding the inclusion of an instrument in a study is necessary. Measures also 
need to be psychometrically tested in a specific cultural context to assure their 
psychometric soundness (Bullinger, 1995; Mathias et al., 1994; Hunt, 1993). 
A minimal requirement for inferring correct translation and international 
validity of an instrument is the forward-backward-translation in the language 
under study, a test of psychometric criteria for healthy (if applicable) and ill 
persons based on a moderate sample size (e.g., at least 100 patients per study), 
and a clear-cut description of that translation and evaluation process (Bullinger 
et al., 1993).
Usually, a simple translation is unlikely to be adequate. It should be recog­
nised, that without rigorous back-translation and pre-testing, the instrument may 
be interpreted differently in the new language (Berkanovic, 1980). Even if the 
translation is adequate, cultural differences can adversely effect an instrument’s 
measurement properties (Deyo, 1984). To be fully confident of an instrument’s 
validity in a new language or culture, a complete repetition of the validation 
process is required (Nord, 1991). The adequate language conversion involves 
the forward and backward translation of the measure and a quality control of the 
translations. The consequent piloting involves discussion of the translated 
version with a health expert group and a small sample test of the questionnaire 
in a convenience sample of persons of different age, sex, health state and edu­
cation, as well as a test of the ordinality and equidistance of response choices. 
Psychometric testing includes examination of classical test theoretical criteria in 
populations differing in health state in terms of reliability (Cronbach’s alpha 
(a)), the validity (convergent, discriminant) and the responsiveness as well as 
the discriminant power in distinguishing populations differing in their medical 
condition (Bullinger, 1995).
The methods of the measurement of QOL must be valid (measure what they 
are supposed to measure), repeatable, sensitive to change (over time or as 
a result of treatment), and acceptable to the subjects (Bulpitt, 1997).
Because there is no QOL instrument that can serve as a gold standard by 
which to judge new QOL instruments, validity must be established in other 
ways. One way is to make logical predictions about relationships between QOL 
and other variables and to see whether these predictions are borne out when the 
instrument is used; this is known as construct validity (MacKeigan and Pathak,
1992).
One possibility for international examination of psychometric performance 
to infer the international validity and reliability of an instrument is to use the 
classical cut-off points for instrument performance obtained from each nation. 
Criteria include discriminant item validity in terms of optimal scale fit, item to 
scale correlation above 0.40, internal consistency coefficients over 0.70 and 
correlation coefficients for validity testing of above 0.50. The discriminant vali­
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dity of the measure, or known-groups validity (based on several patient groups 
known to differ in terms of severity of HRQOL impact), should be established. 
Thus, this approach simply involves generating or collating the key information 
on reliability, validity and sensitivity of an instrument. If, in a given country and 
under diverse conditions, an instrument continues to show excellent psychomet­
ric properties, or has been demonstrated to perform similarly to the original 
instrument, then it can be assumed to be culturally acceptable (Bullinger et al.,
1993).
Validity examines whether the instrument is measuring what it is intended to 
measure. When no gold, or criterion, standard exists, HRQOL investigators 
have borrowed validation strategies from clinical and experimental psycho­
logists. The most rigorous approach for establishing validity is called construct 
validity. A construct is a theoretically derived notion of the domain(s) we want 
to measure. An understanding of the construct will lead to expectations about 
how an instrument should behave if it is valid, namely, the extent to which the 
questionnaire supports predefined hypotheses (Jenkinson et al., 1993). It invol­
ves comparisons between measures and examines the logical relations that 
should exist between a measure and characteristics of patients and patients’ 
groupings (Guyatt et al., 1993). Construct validity is considered to be the main 
requirement of any measuring tool (Baker et al., 1993).
Item-discriminant validity is used to examine the extent to which items 
correlate more closely with the domain to which they belong than with the other 
domains; overall scaling success rate summarises the frequency with which they 
do so, as a percentage of the total number of correlations examined (Jacoby 
et al., 1999).
Internal consistency reliability, using Cronbach’s a coefficients (for group 
comparisons, a minimum value of 0.70 is recommended; for individual patient 
comparisons, a minimum of 0.90) should be sought (Cronbach, 1951). Reliabi­
lity refers to the reproducibility of a measure. In other words, if the instrument 
were administered again, under similar test conditions, to an individual whose 
health status had not changed, would the same score be obtained? If the scores 
obtain contain little random error, they are highly reproducible. There are many 
ways to compute a reliability coefficient, including Cronbach’s a coefficient of 
internal consistency and Pearson’s r or intraclass correlation coefficient for test- 
retest and interrater reliability (Baker, 2001; MacKeigan and Pathak, 1992).
Ideally an instrument should not often produce a zero result (a floor effect) 
or a result of 100% (a ceiling effect) as this will limit the sensitivity of the mea­
sure to change. A zero (as a good) result cannot improve and a 100% result can­
not get worse. Skewness measures the asymmetry of response distributions. The 
weighting of the instrument should be acceptable. Ideally, the instrument should 
have been employed previously so that the problems have been identified, 
assessed and dealt with (Bulpitt, 1997).
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The RAND 36-Item Health Survey 1.0 (RAND-36)
A variety of instruments are available for evaluating health-related quality of 
life in general population. One from among the most widely used questionnaires 
is the RAND 36-Item Health Survey 1.0. It is a brief and intensively tested 
instrument that was derived from longer instruments developed by RAND (a 
contraction of the term research and development) researchers (Santa Monica, 
California) for the Medical Outcome Study (MOS) and the Health Insurance 
Experiment (Cramer, 1994).
The purposes and methods of the RAND study have been fully summarised 
(Hays et al., 1993). The RAND 36-Item Health Survey 1.0 items are identical to 
the MOS 36-item short-form health survey (MOS SF-36) described by Ware 
and Sherboume (1992). These were adapted from longer instruments completed 
by patients participating in the Medical Outcomes Study (Hays and Shapiro,
1992). The conceptual framework is based on the multidimensional World 
Health Organisation definition of health (WHO, 1948). Although the RAND 
version has a slightly different scoring method, it allows users of the MOS SF- 
36 and RAND-36 to relate their findings (Hays et al., 1993). The RAND 36- 
Item Health Survey also forms the core component of two quality of life mea­
sures in epilepsy, ESI-55 (Vickrey et al., 1992) and the QOLIE-89 (Devinsky et 
al., 1995). The RAND-36 has a high validity and reliability rate compared with 
the Nottingham Health Profile and can discriminate between healthy controls 
and subjects who have mild health problems (Van der Zee et al., 1996; Garratt 
et al., 1993). It has been carefully tested, validated, and extensively used for 
patients with chronic disease (Stewart et al., 1989). Due to its long develop­
mental history and use in research as well as in clinical practice, it provides a 
rich database enabling researchers to compare their results. Thus in the 
international context it is possible to carry out research on the cultural univer­
sality vs. differences in quality-of assessment (Bullinger, 1995).
The Quality of Life Inventory in Epilepsy (QOLIE-31)
A diverse consortium of epilepsy and health services researchers (The QOLIE 
Development Group) initiated development of a broader, but epilepsy-specific 
instrument by expanding on the RAND 36-Item Health Survey and ESI-55 
concept of a self-report measure of HRQOL (Vickrey et al., 1992). The 
following three instruments were derived as a result of field testing: QOLIE-89 
(17 scales, 89 items), QOLIE-31 (7 scales, 31 items), and QOLIE-10 (10 items 
selected from the 7 scales in QOLIE-31). The first two instruments have been 
validated extensively to assure that the identified domains relate to different 
issues.
The QOLIE-31 is a 31-item questionnaire that addresses seven domains of 
HRQOL in sub-scales that can be compiled in a summary score reflecting 
experiences in the previous month. The QOLIE-31 was designed to serve as a
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brief assessment of epilepsy-specific and some overall QOL issues. QOLIE-31 
is a more detailed instrument than the QOLIE-IO (Cramer et al., 1996). The 
sub-scales of the QOLIE-31 include seizure worry, overall quality of life, 
emotional well-being, energy/fatigue, cognitive effects, medication effects, 
social function, and overall health. Each domain is addressed by asking several 
questions (ranging from one to six) so that an average of the responses 
represents the score for that sub-scale. The total score is a weighted sum of the 
sub-scale scores. An adult, whose reading comprehension is at fifth grade level, 
can complete the 31 items in approximately 10 minutes (Cramer, 1999).
Sixteen of the QOLEE-31 items were drawn from existing sources and 15 
items were developed de novo by the QOLIE Development Group. The five- 
item emotional well-being and four-item energy/fatigue scales of the QOLIE-31 
are identical to these scales in the RAND 36-Item Health Survey 1.0 (Hays 
et al., 1993). Items in this 36-item measure were adapted from longer instru­
ments completed by patients participating in the Medical Outcomes Study 
(MOS), an observational study of variations in physician practice styles and 
patient outcomes in different systems of health care delivery (Stewart et al.,
1992). The QOLIE-31 cognitive function and social function scales each con­
tain one item incorporated from MOS instruments. The QOLIE-31 also contains 
an overall quality of life scale that is comprised of one item from a study on 
patient preferences (Hadom and Hays, 1991) and one Dartmouth COOP Chart 
(Nelson et al., 1990). One seizure worry item and one cognitive function item 
were originally developed for the ESI-55 (Devinsky, 1993). The single item on 
overall health was adapted from an existing visual analogue scale (Brazier et al.,
1993) and added to the QOLIE-31 subsequent to field testing of the other 30 
items (Cramer et al., 1998).
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AIMS OF THE STUDY
Although epilepsy is one of the oldest known and the most common of the 
chronic neurological disorders the accompanying substantial psychosocial 
problems and limitations on peoples’ everyday-life are still underestimated in 
modem society. Stigmatisation in epilepsy, employment of the people with the 
disease, impact of epilepsy and its therapy on social adjustment as well as the 
QOL measures used in the studies conducted in recent years vary in different 
countries and depend on the society’s background and arrangement in 
healthcare system. The QOL information of the people with epilepsy living in 
the Eastern European countries has been insufficiently investigated.
Therefore, the study was conducted to pursue the following objectives:
• to test the acceptability, reliability and validity of the RAND 36-Item 
Health Survey 1.0 and the QOLIE-31 questionnaires in the groups of 
Estonian people;
• to examine the impact of epilepsy and its treatment on employment status 
and the extent of stigma among individuals with epilepsy;
• to describe the general health status and QOL for patients with epilepsy 
from two different towns of Estonia on the basis of the above-mentioned 
scales;
• to analyse how it is affected by the characteristics of epilepsy ;
• to analyse how it is affected by the socio-demographic characteristics of the 
patients.
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PATIENTS AND METHODS
1. Study design and population
The research took place in 1997-98. The QOL data was collected from respon­
dents with epilepsy living in two towns of Estonia — Tartu and Viljandi. Tartu, 
with a population of 100 977 is the country’s second largest city. Southern 
Estonia revolves around Tartu, which is the intellectual and educational centre 
of Estonia. Viljandi County, with a population of 62 782, is located in south- 
central Estonia (Statistical Office of Estonia, 1998). The administrative centre 
of the county is the town of Viljandi, the country’s sixth largest town by its 
population and is situated 81 kilometres from Tartu. In Tartu, the study 
followed an epidemiological survey of epilepsy (Õun et a l accepted for publi­
cations; Õun et al., accepted for publication-b). The epidemiological survey 
included persons who were residents of Tartu, were aged 20 and over and had, 
before or during the period 01.01.1991-01.01.1996, suffered at least two 
unprovoked epileptic seizures, at least one of them within the previous five 
years. Data collection for the epidemiological study consisted of two parts: data 
registration from a multi-source medical register review and data registration 
from a personal case re-examination. Case records of patients treated at the 
University Hospital, Outpatients’ Clinics, physicians’ offices, emergency rooms 
or the EEG laboratory with a diagnosis of epilepsy, convulsions, syncope, 
amnestic attacks or abnormal involuntary movements were reviewed and 
invitations for re-examination were sent to the relevant persons. During the last 
two years, all the patients were re-examined at least once by a neurologist in 
order to specify the type of their seizures.
2. Diagnostic criteria
The study included persons with epilepsy who were aged 20 and older and had 
had at least two unprovoked epileptic seizures, at least one of them within the 
previous five years. Persons with provoked and acute symptomatic seizures 
were excluded.
3. Clinical data
Our study focused on the analysis of data collected from a sample of 203 
patients in the 20-72 age group. The patients were selected at random from the
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preliminary lists of the epidemiological study conducted in Tartu, excluding 
people who were not capable of understanding Estonian (mostly Russian- 
speakers) because no sufficiently well translated and validated questionnaire 
was available. In Viljandi, primary information about people with epilepsy was 
gathered through the local epilepsy support group, and clinical information was 
abstracted from medical notes held in the County Hospital and Outpatients’ 
Clinic Register. To evaluate the accuracy of diagnoses, the problematic cases 
were investigated and re-examined if necessary. All patients gave their consent 
for participation in the research and the project was approved by the Ethics 
Committee of the University of Tartu. In addition, a control group of 200 
healthy subjects corresponding in age, sex, and educational level was randomly 
selected from among the patients receiving treatment from dentists at the 
University’s Dental Clinic. All of the respondents possessed at least a basic edu­
cation with sufficient ability to read and write, and were capable of understan­
ding and completing the questionnaires.
4. Measures
Clinical information, if needed, was, once again abstracted from medical notes 
and also during the personal re-examination of subjects. Abstracted information 
used in the study related to the aetiology of epilepsy, classification of seizure 
type and current AED therapy. To evaluate the impact of epilepsy on employ­
ment status and perceived stigma, the patients were sent a questionnaire by 
mail. The questionnaire employed a combination of open questions (Appendix 
1) together with previously translated and validated scales (The Stigma of 
Epilepsy Scale, the RAND 36-Item Health Survey 1.0 (Appendix 2) and the 
QOLIE-31 (Appendix 3)). In addition, single items were included which 
referred specifically to feelings of stigmatisation in the area of employment. The 
questionnaire contained a number of scales and questions covering the fol­
lowing issues: (1) Demographic characteristics — information was obtained 
about subjects’ sex, age, marital and employment status, and educational level. 
(2) Economic and financial status — patients were asked to state whether they 
considered it to be “very good”, “good”, “satisfactory”, “moderately bad”, or 
“very bad”. (3) Seizure frequency — patients were asked whether they had had 
seizures once or more in a month, less often than once a month, or not at all in 
the past year. (4) Injuries associated with seizures — subjects, who had had at 
least one seizure in the past year, were asked whether they had had a bum or 
scald, a head injury, milder injuries (including dental injuries), any other 
injuries (unspecified) or no injuries. (5) History of the epilepsy — patients were 
asked about age at first attack. (6) Previous research has shown that patients’ 
perception of the severity of their seizure disorder may be more important than
10 37
seizure frequency in determining their psychological and social well-being 
(Baker et al., 1991). Therefore subjects were asked to assess their seizures as 
“very severe”, “severe”, “medium”, or “light”. (7) AED treatment and side 
effects — patients were asked about the AED they were taking and about the 
experienced side effects during the past month, as well about satisfaction with 
the current treatment and about changes in AED medication in the past year. (8) 
Compliance with medication — patients were asked to state whether they never 
missed taking their AEDs, missed less often than once a month, missed less 
often than once a week, or missed more often than once a week. According to 
other studies, correlation between patient report and objective method have 
been shown to be high (Patrick and Erickson, 1993). (9) Perceived stigma was 
measured with a three-item scale, developed originally for stroke (Hyman, 
1971), adapted for epilepsy and already used in other QOL studies (Baker et al., 
1997a; Jacoby et al., 1996). Respondents with epilepsy had to state whether 
they (a) felt that other people were uncomfortable with them, (b) treated them as 
inferior, or (c) preferred to avoid them. Each of the three items required a yes/no 
response. An individual’s score was the sum of the “yes” responses and the 
higher the score; the greater was the perception of stigma. The internal 
consistency of the scale was examined using Cronbach’s a and found to be 
acceptable (a=0.71) (Cronbach, 1951). The evidence for the construct validity 
of the scale was supported by the data received following the hypotheses that 
patients with frequent seizures and mixed seizure types would score positively 
on the scale. (10) The impact of epilepsy on employment history — those 
currently un- or underemployed were asked whether this was caused by their 
epilepsy, whether they had changed jobs in the preceding two years because of 
epilepsy, and whether they had been treated unfairly at work because of 
epilepsy. Each of the items required a yes/no response.
Patients were divided into three groups by seizure type (as having only 
tonic-clonic, only other types, or both tonic-clonic and other types) and fre­
quency (based on seizure occurrence once or more a month, less often than once 
a month, or not at all in the past year).
(11) Driving license — patients were asked to state whether they had never 
had a driving license, whether they had it, or whether its validity was suspended 
because of their epilepsy. (12) Health status — respondents were asked to 
complete a comprehensive generic health status measure, the RAND 36-Item 
Health Survey 1.0 (RAND-36), which consisted of eight multi-item variables: 
Physical functioning (PF) — ten items, Social functioning (SF) — two items, 
Role limitations due to physical problems (RP) — four items, Role limitations 
due to emotional problems (RE) — three items, Emotional well-being (EW) — 
five items, Energy and vitality (VT) — four items, Bodily pain (BP) — two 
items, and General perception of health (GH) — five items. There was a further 
unsealed single item on changes in respondents’ health over the past year 
(CHG). As indicated in standard RAND-36 scoring algorithms, for each variab­
le item scores were coded, summed, and transformed onto a scale from 0 (worst
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possible health state measured by the questionnaire) to 100 (best possible health 
state) (Rand Health Sciences Program, 1992). (13) Epilepsy-specific data about 
QOL that was collected using the QOLIE-31 questionnaire — respondents were 
asked to complete an epilepsy-specific measure, the Quality of Life in Epilepsy 
Inventory-31 (QOLIE-31) (QOLIE Development Group, 1993), which contai­
ned seven multi-item scales: Seizure worry (SW) — five items, Overall quality 
of life (OQL) — two items, Emotional well-being (EWB) — five items, 
Energy/fatigue (E/F) — four items, Cognitive functioning (COG) — six items, 
Medication effects (ME) — three items, Social functioning (SF) — five items. 
A QOLIE-31 overall score was obtained using a weighted average of the multi­
item scale scores. The QOLIE-31 also included a single item that assessed ove­
rall health. During the scoring procedure, first, the raw precoded numeric values 
of items were converted to 0-100 point scores, with higher converted scores 
always reflecting better QOL. Next, the subtotal scores for each scale were 
summed and divided by the number of items that the respondent answered 
within each scale. The QOLIE-31 overall score was calculated by summing the 
product of each scale score times its weight and summing over all scales.
For the use of both questionnaires, written permission was asked and re­
ceived from the RAND Office of Contract and Grant Services in Santa Monica, 
California, USA, in October 1997.
5. Translation procedure of the questionnaires
The scales were translated into Estonian independently by two native Estonian 
speakers who had an excellent knowledge of English. The translators then met 
to discuss and agree upon common versions of the questionnaires. Subse­
quently, the common versions were evaluated by another native Estonian spea­
ker in terms of conceptual equivalence, linguistic performance and clarity. The 
agreed Estonian forms were then translated back into English and rated. If 
modifications were necessary, reformulation was performed in the Estonian 
versions.
6. Piloting
The translated Estonian versions of the RAND-36 and the QOLIE-31 question­
naires were given for self-assessment to 15 epilepsy patients who visited their 
neurologist at the University’s Outpatients’ Clinic. During individual inter­
views, each item and response choice was carefully discussed as to its meaning 
and connotation with the responders. As a result the wording of five questions
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of the RAND-36 and four questions of the QOLIE-31 was altered slightly. Then 
the questionnaires were mailed by post to 15 epilepsy patients. The goal of this 
administration was to detect problems with the forms in terms of missing data, 
inconsistent answers and ease of administration. No respondent found the 
questionnaires either difficult or too personal.
A question, concerning problems with driving for patients on AED treat­
ment, was excluded during the scoring procedure from the QOLIE-31 question­
naire for those who did not have a driving-license because it did not directly 
assess the Social function domain in these people. The reason was, as in our 
society, it is quite common for older people, especially for women, not to have a 
driving licence or use a car. From 30 patients in the pilot-study, 22 had never 
had a driving licence. From 15 questionnaires mailed to patients, nine of those 
who had reported not having a driving-license had left the question unfilled, 
four reported having had no trouble with it and two marked they had had some 
trouble. Instead, single open questions concerning driving were added to the 
measure.
7. Response to the study and data completeness
Questionnaires were sent to identified individuals by post, with a covering letter 
from the study conducters, explaining the purposes of the study. To those who 
did not respond to the initial questionnaire a reminder was sent about three to 
six weeks later. Questionnaires to be completed individually were mailed to 290 
patients, of whom 225 replied — a response rate of 78%. From all the question­
naires returned, 22 appeared to be unusable; the remaining 203 questionnaires 
were included in the study.
The distribution of responses, by the respondents from the epilepsy group to 
the 36 items of the RAND-36, as well as the number and percentage of patients 
missing each of the 36 items, is given in Table 2. Missing value rates for the 
items were low and did not exceed 1.5% for any item. The total number of 
omitted items per questionnaire was 8.3%. 92% completed all 36 items.
Missing value rates for the items of the QOLIE-31 did not exceed 2% for 
any item. The total number of omitted items per questionnaire was 6.5%. 94% 
completed all 31 items.
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Table 2. RAND-36 item frequency distributions — the epilepsy sample.
Item Nr
Item Missing %
1 2 3 4 5 6 nr
PF1 202 40.1% 33.7% 26.2% 1 0.5
(81) (68) (53)
PF2 202 6.9% 26.7% 66.3% 1 0.5
(14) (54) (134)
PF3 202 10.9% 24.3% 64.9% 1 0.5
(22) (49) (131)
PF4 202 16.3% 34.7% 49.0% 1 0.5
(33) (70) (99)
PF5 202 2.5% 18.8% 78.7% 1 0.5
(5) (38) (159)
PF6 202 17.3% 31.2% 51.5% 1 0.5
(35) (63) (104)
PF7 202 16.3% 20.3% 63.4% 1 0.5
(33) (41) (128)
PF8 202 5.9% 15.4% 78.7% 1 0.5
(12) (31) (159)
PF9 202 3.5% 9.0% 87.5% 1.0
(7) (18) (176)
PF10 202 2.5% 9.4% 88.1% I 0.5
(5) (19) (178)
RP1 202 43.1% 56.9% 1 0.5
(87) (115)
RP2 202 54.5% 45.5% 1 0.5
(110) (92)
RP3 202 49.5% 50.5% 1 0.5
(100) (102)
RP4 202 50.0% 50.0% 1 0.5
(101) (101)
RE1 202 45.1% 55.0% 1 0.5
(91) (111)
RE2 202 61.4% 38.6% 1 0.5
(124) (78)
RE3 202 47.0% 53.0% 1 0.5
(95) (107)
EF1 201 16.9% 29.9% 22.4% 18.9% 10.5% 1.5% 1.0
(34) (60) (45) (38) (21) (3)
EF2 202 21.8% 20.3% 27.2% 19.3% 7.9% 3.5% 1 0.5
(44) (41) (55) (39) (16) (7)
EF3 202 2.5% 9.4% 15.8% 20.8% 25.3% 26.2% 1 0.5
(5) (19) (32) (42) (51) (53)
EF4 202 9.9% 10.9% 24.8% 28.7% 21.3% 4.5% 1 0.5
(20) (22) (50) (58) (43) (9)
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Item Missing
uem ГЧГ 1 2 3 4 5 6 nr
EW1 201 0.5% 9.0% 16.9% 25.9% 31.8% 15.9% 2 1.0
(1) (18) (34) (52) (64) (32)
EW2 202 2.0% 5.0% 12.9% 17.8% 20.8% 41.6% 1 0.5
(4) (10) (26) (36) (42) (84)
EW3 202 4.5% 19.3% 35.2% 15.4% 20.3% 5.5% 1 0.5
(9) (39) (71) (31) (41) (11)
EW4 202 1.5% 10.9% 14.9% 21.8% 31.7% 19.3% 1 0.5
(3) (22) (30) (44) (64) (39)
EW5 202 7.4% 26.7% 25.7% 21.8% 15.8% 2.5% 1 0.5
(15) (54) (52) (44) (32) (5)
SF1 202 3.5% 16.5% 15.5% 28.5% 36% 3 1.5
(7) (33) (31) (57) (72)
SF2 202 5.0% 12.9% 22.8% 17.8% 41.6% 1 0.5
(10) (26) (46) (36) (84)
BP1 202 2.5% 11.4% 19.8% 17.3% 20.8% 28.2% 1 0.5
(5) (23) (40) (35) (42) (57)
BP2 202 5.5% 10.9% 21.3% 23.3% 39.1% 1 0.5
(П ) (22) (43) (47) (79)
GH1 202 16.8% 55.9% 22.8% 3.5% 1.0% 1 0.5
(34) (113) (46) (75) (2)
GH2 202 11.9% 15.4% 32.2% 24.3% 16.3% 1 0.5
(24) (31) (65) (49) (33)
GH3 202 23.8% 22.3% 22.3% 24.8% 6.9% 1 0.5
(48) (45) (45) (50) (14)
GH4 202 6.4% 13.9% 44.1% 15.8% 19.8% 1 0.5
(13) (28) (89) (32) (40)
GH5 202 31.7% 20.3% 20.3% 23.8% 4.0% 1 0.5
(64) (41) (41) (48) (8)
CHG 202 4.5% 22.3% 51.5% 16.8% 5.0% 1 0.5
(9) (45) (104) (34) (10)
8. Psychometric analyses
RAND-36
As Table 3 shows, means and standard deviations (SD) of the scales were in the 
range of 44-77 (SD 21-42) for the epilepsy group and in the range of 66-88 (SD 
9-33) in the control group. In the epilepsy group, mean and median scores were 
higher for Physical function and lower for General health. Skewness, measuring
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the asymmetry of response distributions, was most marked for Physical function 
in the epilepsy group and for Role -  physical in the control group. But most of 
the scales were negatively skewed, meaning that subjects more often gave 
responses representing positive health states. There were substantial ceiling 
effects for four domains — Physical functioning, Role — physical, Role — 
emotional, Social functioning in both groups, in the epilepsy group in addition 
to these — for Bodily pain. Floor effects were significant in two domains in the 
epilepsy group: 31% and 32.5% of subjects had the minimum possible score in 
the Role — physical and Role — emotional domains, respectively. The internal 
consistency coefficients, being above 0.70 for all dimensions, met the level 
acceptable for group comparisons. The internal consistency coefficients ranged 
from 0.75 to 0.92. Scaling assumptions were tested in two ways. Correlations 
between items and hypothesised scales were substantial within each scale and 
reached the level of >0.40 in all instances, supporting the reliability of the 
RAND-36 scales in both groups. In the epilepsy group the lowest median item- 
total correlation was 0.53 for general health, the highest 0.84 for bodily pain. 
Discriminant validity was considered acceptable when the correlation exceeded 
all correlation between items and other scales. All the eight scales in both 
groups passed this level.
The descriptive statistics and reliability data is given in Tables 3 and 4.
Table 3. RAND-36 sub-scale descriptive statistics.
RAND-36
sub-scales
Mean
(0-100) Median SD Range
Skew­
ness
Kurto-
sis
Floor Ceiling
(%) (%)
The epilepsy group
Physical 76.56 85.00 24.26 100.00 -1.14 0.55 1.0 18.2
functioning
Role-physical 50.62 50.00 42.10 100.00 -0.01 -1.69 31.0 33.5
Role-emotional 48.60 33.33 41.59 100.00 0.10 -1.62 32.5 32.5
Energy/ 47.64 50.00 22.14 100.00 0.01 -0.73 1.0 0.5
fatigue
Emotional 59.80 60.00 20.49 96.00 -0.27 -0.73 0 0.5
well-being
Social 69.40 75.00 27.68 100.00 -0.54 -0.78 1.5 28.1
functioning
Pain 67.69 70.00 28.67 100.00 -0.55 -0.73 2.5 26.1
General health 43.89 45.00 22.46 95.00 0.12 -0.92 2.0 0
The control group
Physical 87.20 87.00 9.42 30.00 -0.15 -0.83 0 25.0
functioning
Role-physical 86.71 100.00 20.76 100.00 -2.36 6.70 3.0 59.0
Role-emotional 69.13 66.00 33.11 100.00 -0.66 -0.75 8.5 45.0
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RAND-36
sub-scales
Mean
(0-100) Median SD Range
Skew­
ness
Kur-
tosis
Floor Ceiling
(%) (%)
Energy/fatigue 65.54 64.00 12.36 76.00 -0.19 0.90 0 0.5
Emotional
well-being 67.12 64.00 16.92 72.00 -0.05 -0.27 0 3.0
Social functioning 87.82 88.00 11.50 62.00 -1.11 1.83 0 32.5
Pain 78.97 80.00 12.44 78.00 -1.94 5.72 0 3.5
General health 66.85 64.00 14.09 60.00 0.54 0.25 0 3.0
Table 4. Results of scaling success tests and reliability estimates.
Dimension Internal
consis­
tency3
Homo-
genityb
Item
discriminant
validity0
Cron­
bach’s a
Reliability
coefficients
The epilepsy group
Physical functioning 0.55-0.80 0.55 0.21-0.70 0.92 0.91
Role limitations 0.67-0.76 0.61 0.34-0.63 0.86 0.86
(physical problems) 
Role limitations 0.58-0.67 0.56 0.31-0.60 0.79 0.78
(emotional problems) 
Energy/fatigue 0.59-0.73 0.57 0.35-0.69 0.84 0.83
Emotional well-being 0.52-0.75 0.55 0.22-0.74 0.86 0.85
Social functioning 0.62 0.63 0.49-0.61 0.77 0.77
Pain 0.84 0.84 0.52-0.67 0.91 0.90
General health 0.54-0.79 0.53 0.31-0.64 0.85 0.83
The control group
Physical functioning 0.57-0.72 0.55 0.44-0.70 0.77 0.75
Role limitations 0.42-0.69 0.41 0.35-0.61 0.76 0.78
(physical problems) 
Role limitations 0.58-0.76 0.52 0.55-0.72 0.80 0.80
(emotional problems) 
Energy/fatigue 0.56-0.68 0.55 0.40-0.65 0.76 0.75
Emotional well-being 0.68-0.73 0.60 0.57-0.70 0.88 0.88
Social functioning 0.61 0.59 0.42-0.60 0.79 0.78
Pain 0.53-0.76 0.48 0.48-0.69 0.82 0.81
General health 0.47-0.69 0.50 0.43-0.63 0.74 0.75
“Correlations, corrected for overlap, between items and hypothesised scales, 
bAverage inter-item correlation 
Correlations between items and other scales
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QOLIE-31
As Table 5 shows, means and standard deviations of the scales were in the 
range of 48-64 (SD 18-26). The mean and median scores were higher for 
medication effects and lower for Energy/fatigue. Skewness was most marked 
for Seizure worry. But also most of the scales were negatively skewed, meaning 
that subjects more often gave responses representing positive health states. 
There were substantial ceiling effects for two domains — Energy/fatigue and 
Social functioning. Floor effects were significant in two domains: 3.45% and 
1.97% of subjects had the minimum possible score in the Seizure worry and 
Medication effects domains, respectively. The internal consistency coefficients, 
being above 0.70 for all dimensions, met the level acceptable for group 
comparisons. The internal consistency coefficients ranged from 0.71 to 0.88. 
Scaling assumptions were tested in two ways. Correlations between items and 
hypothesised scales were substantial within each scale and reached the level of 
>0.40 in all instances, supporting the reliability of the QOLIE-31 scales. The 
lowest median item-total correlation was 0.43 for Medication effects, the 
highest 0.62 for Overall quality of life. Discriminant validity was considered 
acceptable when correlation exceeded all correlation between items and other 
scales. All the seven scales passed this level.
The data about the descriptive statistics and reliability is given in Tables 5 
and 6.
Table 5. QOLIE-31 sub-scale descriptive statistics.
QOLIE-31
sub-scales
Mean
(0-100) Median SD Range
Skew­
ness
Kurto-
sis
Floor
(%)
Ceiling
(%)
Seizure 54.67 60 26.26 95 -0.43 -0.97 3.45 0.49
worry
Overall qua­ 49.18 50 17.59 95 0.31 0.12 0.49 0.49
lity of life 
Emotional 60.14 60 19.95 100 -0.30 -0.75 0.49 0.49
well-being
Energy/ 48.40 50 20.17 85 -0.11 -0.70 0.49 4.43
fatigue
Cognitive 59.41 61.95 23.75 92.50 -0.32 -0.85 0.49 0.99
functioning
Medication 63.64 63.90 27.70 88.90 0.11 1.05 1.97 0.49
effects
Social 63.54 65 25.08 95 -0.29 -0.83 0.49 11.33
functioning
Overall 57.38 50 18.50 100 0.01 0.2 0 0
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Table 6. Results of scaling success tests and reliability estimates.
Dimension
Internal
consis­
tency8
Homo-
genityb
Item
discriminant
validity0
Cron­
bach’s a
Reliability
coefficients
Seizure worry 0.59-0.81 0.56 0.21-0.57 0.86 0.86
Overall quality of life 0.62 0.62 0.28-0.67 0.77 0.77
Emotional well-being 0.59-0.75 0.55 0.23-0.73 0.85 0.86
Energy/fatigue 0.53-0.67 0.50 0.19-0.69 0.79 0.80
Cognitive functioning 0.62-0.75 0.55 0.28-0.59 0.88 0.88
Medication effects 0.38-0.50 0.43 0.20-0.48 0.72 0.71
Social functioning 0.51-0.65 0.47 0.30-0.64 0.77 0.78
Overall 0.74 - - 0.89 0.90
Correlations, corrected for overlap, between items and hypothesised scales. 
bAverage inter-item correlation 
Correlations between items and other scales
9. Validity
Validity of both scales was assessed using discriminant techniques. The RAND- 
36's and QOLIE-3l’s ability to distinguish between high and a low symptom 
load was determined assessing by seizure type and frequency.
RAND-36
The descriptive statistics and features of score distribution for the RAND-36 
scales are detailed in Tables 7 and 8. Variance between seizure types was sta­
tistically significant in five RAND-36 domains. The comparisons between 
groups were investigated for each domain using Tukey’s studentized range test 
at the 0.05 level. Patients who did not have generalised tonic-clonic seizures or 
multiple seizure types had significantly higher scores in the Role — physical 
and Social functioning. Those who had multiple seizure types had lower scores 
than those with only tonic-clonic seizure types or those with other types of 
seizures only in the Role — emotional. Those who experienced multiple seizure 
types scored significantly lower in the Emotional well-being and Bodily pain 
domains compared to those who did not have generalised tonic-clonic seizures. 
(Fig. 1)
Variance between seizure frequency statuses was statistically significant in 
seven domains. The differences were significant between all the three groups in 
the Role — emotional domain. Between those who had not had seizures in the 
past year and those who had had seizures at least once a month or less often 
than once a month the differences were significant in the Role limitations -  
physical, Energy/fatigue, and General health domains. Those experiencing
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seizures once or more in a month scored significantly worse in the Role 
limitations — emotional, Emotional well-being and Social functioning compa­
red to those who had been seizure-free in the last year. In the Bodily pain 
domain, the differences were significant between those having seizures once or 
more in a month compared to those who had had seizures less often than once a 
month or had not had them in the last year. (Fig. 2)
Discriminative power was examined by comparing RAND-36 score profiles 
of the healthy respondents and respondents with epilepsy. As shown in Fig. 3, 
the respondents with epilepsy scored significantly lower in all RAND-36 
domains than the controls (p<0.001), indicating that their perceived health status 
was poorer. The differences were most remarkable in Role — physical, Role — 
emotional, Social functioning and General health domains. (Table 9)
PF R P _______ R £ ________EF _  EW________ SF___  BP CHG
! -  ♦  • Tonic-clonic only ■  Tonic-donic and others 1 
I -A --O th ers  only_______________ ,_____________________ j
Fig. 1. Comparison of mean scores for the RAND-36 health status measure by seizure 
type.
* Test of significance was Kruskal-Wallis one-way analysis of variance.
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Table 7. Descriptive statistics and features of score distributions for the RAND-36 Health Survey by seizure type.
Domain
Tonic-clonic only (n=84) Tonic-clonic and others (n=61) Others only (n=58) p-value*
Mean Median Cl SEM Mean Median Cl SEM Mean Median Cl SEM
Physical functioning 74.5 87.5 68.7-80.4 2.9 74.2 75 67.4-79.0 2.9 83.0 90 77.7-88.4 2.7 0.06
Role-physical 48.5 25 39.1-57.9 4.7 43.9 25 32.5-55.2 5.7 60.8 62.5 51.2-70.3 4.8 0.05
Role-emotional 51.6 33.3 42.5-60.7 4.6 39.9 33.33 29.5-50.3 5.2 53.5 66.66 42.6-64.3 5.4 0.03
Energy/fatigue 46.0 45 40.9-51.2 2.6 45.2 50 39.7-50.6 2.7 52.6 55 47.2-57.9 2.7 0.1
Emotional well-being 60.8 64 56.4-65.1 2.2 55.2 56 49.5-60.9 2.8 63.2 64 58.3-68.2 2.5 0.02
Social functioning 67.7 75 61.6-73.9 3.1 62.5 62.5 55.4-69.6 3.6 79.1 87.5 72.8-85.4 3.1 0.006
Bodily pain 68.4 68.75 62.2-74.6 3.1 60.1 67.5 52.2-67.9 3.9 74.6 77.5 68.1-81.1 3.3 0.04
General health 42.1 40 37.4-46.9 2.4 43.9 40 37.6-50.1 3.1 46.5 45 40.9-52.0 2.8 0.4
Cl, 95% confidence interval; SEM, standard error of the mean.
* Variance between seizure types. Test of significance was Kruskal-Wallis one-way analysis of variance.
Table 8. Descriptive statistics and features of score distributions for the RAND-36 Health Survey by seizure frequency status in the last year.
Domain
>1 seizure a month (n=53) <1 seizure a month (n=81) seizure free (n-69) p-value*
Mean Median Cl SEM Mean Median Cl SEM Mean Median Cl SEM
Physical functioning 73.0 75 67.3-78.7 2.8 74.3 85 68.5-80.2 2.9 81.9 90 76.3-87.5 2.8 0.07
Role-physical 33.5 25 23.4-43.6 5.0 49.4 50 40.3-58.5 4.6 65.2 100 55.1-75.4 5.1 0.0001
Role-emotional 27.0 30 17.7-36.4 4.7 49.0 33.33 39.9-58.1 4.6 64.7 100 55.0-74.4 4.9 0.0001
Energy/fatigue 45.1 50 39.7-50.5 2.7 43.2 40 38.2-48.2 2.5 54.8 60 49.5-60.1 2.6 0.004
Emotional well-being 55.1 56 49.6-60.6 2.7 58.4 60 53.8-63.0 2.3 65.0 72 60.3-69.8 2.4 0.02
Social functioning 59.2 62.5 51.6-66.8 3.8 69.1 75 63.0-75.3 3.1 77.5 87.5 71.5-83.5 3.0 0.001
Bodily pain 56.2 57.5 48.1-64.3 4.0 68.1 77.5 61.8-74.4 3.1 76.1 80 69.9-82.2 3.1 0.0006
General health 39,3 40 33.6-44.9 2.8 41.0 40 36.0-45.9 2.5 50.9 50 45.4-56.3 2.7 0.005
Cl, 95% confidence interval; SEM, standard error of the mean.
* Variance between seizure frequencies. Test of significance was Kruskal-Wallis one-way analysis of variance.
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Fig. 2. Comparison of mean scores for the RAND-36 health status measure by seizure 
frequency status.
* Test of significance was Kruskal-Wallis one-way analysis of variance.
Table 9. Mean scores of dimensions of RAND-36 questionnaire
Dimension Epilepsygroup
Control
group p-value*
Physical functioning 76.56 87.20 0.0001
Role limitations 50.62 86.71 0.0001
(physical problems)
Role limitations 48.60 69.13 0.0001
(emotional problems)
Energy/fatigue 47.64 65.54 0.0001
Emotional well-being 59.80 67.12 0.001
Social functioning 69.40 87.82 0.0001
Bodily pain 67.69 78.97 0.0001
General health 43.89 66.85 0.0001
* Variance between groups. Test of significance was Kruskal-Wallis one-way analysis 
of variance.
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Fig. 3. Discriminative power of RAND-36.
Comparison of mean scores for the RAND-36 health status measure: people with 
epilepsy and the control group.
* Test of significance was Kruskal-Wallis one-way analysis of variance
QOLIE-31
The descriptive statistics and features of score distribution for the QOLIE-31 
scales are detailed in Tables 10 and 11. Variance between seizure types was 
statistically significant in four QOLIE-31 domains. The comparisons between 
groups were investigated for each domain using Tukey’s studentized range test 
at the 0.05 level.
Patients who did not have generalised tonic-clonic seizures or multiple 
seizure types had significantly higher scores in the Overall quality of life and 
Social functioning domains. Those who had multiple seizure types had lower 
scores than those with only tonic-clonic seizure types or those with other types 
of seizures only in the Seizure worry and Medication effects. Those who 
experienced multiple seizure types scored significantly lower in the Seizure 
worry, Medication effects and Social functioning domains compared to those 
who did not have generalised tonic-clonic seizures. (Fig. 4) The overall score of 
the QOLIE-31 was significantly different between all the three groups of 
seizure types.
Variance between seizure frequency statuses was statistically significant in 
all seven domains. The differences were significant between all the three groups 
in the Seizure worry, Medication effects and Social functioning domain. 
Between those who had not had seizures in the past year and those who had had 
seizures at least once a month or less often than once a month, there were 
significant differences in the Overall quality of life, Emotional well-being, 
Energy/fatigue, Cognitive function domains and between the values of the 
overall score of the questionnaire. (Fig. 5)
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Table 10. Descriptive statistics and features of score distributions for the QOLIE-31 by seizure type.
Domain
Tonic-clonic only (n=84) Tonic-clonic and others (n=61) Others only (n=58) p-value*Mean Median Cl SEM Mean Median Cl SEM Mean Median Cl SEM
Seizure worry 56.27 60.8 50.8-61.7 2.8 47.83 48.3 40.9-54.8 3.5 59.52 65.7 52.8-66.3 3.4 0.04
Overall quality of life 47.89 50.0 44.2-51.6 1.8 46.27 45.0 41.4-51.2 2.5 54.09 50.0 49.9-58.3 2.1 0.03
Emotional well-being 60.91 62.0 56.7-65.1 2.1 56.85 52.0 51.2-62.5 2.8 62.48 68.0 57.6-67.3 2.4 0.27
Energy/fatigue 46.19 45.0 41.5-50.8 2.3 47.54 45.0 42.4-52.7 2.6 52.50 55.0 47.7-57.3 2.4 0.17
Cognitive functions 60.54 66.1 54.9-66.1 2.8 55.43 56.1 49.5-61.3 2.9 61.96 62.6 56.4-67.5 2.8 0.28
Medication effects 65.04 66.7 59.3-70.8 2.9 58.43 61.1 52.8-66.2 3.4 67.10 62.5 57.6-71.4 3.5 0.05
Social functioning 63.51 65.6 57.9-69.1 2.8 57.68 57.5 51.0-64.4 3.4 69.75 68.8 64.2-75.3 2.8 0.03
Overall 57.50 58.0 53.4-61.6 2.1 53.40 51.3 48.4-58.4 2.5 61.40 59.6 57.1-65.7 2.1 0.05
Cl, 95% confidence interval; SEM, standard error of the mean.
* Variance between seizure types. Test of significance was Kruskal-Wallis one-way analysis of variance.
Table 11. Descriptive statistics and features of score distributions for the QOLIE-31 by seizure frequency status in the last year.
Domain
>1 seizure a month (n=53) <1 seizure a month (n=81) seizure free (n=69) p-value*Mean Median Cl SEM Mean Median Cl SEM Mean Median Cl SEM
Seizure worry 44.76 48.0 37.2-52.3 3.7 53.95 62.7 48.5-59.4 2.8 63.12 70.0 57.2-69.0 3.0 0.0005
Overall quality of life 46.79 50.0 43.4-50.1 1.7 45.15 45.0 41.2-49.1 2.0 55.73 55.0 51.2-60.3 2.3 0.0005
Emotional well-being 57.28 56.0 51.9-62.7 2.7 57.09 60.0 52.6-61.6 2.3 65.91 72.0 61.4-70.4 2.3 0.01
Energy/fatigue 46.51 45.0 41.2-51.8 2.7 44.51 45.0 40.1-48.9 2.2 54.42 55.0 49.6-59.3 2.4 0.008
Cognitive functions 53.10 57.0 47.5-58.7 2.8 56.85 61.1 51.7-62.0 2.6 67.27 73.6 61.3-73.3 3.0 0.002
Medication effects 54.98 55.6 47.4-62.5 3.8 59.57 58.3 54.0-65.2 2.8 75.08 77.8 69.6-82.5 3.2 0.0001
Social functioning 53.36 56.3 47.1-59.6 3.1 61.24 62.5 56.1-66.4 2.6 74.07 82.5 68.1-80.1 3.0 0.0001
Overall 51.50 50.9 47.0-56.0 2.3 54.50 54.4 50.7-58.4 1.9 65.20 69.3 60.7-69.8 2.3 0.0001
Cl, 95% confidence interval; SEM, standard error of the mean.
Variance between seizure frequencies. Test of significance was Kruskal-Wallis one-way analysis of variance.
Fig. 4. Comparison of mean scores for the QOLIE-31 by seizure type. 
Test of significance was Kruskal-Wallis one-way analysis of variance.
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Fig. 5. Comparison of mean scores for the QOLIE-31 by seizure frequency.
* Test of significance was Kruskal-Wallis one-way analysis of variance.
7. Statistical methods
The data were analysed using statistical analysis package SPSS Professional 
Statistics1 M 7.5 (SPSS Inc., 1997). Test of significance was one-way analysis of 
variance (ANOVA). Attention is drawn to results which differences were 
significant at the 5% level or less (p<0.05). The questionnaires were evaluated 
using the data completeness at an individual item and scale level, correlation 
between items and hypothesised scales, correlation between items and other 
scales, average inter-item correlation, internal-consistency reliability (Cron­
bach’s a) and score distributions (floor and ceiling effects, skewness and kurto-
sis). 95% confidence intervals (Cl) were computed to define the range of varia­
tion around the mean. Construct validity was assessed in connection with sei­
zure frequency and seizure type following hypotheses that patients with 
frequent seizures and patients with tonic-clonic or multiple seizure types would 
have poorer health status. To test for such comparisons between groups, 
Tukey’s studentized range test was used for each variable.
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RESULTS
1. Socio-demographic characteristics of the sample
The main data of the respondents from Tartu and Viljandi is given 
comparatively in Table 12. Unfortunately, when analysed separately, there were 
no remarkable statistically significant differences found either between the 
groups or with the factors. This is the reason why the results of the patients 
from two towns were summed up and interpreted together. The median age of 
the study population was 41 years (25th and 75th percentiles 29 and 57). The 
respondents of the study were divided into five age groups: 20-29 years — 
54 (26.6%), 30-39 years — 42 (20.7%), 40-49 years — 35 (17.2%), 50-59 
years — 28 (13.8%), and 60 years and older — 44 (21.7%). Men accounted for 
48.8% (99). 82 (40.9%) were married or cohabiting, 84 (41.4%) were single, 21 
(10.3%) were divorced and 15 (7.4%) were widowed. 90 (44.3%) had less than 
primary (lower than 8th grade) or primary education (8th or 9th grade), and 113 
(55.7%) high school (11th or 12th grade) or university education. 67 (33%) 
were working full-time, 87 (41.9%) were un- or underemployed and 49 (24.1%) 
were retired or receiving disability pension. (Table 13) Only one person (0.5%) 
described his economic and financial status as very good, 17 (8.5%) — as good, 
119 (59%) — as satisfactory, 53 (26.2%) — as moderately bad, 12 (5.9%) — 
as very bad. 71.4% (145) of respondents had never had a driving license, 17.2% 
(35) had a driving license and in 11.3% (23) the driving license was invalidated 
because of their epilepsy.
The median age of the control group was 40 (25th and 75th percentiles 27 
and 56) years. 98 (49%) were men. 16 (8%) had less than primary education 
(lower than 8th level), 64 (32%) had primary education (8th or 9th level), 98 
(49%) had high school education, and 11% had graduated from university.
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Table 12. The main comparative results of the respondents from Tartu and Viljandi.
Parameter
Respondents from 
Tartu 
(total 122)
Respondents from 
Viljandi 
(total 81)
n % n %
Median age 42 years 39 years
Sex (M/F) 56/66 45.9/54.1 43/38 53.1/46.9
Marital status
married/cohabiting 55 45.1 28 34.6
single 45 36.9 39 48.1
divorced 14 11.5 7 8.6
widowed 8 6.5 7 8.6
Employment status
full-time 40 32.8 27 33.3
underemployed 45 36.9 20 24.7
unemployed 7 5.7 15 18.6
retired or receiving disablement 30 24.6 19 23.4
pension
Education
less than primary 8 6.6 14 17.3
(lower than 8th grade)
primary (8th or 9th grade) 41 33.6 27 33.3
high school (11th or 12th grade) 60 49.2 33 40.7
university 13 10.7 7 8.6
Duration of epilepsy
up to 1 year 6 4.9 5 6.2
2-5 years 22 18.0 23 28.4
6-10 years 22 • 18.0 24 29.6
11-20 years 29 23.8 15 18.5
over 20 years 43 35.3 14 17.3
Age at onset
under 10 years 15 12.3 5 6.2
11-20 years old 38 31.1 30 37.0
21-30 years old 25 20.5 13 16.0
31-40 years old 17 13.9 19 23.5
41-50 years old 11 9.0 4 4.9
over 50 years old 16 13.1 10 12.3
Seizure type
tonic-clonic only 47 38.5 37 45.7
tonic-clonic and others 51 41.8 10 12.3
others only 24 19.7 34 42.0
Seizure frequency status in the last 
year
seizure free 39 32.0 30 37.0
<1 seizure a month 46 37.7 35 43.2
>1 seizure a month 37 30.3 16 19.8
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Parameter
Respondents from 
Tartu 
(total 122)
Respondents from 
Viljandi
(total 81)
n % n %
Medication
free of medication 17 13.9 6 7.4
on AED treatment 105 86.1 75 92.6
Of those receiving AED 
medication
on monotherapy 88 83.8 63 84.0
receiving 2 AEDs 11 10.5 11 14.7
receiving >3 AEDs 6 5.7 1 1.3
Type of drug
carbamazepine 64 72.7 49 77.8
valproate 8 9.1 7 11.1
primidone 6 6.8 6 9.5
phenytoin 5 5.7 0 0
phenobarbital 3 3.4 1 1.6
bensobarbital 2 2.3 0 0
Side-effects of the AED therapy
Yes 91 74.6 62 76.5
No 31 25.4 19 23.5
Number of reported side-effects
One 16 17.6 5 8.1
Two 15 16.5 4 6.4
Three or more 60 65.9 53 85.5
Table 13. Socio-demographic characteristics of the study respondents.
Parameter Studyrespondents
%
Age (median) 
Sex (M/F)
41 years 
99/104 48.8/51.2
Marital status
married/cohabiting 83 40.9
single 84 41.4
divorced 21 10.3
widowed 15 7.4
Employment status
full-time 67 33.0
underemployed 65 31.9
unemployed 22 11.0
retired or receiving disablement pension 49 24.1
Education
less than primary (lower than 8th grade) 22 10.8
primary (8th or 9th grade) 68 33.5
high school (11th or 12th grade) 93 45.8
university 20 9.9
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2. Epilepsy characteristics of the sample
The main disease characteristics are presented in Table 14. The median age of 
the onset of epilepsy was 26.9 years, and the median duration of epilepsy was 
11.3 years (25th and 75th percentiles 5.8 and 22.4). Patients were divided into 
five groups by duration of the disease and into six groups by age at onset of 
their epilepsy. 84 (41.4%) reported having only tonic-clonic seizures, 61 (30%) 
reported having both tonic-clonic and other types of seizures, and 58 (28.6%) 
reported having only other types of seizures. Almost a third (69, 34%) had been 
seizure-free in the last year, 81 (39.9%) had less than one seizure a month, and 
53 (26.1%) had one or more seizures a month. Of those who had had at least 
one seizure in the past year (134 patients), 19 (14%) reported having serious 
injuries (bum, scald), 51 (38%) head injuries, 29 (22%) milder injuries or 
headache, 7 (5%) other injuries. More than a fifth (28, 21%) had not expe­
rienced any injuries. Those having seizures once or more in a month (x2=11.89, 
df=2, p=0.001) and those having multiple or generalised tonic-clonic seizure 
types (%2=9.94, df=2, p=0.009) were more likely to report a seizure-related 
injury. 15 (7.4%) described their seizures as very severe, 61 (30%) as severe, 84 
(41.4%) as moderate, and 43 (21.2%) as light. There was a significant 
correlation with the subjective assessment about the severity of the seizures 
(those assessing their seizures as very severe or severe and those considering 
them moderate or light were counted together) with reported seizure-related 
injuries (x2==15.24, df=4, p=0.003). 180 (88.7%) were receiving AED treatment. 
151 (83.9%) of them were receiving monotherapy. The majority (113, 74.8%) 
of those on monotherapy were receiving carbamazepine. The most commonly 
experienced side effects were non-specific: memory problems (31%), tiredness 
(25%), sleepiness (20%), headache (20%) and nervousness (20%). (Table 15) 
From those experiencing any of the symptoms associated with the AED 
treatment, the majority (113, 73.9%) reported having three or more. A third of 
subjects (50, 33%) reported no side effects. The majority of respondents (142, 
78.8%) on AED treatment described their epilepsy as very or fairly well 
controlled by this, 38 (21%) stated that the level of control was unsatisfactory. 
Almost two fifths of respondents 74 (41.1%) receiving medication had changed 
it at least once in the past year; 51 (68.4%) had changed it once, 17 (22.8%) 
twice and 6 (8.8%) three or more times. 59 (79.3%) of those who had changed 
their medication once in the past year had changed it because of unsatisfactory 
control and 15 (20.7%) because of side effects. Compliance with medication: 
101 (56%) of respondents said they never missed taking AEDs, 41 (23%) 
reported missing on average once a month, 25 (14%) reported missing once a 
week, and 13 (7%) more than once a week. 36 (17.7%) had some other disease 
or health problem in addition to epilepsy and 24 (11.8%) were receiving medi­
cal treatment because of these. The most common additional diseases were 
cardiovascular 14 (39%) and rheumatological 12 (33%), followed by the
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diseases of the lungs 5 (13.9%), endocrinological 3 (8.3%), gastrointestinal
1 (2.8%) and renal diseases 1 (2.8%).
Table 14. Disease characteristics of the study respondents.
Parameter Study respondents %
Duration of epilepsy (median) 11.3 years
up to 1 year 11 5.4
2-5 years 45 22.2
6-10 years 46 22.7
11-20 years 44 21.7
over 20 years 57 28.1
Age at onset
under 10 years 20 9.9
11-20 years old 68 33.5
21-30 years old 38 18.7
31-40 years old 36 17.7
41-50 years old 15 7.4
over 50 years old 26 12.8
Seizure type
tonic-clonic only 84 41.4
tonic-clonic and others 61 30.0
others only 58 28.6
Seizure frequency status in the last year
seizure free 69 34.0
<1 seizure a month 81 39.9
>1 seizure a month 53 26.1
Medication
free of medication 23 11.3
on AED treatment 180 88.7
Of those receiving AED medication
on monotherapy 151 83.9
receiving 2 AEDs 22 12.2
receiving >3 AEDs 7 3.9
Type of drug
carbamazepine 113 74.8
valproate 15 9.9
primidone 12 7.9
phenytoin 5 3.4
phenobarbital 4 2.7
bensobarbital 2 1.3
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Table 15. Subjects’ reports of AED side effects by type of the three most often used 
AEDs (number of subjects reporting side effects always, often, or sometimes in the last 
month; in patients receiving monotherapy only).
Reported side effect CBZ n=l 13
VPA
n=15
PRIM
n=12 p-value*
Dizziness 12 0 2 NS
Tiredness 28 5 4 NS
Unsteadiness 16 0 4 0.02
Nausea/vomiting 7 0 1 NS
Skin itch, rash 11 1 3 NS
Sleepiness 26 4 2 NS
Mood changes 19 1 3 NS
Nervousness/agitation 26 3 0 NS
Headache 24 0 5 0.01
Shaky hands 12 3 1 NS
Weight gain 3 2 1 NS
Heart problems 18 0 4 0.03
Hair loss 6 1 0 NS
Difficulty in concentrating 18 3 1 NS
Memory problems 38 2 6 NS
Slurred speech 6 1 0 NS
Double/blurred vision 8 1 0 NS
CBZ-carbamazepine; VPA-valproate; PRIM-primidone.
* Test of significance was x2; NS-not significant.
3. Perceived stigma
More than half of all respondents (106, 52.4%) felt stigmatised by their 
epilepsy. 25 (24.7%) answered “yes” to all three items and this shows that they 
were highly stigmatised. Respondents were more likely to feel stigmatised if 
they had frequent seizures (% =23.57, df=6, p<0.0001) or mixed seizure types 
(%2= 20.65, df=6, p<0.009). (Table 16) At the same time, only 76 (37.4%) 
considered their seizures very severe or severe. Those who had experienced 
seizures during the last year (%2=18.63, df=l, p<0.0001) and those who had 
tonic-clonic type of seizures only or together with other seizure types (x2=7.02, 
df=l, p<0.008) were more likely to score highly (to give two or three “yes” 
answers) on the stigma scale. Stigmatisation was more common among those 
having university or high school education (%2=12.89, df=6, p<0.05). No diffe­
rences were found in scores on the stigma scale by sex, marital status, or 
employment status.
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Table 16. Reported stigma by seizure type and frequency.
Score on stigma scale
Parameter 0 1 2 3
Seizure type
Tonic-clonic only (n=84) 46.4% 27.5% 11.6% 14.5%
Tonic-clonic and other (n=61) 29.8% 27.7% 23.4% 19.1%
Other only (n=58) 65.4% 17.3% 13.5% 3.8%
X2=20.65, p<0.009
Seizure frequency
One or more a month (n=53) 25.6% 27.9% 27.9% 18.6%
Less than one a month (n=81) 45.6% 27.9% 11.8% 14.7%
None in past year (n=69) 68.8% 17.2% 12.1% 6.9%
X2=23.57, p<0.0001
4. Employment status
A third of all respondents were working full-time. Employment status (working 
either full-time or being underemployed; those retired or receiving disability 
pension were excluded) was significantly related to age (%2= 12.02, df=4, 
p=0.03), seizure frequency (%2=10.81, df=2, p=0.004), age at the onset of 
seizures (x2=15.13, df=5, p=0.01) and education (x2=11.38, df=3, p=0.01). 54 
(62%) of those who were un- or underemployed named epilepsy as the 
significant reason for it. Respondents with frequent seizures were more likely to 
believe it (x2=11.03, df=2, p=0.001). During the last two years, 47 (29%) of 
respondents had changed jobs (meaning a change of workplace, not change of 
speciality or loss of job). Men (%2=7.07, df=l, p<0.003) and those with frequent 
seizures (x2=1L79, df=2, p<0.006) were more likely to do this. 74 (44%) said 
that they had been treated unfairly at work or when getting a job. There were 
significant interactions between this opinion and seizure frequency, type and 
education: respondents with frequent seizures (%2= 16.26, df=2, p=0.0001), 
respondents having tonic-clonic or multiple seizure types (%2=8.94, df=l, 
p=0.002) and respondents who had lower than high school education (%2=7.32, 
df=l, p=0.007) were more likely to report this. Although it was not asked, 
several respondents commented on the fact that they had hidden their diagnosis 
of epilepsy from employers and colleagues because of the fear of discrimination 
and shame. Also, there was a significant interaction between full-time work and 
educational level (those retired or receiving a disablement pension were 
excluded): the higher the person’s education, the more likely he or she was to be 
working full-time (%2=12.12, df=6, p=0.04).
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5. Results of the RAND-36 
(including comparison with the control group)
The results of the final models fitted to each RAND-36 domain score, including 
the factors that remain significant after controlling for the others, are shown in 
Table 17. Each multi-factor model is a main effect model (no significant 
interactions were found between the factors). Pairs of groups of significantly 
different factors were compared using Tukey HSD or Bonferroni’s procedures. 
Scores of the RAND-36 domains were first compared in terms of the clinical 
variables. Significant differences were found for seizure frequency in all 
domains, except the Physical functioning domain. Seizure-free patients scored 
significantly higher than patients who had experienced seizures during the last 
year in the Role limitations — physical, Energy/fatigue, Bodily pain, and 
General health domains. The difference between those who had had seizures 
once or more in a month compared to those having seizures less often than once 
a month or not having seizures during the last year was significant in the Role 
limitations-emotional, Emotional well-being, and Social functioning domains.
In the Role limitations-physical domain, age, stigmatisation, stigma severity, 
and age at onset of epilepsy became significant after controlling for seizure 
frequency. Younger people were less likely to score low in this domain, and 
there were significant differences between the 20-29 and 30-39 age groups 
compared to people who belonged to the 60 years and over age group. Mean 
scores for this domain were significantly lower for those who were stigmatised, 
and for those who expressed very strong feelings of stigma (gave three “yes” 
answers on the stigma scale) compared to those who expressed less (one “yes” 
answer). Later age at onset was associated with lower scores, differences were 
significant between those for whom epilepsy had been diagnosed at the age of 
41-50 or above 50 compared to those for whom it had been diagnosed at an age 
under 20.
In the Role limitations — emotional domain, mean scores were significantly 
lower for those who were stigmatised and for those who expressed very strong 
feelings of stigma (gave three “yes” answers on the stigma scale) compared to 
those who expressed themselves less strongly (one “yes” answer).
In the Energy/fatigue domain, employment status, duration of epilepsy, and 
age at onset of epilepsy were significant. In this domain, mean scores were 
significantly lower for those currently unemployed, in comparison to those who 
were in full-time or underemployed work, for those who had suffered from 
epilepsy for two to five, and six to ten years compared to those who had 
suffered longer and for those whose epilepsy had been diagnosed at the age of 
41-50 or over 50 compared to those for whom it had been diagnosed at an age 
under 20 years.
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Table 17. Results of the RAND-36 using analysis of variance models.
Domains Factors Mean square ratio p-value
Physical functioning Stigmatisation 4.78 0.03
Age at onset 3.65 0.001
Current age 4.39 0.001
Role limitations Seizure frequency 9.27 0.0001
(physical problems) Current age 3.54 0.02
Stigmatisation 8.93 0.003
Stigma severity 4.16 0.02
Age at onset 3.15 0.01
Role limitations Seizure frequency 13.89 0.0001
(emotional problems) Stigmatisation 7.91 0.005
Stigma severity 3.47 0.03
Energy/fatigue Seizure frequency 24.20 0.0001
Employment 3.26 0.02
Duration of disease 3.27 0.02
Age at onset 2.66 0.03
Emotional well-being Seizure frequency 3.96 0.03
Stigmatisation 4.27 0.04
Duration of disease 3.27 0.02
Social functioning Seizure frequency 11.88 0.0001
Stigmatisation 6.98 0.01
Stigma severity 8.83 0.0007
Employment 23.85 0.0001
Seizure type 5.88 0.003
Age at onset 3.34 0.007
Bodily pain Seizure frequency 7.76 0.0006
Duration of disease 2.44 0.05
General health Seizure frequency 5.36 0.005
Age at onset 3.25 0.009
Stigmatisation 4.69 0.03
Stigma severity 3.82 0.03
In the Emotional well-being domain, those who were stigmatised had signi­
ficantly lower scores than those who were not and of those who had suffered 
from epilepsy two to five years compared to those who had suffered more than 
twenty years.
In the Social functioning domain, stigmatisation, stigma severity, employ­
ment status, seizure type, and age at onset of seizures became significant. 
Significantly lower scores were obtained by those who were stigmatised, those 
who expressed very strong feelings of stigma (gave three “yes” answers) com­
pared to those who did not feel this so strongly (one “yes” answer), those who 
were currently unemployed compared to those who were in full-time employ­
ment or underemployed, those who experienced either tonic-clonic or multiple 
seizure types compared to those who had only other types of seizures, and those
62
for whom epilepsy had been diagnosed at the age of 41-50 or over 50 compared 
to those for whom it had been diagnosed at an age under 20 years.
In the Bodily pain domain, lower scores were related to a shorter (2-5 years) 
rather than longer (11-20 and more than 20 years) duration of epilepsy.
In the General health domain, mean scores were significantly lower for those 
whose epilepsy had been diagnosed at the age of 41-50 or over the age of 50 
compared to those for whom it had been diagnosed at under the age of 20. 
Those who were stigmatised also scored significantly lower than those who 
were not, and those who expressed very strong feelings of stigma (gave three 
“yes” answers) in comparison to those who did not (one “yes” answer).
In the Physical functioning domain, stigmatisation, age at onset, and current 
age were found to be significant. Mean scores in this domain were significantly 
lower for those who were stigmatised compared to those who were not and for 
those aged 60 years or older compared to those 20-29 years old. The overall 
pattern of variation in terms of age at onset was similar to that in the General 
health domain.
6. Results of the QOLIE-31
As with the RAND-36 questionnaire, scores of the QOLIE-31 domains were 
first compared in terms of the clinical variables. Significant differences were 
found for seizure frequency in all domains. The results of the final models after 
controlling for seizure status are shown in Table 18.
In the Seizure worry domain, seizure type, education, type of AED therapy, 
stigmatisation and stigma severity remained significant. Significantly lower 
scores were obtained by those who experienced either tonic-clonic or multiple 
seizure types compared to those who had only other types of seizures, those 
who had high school or university education compared to those who had pri­
mary or less than primary education, those who were on polytherapy compared 
to those on monotherapy, those who were stigmatised, and those who expressed 
very strong feelings of stigma (gave three “yes” answers) compared to those 
who did not (one “yes” answer).
In the Overall quality of life domain, seizure type, stigmatisation, age at onset, 
marital status, employment, type of AED therapy and AED side effects remai­
ned significant. Significantly lower scores were obtained by those who expe­
rienced either tonic-clonic or multiple seizure types compared to those who had 
only other types of seizures, those who expressed very strong feelings of stigma 
(gave three “yes” answers) compared to those who did not (one “yes” answer), 
those for whom epilepsy had been diagnosed at the age of 41-50 or above 50 
compared to those for whom it had been diagnosed at an age under 20, those 
who were married or cohabiting compared to those who were single, those who 
were currently unemployed compared to those who were in full-time employment
63
Table 18. Results of the QOLIE-31 using analysis of variance models.
Domains Factors Mean square ratio p-value
Seizure worry Seizure frequency 25.46 0.0001
Seizure type 4.26 0.03
Education 2.45 0.04
Type of AED therapy 3.89 0.005
Stigmatisation 5.73 0.001
Stigma severity 5.68 0.02
Overall quality of life Seizure frequency 15.47 0.0001
Seizure type 12.86 0.004
Stigmatisation 8.35 0.007
Age at onset 7.32 0.008
Marital status 4.12 0.01
Employment 3.68 0.03
Type of AED therapy 3.53 0.03
AED side effects 2.75 0.04
Emotional well-being Seizure frequency 6.36 0.001
Duration of epilepsy 4.25 0.003
Employment 3.78 0.04
AED side effects 2.74 0.05
Energy/fatigue Seizure frequency 7.36 0.0007
Age at onset 4.71 0.004
Employment 4.24 0.02
AED side effects 2.52 0.05
Cognitive function Seizure frequency 9.36 0.0003
Age at onset 4.71 0.006
Education 4.42 0.009
Type of AED therapy 3.59 0.01
AED side effects 2.82 0.04
Stigmatisation 2.63 0.04
Medication effects Seizure frequency 6.47 0.003
AED side effects 3.92 0.007
Stigmatisation 3.54 0.03
Stigma severity 2.94 0.05
Social functioning Seizure frequency 15.63 0.0001
Marital status 4.27 0.006
Employment 5.76 0.005
AED side effects 3.38 0.03
Stigmatisation 3.41 0.03
Stigma severity 3.35 0.05
Overall Seizure frequency 11.24 0.0001
Stigmatisation 4.67 0.03
Stigma severity 4.83 0.01
Age at onset 3.74 0.01
AED side effects 3.95 0.05
Type of AED therapy 3.48 0.05
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or underemployed, those who were on polytherapy compared to those on mono­
therapy, arid those who stated having experienced side effects of the AEDs.
In the Emotional well-being domain, duration of epilepsy, employment, and 
AED side effects remained significant. Significantly lower scores were obtained 
by those who had suffered from epilepsy for two to five years compared to 
those who had suffered more than twenty years, those who were currently 
unemployed compared to those who were in full-time employment or underem­
ployed, and those who stated having experienced side effects of the AEDs.
In the Energy/fatigue domain, age at onset, employment, and AED side 
effects remained significant. In this domain, scores were significantly lower for 
those whose epilepsy had been diagnosed at the age of 41-50 or over 50 
compared to those for whom it had been diagnosed at an age under 20 years, for 
those who were currently unemployed compared to those who were in full-time 
employment or underemployed, and for those who stated having experienced 
side effects of the AEDs.
In the Cognitive functions domain, age at onset, education, type of AED the­
rapy, AED side effects, and stigmatisation remained significant. Significantly 
lower scores were obtained by those for whom epilepsy had been diagnosed at 
the age of 41-50 or over 50 compared to those for whom it had been diagnosed 
at an age under 20 years, those who had had primary or less than primary 
education compared to those who had high school or university education, those 
who were on poly therapy compared to those on monotherapy, those who stated 
having experienced side effects of the AEDs and those who were stigmatised.
In the Medication effects domain, AED side effects, stigmatisation, and 
stigma severity remained significant. Significantly lower scores were obtained 
by those who stated having experienced side effects of the AEDs, those who 
were stigmatised, and those who expressed very strong feelings of stigma (gave 
three “yes” answers) compared to those who did not (one “yes” answer).
In the Social functioning domain, marital status, employment, AED side 
effects, stigmatisation, and stigma severity remained significant. Significantly 
lower scores were obtained by those who were single, divorced or widowed 
compared to those who were married, for those who were currently unemployed 
or retired compared to those who were in full-time employment or unde­
remployed, those who stated having experienced side effects of the AEDs, those 
who were stigmatised, and those who expressed very strong feelings of stigma 
(gave three “yes” answers) compared to those who did not (one “yes” answer).
In the Overall score, stigmatisation, stigma severity, age at onset, AED side 
effects, and type of AED therapy remained significant. Significantly lower sco­
res were obtained by those who were stigmatised, those who expressed very 
strong feelings of stigma (gave three “yes” answers) compared to those who did 
not (one “yes” answer), those for whom epilepsy had been diagnosed at the age 
of 41-50 or over 50 compared to those for whom it had been diagnosed at an 
age under 20 years, those who stated having experienced side effects of the 
AEDs, and those who were on polytherapy compared to those on monotherapy.
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DISCUSSION
1. Study area and socio-demographic characteristics 
of the study population
Our study focused on adults living in the community. To give a more extensive 
and accurate survey, the sample for the study was drawn from two Estonian 
towns differing from each other in several respects. One of them (Tartu) 
represented the country’s urban society and the other (Viljandi), a mainly pro­
vincial and rural population. On January 1, 1997 the estimated prevalence ratio 
of active epilepsy in Tartu was 5.3 per 1,000 (Õun et al., accepted for publi­
cation^). To test the consecutiveness of the study the percentages of sex and 
age structure of the epileptic people in the present study were compared with 
the same data available about the epileptic people of Tartu. As shown in Table
19, there were no significant differences. When the data originating from two 
different towns was analysed separately, there were no remarkable statistically 
significant differences found either between the groups or with the factors 
except for the seizure frequency. That was possibly due to the too small groups 
of respondents.
Table 19. Comparison of sex and age structure of Tartu epileptic people and epileptic 
people of Tartu included in the present study.
Parameter
Among adults with 
epilepsy in Tartu
Among adults with epilepsy 
in Tartu in the present study p-value*
n % n %
Sex
male 172 55.7 56 45.9 0.07
female 137 44.3 66 54.1
Age groups
20-29 years 53 17.2 26 21.3 0.3
30-39 years 74 23.9 27 22.1 0.7
40-49 years 70 22.6 24 19.7 0.5
50-59 years 54 17.5 20 16.4 0.8
>60 years 58 18.8 25 20.5 0.7
Total 309 100.0 122 100.0
* t-test
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2. Treatment, sldeeffects and 
seizure-related injuries.
The clinical characteristics of the present study were similar to most other series 
of prevalence cases of epilepsy (Forsgren, 1992; Joensen, 1986; Keränen, 
1989). Most of the study respondents had generalised seizures with or without 
other seizure types, the average duration of the disease was 11 years and 
patients were predominantly on carbamazepine monotherapy. More than half of 
those who had experienced seizures during the last year reported having injuries 
related to them. Findings regarding the rate and severity of seizure-related 
injuries were slightly higher compared with the results of studies conducted in 
other countries (Baker et al., 1997a; Buck et al., 1997). Beran (1989) has poin­
ted out that the purpose of treating epilepsy may not necessarily be that of sei­
zure eradication but rather the maximal improvement of QOL for the patient. In 
comprehensive management, the treating physician must very seriously con­
sider the influence of the therapy on the patients’ QOL (Kugoh, 1996). 84% of 
the study respondents were receiving monotherapy. This was higher compared 
to the other studies (Jacoby et al., 1996; Baker et al., 1997a; Ribeiro et al., 
1998). The explanation is that all of the patients from Tartu were participating 
in an epidemiological survey and consulted by an epileptologist, which often 
resulted in the correction of medication. The number of untreated cases (11%) 
was not high and probably reflects insufficient compliance. However, AED 
prescription patterns had some distinctive features. Carbamazepine was a much 
more frequently reported drug than in other studies, while the percentage of 
those using valproate or phenytoin was lower. To surprise, two patients reported 
taking bensobarbital — a drug that is no longer officially used in Estonia. 
Significant numbers of study respondents (67%) reported side effects from the 
AEDs; the most commonly experienced side effects were non-specific. In the 
past year, 41% of respondents had changed their medication, at present 78% 
stated that the level of seizure control was satisfactory.
3. The problem of stigmatisation
The problem of stigmatisation has been projected in a number of studies as one 
of the most common social problems faced by persons with epilepsy (Baker et 
al., 1996; Placencia et al., 1995; Baker et al., 1999; Jacoby, 1994; Baker et al., 
1997b). As stigmatisation is difficult to compare, the results were collated only 
with the results from the European study (Baker et al., 1997a) where the same 
scale was used for measuring stigma. According to this, the highest proportions 
of stigmatised persons (over 60%) were found among the respondents from two 
highly developed countries, i.e. France and Germany. The study also included
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respondents from Poland, the Czech Republic and Hungary, where the 
percentages of stigma were 32, 55 and 52, accordingly. According to this study, 
the levels of stigma among people with epilepsy were also high (52%) in spite 
of the fact that 40% of the study’s respondents had less than one seizure a 
month and 34% had been seizure-free in the last year. The majority of patients 
stated that they were nevertheless satisfied with the current treatment and the 
percentage of stigmatisation in general and the percentage of severely 
stigmatised persons was high. The factors influencing the development and 
maintenance of stigma in different countries are diverse but in general, the 
higher percentage of stigmatisation could be a characteristic of Eastern Euro­
pean countries and could be the result of a general lack of knowledge and of 
indifference, since the individual’s health and well-being were not valued, for a 
long period, due to the complicated political status. Respondents were more 
likely to feel stigmatised by epilepsy if they had frequent seizures or a 
combination of seizure types — findings that were in agreement with the results 
of other studies (Baker et al., 1997a; Baker et al., 1999; Jacoby, 1994; Jacoby et 
al., 1996). Stigmatisation was more common among educated persons.
4. Employment
Unemployment and part-time employment, being much more frequent in the 
epilepsy population than in general, have been identified as being among the 
most serious problems facing people with epilepsy (Masland, 1985; Broughton 
et al., 1984). The percentage of people working full-time and part-time was 65 
in the present study; 11% were unemployed. This is not considered high 
because, according to the data of the labour force surveys of the Statistical 
Office of Estonia, the percentage of employees (both employed and 
underemployed) residing in Tartu and aged 20 years and more on January 1, 
1998 was 63%, the unemployment rate was 9.5%, and 25.5% were pensioners 
receiving the state pension (Statistical Office of Estonia, 1997). Compared to 
the findings of a U.K. study by Jacoby et al. (1996) who found that the 
percentage of unemployed people was 10 and that of employed people was 35, 
the results indicate that the condition of our people with epilepsy is not much 
worse. At the same time, more than half of the study’s respondents believed that 
they had employment problems caused by their disease. A little less than half 
stated that they were being treated unfairly at work. Perceived discrimination 
may not always correspond to real discrimination (Scambler and Hopkins, 
1980). The findings of this study do not provide evidence of active 
discrimination against people with epilepsy. 55.7% of respondents had at least 
high school education and problems connected with unemployment or part-time 
employment, were not much expressed among this group. Not surprisingly,
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seizure frequency was positively related to the unemployed and underemployed 
workers but no relationship could have been found with the type of seizures. 
The finding supports the data of previous research in which lower seizure 
frequency had been related to the greater likelihood of being employed (Rodin 
et al., 1972; Scambler and Hopkins, 1980; Jacoby, 1995). The results of the 
study showed very clearly that there are a variety of reasons for the existence of 
the stigma. Although it has been found that unemployment and employment 
problems are on the whole the main source of the stigma (Collings, 1990c; 
Jacoby, 1994; Jacoby, 1995), the most educated respondents in the study, who 
had jobs, were even more stigmatised.
5. General health status assessed 
by the RAND-36
To assess general health status, a generic self-completed multidimensional 
instrument — the RAND 36-Item Health Survey 1.0 was used. This is 
developed as a measure of health status or health outcome for use in cross- 
sectional and longitudinal studies (König-Zahn et al., 1997). Although the ques­
tionnaire has been quite widely used, it has been described that different ethnic 
or cultural groups may interpret same items of the questionnaire differently 
(Gilson et al., 1980; Deyo, 1984). Different disease groups can also score too 
close to the bottom or top of the range, thus limiting the usefulness of a scale for 
comparing disease-burden profiles (McHomey et al., 1994).
In general, the translation and pilot testing of the Estonian version demonst­
rated a satisfactory feasibility of the form and suggested that the response 
choices in the Estonian version were ordinal and comparable to the response 
choices in the U.S. version. The response rate was 78%. The results of the item 
descriptive statistics showed a high completeness of data (over 98.5% on the 
item level) and a good distribution across response choices on the scale levels. 
The application of the RAND-36 showed very good to satisfactory psycho­
metric results in terms of scale characteristics with reliability coefficients above
0.70. The questionnaire has been criticised for its ceiling and floor effects 
(Jacoby et al., 1999). In this study, high ceiling effects associated with most of 
the domains were found. For the epilepsy group both floor and ceiling effects 
were low for Emotional well-being, Vitality and General health. Floor effects in 
the epilepsy sample were negligible for six scales, ceiling effects for three — 
Emotional well-being, Vitality and General health. The construct validity of the 
scale was supported by the findings that those with frequent seizures did poorly 
compared to those who experienced infrequent seizures or were currently 
seizure-free. This expected finding was in accordance with other studies (Baker 
et al., 1997a; Jacoby et al., 1996; Ribeiro et al., 1998; Malmgren et al., 1997;
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Devinsky and Cramer, 1997). Although the differences between seizure types 
were not significant in all the RAND-36 domains, there was a clear tendency 
towards a greater likelihood of lower scores in the case of patients suffering 
from generalised tonic-clonic seizures. Patients who experienced both genera­
lised tonic-clonic and other types of seizures did poorly compared to the others, 
which was to be expected (Baker et al., 1997a; Jacoby et al., 1996; Devinsky 
and Cramer, 1997). Discriminant validity was highly acceptable. People with 
epilepsy had significantly lower scores than the controls in all domains. Though 
the emotional well-being of the study respondents was not much worse than that 
of the control group, their social functioning was significantly lower and 
limitations due to emotional problems were more expressed. The results of the 
European study had previously drawn attention to the fact that it was unclear 
why respondents with epilepsy scored relatively poorly on the domain concer­
ned with physical function (Baker et al., 1997a). Although current seizure acti­
vity remained the most important predictor, there was a concomitant importance 
of socio-demographic variables (current age and employment status) to QOL. 
Older people and people who were currently unemployed were more likely to 
score lower. The other substantial disease characteristics in explaining the 
variation in the scores of several domains after controlling for seizure status 
were age at onset of epilepsy, duration of disease, and seizure type. Age at onset 
became significant in the case of Physical functioning, Role limitations — 
physical, Energy/fatigue, Social functioning, and General health. In all those 
domains, later age at onset was associated with lower scores. Dominian et al. 
(1963) have reported an association between depression and older age at onset, 
Jacoby et al. (1996) considered older age at onset to be implicated in feelings of 
depression and stigma. Duration of disease was significant in the case of 
Energy/fatigue, Emotional well-being and Bodily pain. Here, a shorter time of 
duration of epilepsy was related to lower scores. Seizure type became signi­
ficant in relation to Social functioning — those who experienced either tonic- 
clonic or multiple seizure types scored significantly lower than those who had 
only other types of seizures. Jenkinson et al. (1993) mentioned that the instru­
ment has its limitations — for instance containing no variable on sleep. 
However, it gives a good survey of the general health status of the people and 
enables an adequate health assessment comparison between the groups of 
patients with disease of varying severity.
6. Quality of life in epilepsy assessed 
by the QOLIE-31
The Estonian version of the QOLIE-31 showed psychometric properties com­
parable to those of the American version, and thus may be used as a specific
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measure of QOL in our population with epilepsy. The construct validity of the 
questionnaire was supported by the findings based on the values of the overall 
score that those with frequent seizures did poorly compared with those who 
experienced infrequent seizures or were currently seizure free. There was a clear 
tendency toward a greater likelihood of lower scores among patients with more 
frequent seizures. The overall score values of the three groups of patients with 
different seizure frequency were, statistically, significantly different between 
those who had not had seizures in the past year and those who had had seizures 
at least once a month or less often than once a month. Variance between seizure 
frequency statuses was statistically significant in all seven domains. The overall 
score of the QOLIE-31 was significantly different between all the three groups 
of seizure types: patients who had multiple seizure types had the lowest value, 
followed those who experienced generalised tonic-clonic seizures and those 
with other types only had the highest values. Variance between seizure types 
was statistically significant in four domains.
The most important predictor in assessing the QOL was seizure frequency. 
The other substantial disease characteristics after controlling for seizure status 
were seizure type, type of AED therapy, AED side effects, age at onset, and 
duration of epilepsy. Seizure type became significant in the case of Seizure 
worry and Overall quality of life. In both cases, people having generalised 
tonic-clonic seizures, either only or together with some other type of seizure, 
scored lower. Type of AED therapy became significant in relation to Seizure 
worry, Overall quality of life, Cognitive functions and the overall score. In all 
these cases, people receiving polytherapy had lower scores compared to these 
on monotherapy. People who stated experiencing AED side effects got lower 
values of the domains in Overall quality of life, Emotional well-being, 
Energy/fatigue, Cognitive function, Medication effects and in the overall score 
compared to those who reported no side-effects. Age at onset became 
significant in the case of Overall quality of life, Energy/fatigue, Cognitive 
function and in the case of overall score. In all those cases differences were 
significant between two groups of patients: lower scores were obtained by those 
for whom epilepsy had been diagnosed at the age of 41-50 or over 50 compared 
to those for whom it had been diagnosed at an age under 20 years. Duration of 
epilepsy remained significant only in the case of Emotional well-being where 
significantly lower scores were obtained by those who had suffered from 
epilepsy two to five years compared to those who had suffered more than 
twenty years. The other substantial socio-demographic variables included edu­
cation, stigmatisation, stigma severity, marital status and employment. Edu­
cation was significant in the case of two domains: Seizure worry and Cognitive 
function. In Seizure worry, lower scores had those who had higher education, 
while in Cognitive function domain, it was opposite: lower scores were 
obtained by those who had primary or less than primary education. Stig­
matisation was significant in assessing Seizure worry, Cognitive function, 
Medication effects and Social functioning domains, and the overall score. In all
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cases lower values were obtained by those who were stigmatised. Stigma 
severity became significant in three domains (Seizure worry, Medication 
effects, Social functioning) and in the overall score. In all cases differences 
were significant between two groups: those who expressed very strong feelings 
of stigma (gave three “yes” answers) compared to those who did not (one “yes” 
answer). Marital status was significant in assessing Overall quality of life and 
Social function domains. In the first case, lower scores were obtained by those 
who were married or cohabiting compared to those who were single, in the 
second case, significantly lower scores were obtained by those who were single, 
divorced or widowed compared to those who were married. Employment be­
came significant in four domains where being in a paid job was always asso­
ciated with higher scores.
As the QOLIE-31 questionnaire is a relatively new measure, there is not 
much data about its use in the QOL studies. The averages for the Estonian pa­
tients of all domains were compared to the available data from USA (Devinsky 
et al., 1995), Spain (Torres et al., 1999) and Hungary (Lam et al., 2001). (Table 
20) The SDs did not show a significant difference between the groups. The 
overall scores of the scale were highest for the USA and Spain, followed by 
Estonia and Hungary. The values of the domains of the Estonian QOLIE-31 
were significantly lower compared to three other countries in the Overall quality 
of life domain. In the Energy/fatigue domain, the average differed significantly 
only from the data from the USA and Spain. To surprise, in the Medication 
effects domain the average value of the Estonian epilepsy group was signi­
ficantly higher compared to the same data from the USA and Hungary. That can 
be explained, at least partly, by the fact that the people with epilepsy from Tartu 
were during the epidemiological study consulted by a neurologist in terms of 
their treatment problems. The authors of the Hungarian study (Lam et al., 2001) 
have explained their higher value in this domain compared to the USA by the 
different mental health expectations, the difference in the expected efficacy of 
treatment, the confidence in doctors and by the different circumstances and 
opportunities open to people from developed countries and from Eastern 
European countries. This may indicate that because of their disease our people 
judge themselves to be at a greater disadvantage with respect to their social 
status. This is why they have greater confidence in the doctors and the treat­
ment. The averages of the domains of the Estonian QOLIE-31 were most simi­
lar to those of the Hungarian epilepsy group. Also, there was no statistically 
significant difference in the value of the overall score. The averages were 
generally lower (the negative judgement) compared to the American and 
Spanish data but they changed in parallel with it. The lower overall score 
compared to the data from the USA and Spain can be explained by the 
difference in economic and social status and by the difference in both the social 
judgement and ability to cope with the disease.
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Table 20. Comparison of the mean scores of the QOLIE-31 domains of the respondents 
from USA, Spain, Hungary and Estonia.
Averages (SD) of the QOLIE-31 domains
Domains USA Spain Hungary Estonia
(n=304) (n=252) (n=170) (n=203)
Seizure worry 58.29 (25.76) 51.47 (29.73) 53.95 (28.53) 54.67 (26.26)
Overall quality of life 67.17(18.38)* 63.80(16.95)* 55.45 (19.32)* 49.18(17.59)
Emotional well-being 67.20(19.28)* 61.78(19.13) 58.28(18.48) 60.14(19.95)
Energy/fatigue 55.30 (21.10)* 60.89 (20.27)* 49.68(17.68) 48.40 (20.17)
Cognitive function 59.96 (22.76) 60.32 (23.80) 59.26 (20.23) 59.41 (23.75)
Medication effects 55.34 (30.52)* 60.30 (29.10) 57.39 (31.13)* 63.64 (27.70)
Social functioning 67.25 (26.88) 66.44 (27.96) 56.88 (23.60)* 63.54 (25.08)
Overall score 62.87(16.31)* 61.77(17.33)* 56.45 (16.50) 57.38 (18.50)
* The means different from the corresponding results of the Estonian epilepsy group at
0.05 significance level (t-test).
Also, the results the QOLIE-31 of the patients from USA, Hungary and Estonia, 
who were seizure free, were compared. (Table 21) The same tendency was 
found when comparing the results of the QOLIE-31 according to seizure 
frequency (and severity). The Estonian seizure free patients rated their Overall 
quality of life as being much lower than American and Hungarian patients; the 
Medication effects domain was rated higher. The averages of the other domains 
were in the middle, being higher than the same values of Hungary and lower 
than the averages given by the American patients. Although when comparing 
the data it was not possible to calculate statistical significance, the averages of 
the seizure free patients reflected the same tendency as shown by the whole 
groups of respondents with epilepsy in Table 20. In brief, one can say that our 
people with seizure free epilepsy suffer more from prejudices than seizure free 
patients in the USA.
Table 21. Comparison of the mean scores of the QOLIE-31 of seizure free patients 
from USA, Hungary and Estonia.
Domains Seizure free
n(%)=
USA 
21 (6%)
Hungary
50 (29%)
Estonia 
69 (34%)
Seizure worry 74.90 53.78 63.12
Overall quality of life 72.00 62.24 55.73
Emotional well-being 73.40 59.92 65.91
Energy/fatigue 63.00 47.86 54.42
Cognitive function 70.75 62.10 67.27
Medication effects 56.80 59.58 75.08
Social functioning 77.70 65.74 74.07
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CONCLUSIONS
The research took place in 1997 through 1998 and followed an epidemio­
logical survey of epilepsy in Tartu. The study was based on the analysis of 
data collected from a sample of 203 patients, aged 20-72 years, from Tartu 
and Viljandi County. All the respondents from Tartu and the problematic 
cases from Viljandi County included in the study were re-examined at least 
once to specify the type of their seizures and that excludes cases with 
provoked and acute symptomatic seizures.
A profound translation and psychometric testing phase preceded the 
inclusion of the RAND-36 and QOLIE-31 questionnaires in the research. It 
showed that both of them were reliable and valid descriptive health status 
measures for the Estonian epilepsy population.
74% of study respondents had less than one seizure a month, of these 34% 
had been seizure-free in the last year. 78% of the patients stated being satis­
fied with the current treatment. Despite this the stigmatisation in general 
(52.4%) and the percentage of severely stigmatised (24.7%) was high. 
Being aware of the limitations to the generalisability of the study in the 
interpretation of the results, due to a relatively small and somewhat biased 
sample size; it can be quite clearly said that one of the main problems of 
epileptic people in Estonia is their perception of stigmatisation.
Although the percentage of full-time and underemployed people in the 
study was not lower than in the general population, more than half of the 
respondents believed that they had employment problems caused by their 
epilepsy. A little less than half stated that they were being treated unfairly at 
work.
The characteristics describing the disease, its medication and complications 
were generally in accordance with the data from other countries, and also 
marital and educational status (except when assessing the stigmatisation) 
were not statistically significant.
People with epilepsy had significantly lower scores than the controls in all 
domains of the RAND-36. Though the emotional well-being of the study 
respondents was not much worse than that of the control group, their social 
functioning was significantly lower and limitations due to emotional prob­
lems more expressed. Although current seizure activity remained the most 
important predictor, there was a concomitant importance of socio-demo­
graphic variables (current age and employment status) to the scores of 
domains of the RAND-36. The other substantial disease characteristics, in 
explaining the variation in the scores of several domains after controlling 
for seizure status, were age at onset of epilepsy, duration of disease, and 
seizure type.
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7. The most important predictor in assessing the QOL with the QOLIE-31 was 
seizure frequency. The other substantial disease characteristics after cont­
rolling for seizure status were seizure type, type of AED therapy, AED side 
effects, age at onset, and duration of epilepsy. The socio-demographic 
variables influencing the averages of the domains included education, 
stigmatisation, stigma severity, marital status and employment. On the basis 
of the averages of the domains the Estonian people with epilepsy rated their 
Overall quality of life as the lowest and the average of the Medication 
effects domain was higher then expected. The results of the QOLIE-31 were 
comparable with those obtained in other countries. The values of the 
domains were generally lower than in developed countries (USA, Spain) 
and similar to those given in another Easten European country (Hungary).
8. The findings of this study confirm that remarkable psychosocial problems 
accompany the diagnosis of epilepsy. The study demonstrated QOL decrea­
ses in subjects with epilepsy.
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SUMMARY IN ESTONIAN
Epilepsiahaigete elukvaliteet Eestis
Sissejuhatus
Epilepsia on krooniline haigus, mille korral normaalse neuroloogilise funkt­
siooniga perioodid vahelduvad harvade, lühikeste hoogude-perioodidega. Mit­
mete krooniliste haiguste puhul esinev haigusnähtude avaldumise ootamatus, 
mis tekitab inimeses pideva kindlusetustunde, on epilepsia puhul eriti 
väljendunud. Epilepsia tõttu suuremal või vähemal määral esile kerkivad 
psühhosotsiaalsed probleemid kaaluvad sageli üles hoogude ja nende raviga 
seotud probleemid. Stigma (sisemise häbitunde või märgistatuse) tunnetamine 
võib muuta inimese iseloomu nii, et tal tekivad tõsised suhtlemisprobleemid, 
mis omakorda tekitavad raskusi ja langetavad motivatsiooni toimetulekuks 
ühiskonnas. Uuringutega on esile tõstetud mitmeid erilist tähelepanu väärivaid 
valdkondi (Baker et a i ,  1997a). Epilepsiaga isikutel on tihti vähenenud enesest 
lugupidamine, sagedamini kui rahvastikus keskmiselt esineb neil ärevushooge 
ja depressiooni. Nende hulgas tuleb keskmisest sagedamini ette töötust või 
tööga alahõivatust, samuti on selles inimgrupis suurem sotsiaalne isolatsioon ja 
madalam abielus olevate inimeste protsent. Epidemioloogiliste uuringute järgi 
alluvad 70-80%-l epilepsiaga inimestest hood hästi antiepileptilisele (AE) ravile 
(Sander, 1993) ning nende puhul epilepsia otseselt elukvaliteeti alandada ei 
tohiks. Ülejäänud 20-30% puhul, kelle hood on kroonilised ja alluvad raskesti 
ravile, on olukord tunduvalt komplitseeritum. Teistes riikides läbiviidud uurin­
gud on selgelt näidanud, et suhe epilepsia raskuse ja selle mõju vahel elu­
kvaliteedile on kompleksne ja selle hindamisel tuleb arvesse võtta mitmeid 
erinevaid faktoreid, kaasa arvatud patsiendi enda arvamus (Jacoby et a i ,  1996).
Uuringu eesmärgid
1. Kontrollida epilepsiahaigete elukvaliteedi uuringus kasutatavate mujal välja­
töötatud küsimustike RAND-36 (RAND 36-Item Health Survey 1.0) ja 
QOLIE-31 (Quality of Life Inventory in Epilepsy-31, versioon 1.0) vastu­
võetavust, usaldusväärsust ja valiidsust Eesti inimestel.
2. Uurida epilepsia ja selle ravi mõju tööhõivele ning epilepsiaga sageli 
kaasneva stigma ulatust patsientide hulgas.
3. Kirjeldada ülalmainitud küsimustike abil suuremas osas kahest Eesti linnast 
pärit epilepsiaga patsientide üldist tervislikku seisundit ja hinnata nende 
elukvaliteeti.
4. Leida ja analüüsida seoseid epilepsia kliiniliste näitajate ja epilepsiahaigete 
elukvaliteedi vahel.
5. Leida ja analüüsida seoseid patsientide demograafiliste näitajate ja elukvali­
teedi vahel.
Patsiendid ja meetodid
Uuring toimus aastatel 1997-98 ning hõlmas 203 epilepsiaga inimest Tartust ja 
Viljandimaalt. Algandmed patsientide kohta pärinesid Tartus varem läbiviidud 
epidemioloogilise uuringu tulemustest ning Viljandis kohaliku epilepsiaühingu 
(Viljandimaa Epilepsia Ühing) nimekirjadest. Kliinilised andmed täpsustati 
kasutades Viljandi maakonnahaigla ja polikliiniku ning Tartu Maaijamõisa 
Haigla ja polikliiniku meditsiinilist dokumentatsiooni. Kõik inimesed, kelle 
puhul epilepsia anamnees ning kliinilised andmed (peamiselt hoo tüüp) jäid 
ebaselgeks, kutsuti kordusvastuvõtule. Käesolev uuring hõlmas 20-aastaseid ja 
vanemaid epilepsiaga inimesi, kel oli esinenud vähemalt kaks provotseerimata 
epileptilist hoogu, neist vähemalt üks viimase viie aasta jooksul.
Uuringu eelselt viidi läbi küsimustike tõlkimine eesti keelde, nende vali- 
deerimine ning pilootuuring 30 Tartu linna epilepsiaga inimese hulgas, mis 
näitas, et küsimustikud olid üldiselt mõistetavad ning inimestele kergesti täide­
tavad. Võrdlemaks üldist tervislikku seisundit peegeldava küsimustiku tulemusi, 
moodustati vanuse, soo ja haridustaseme poolest samane 200 inimesest koosnev 
kontrollgrupp. Et hinnata epilepsia mõju patsientide üldisele tervislikule seisun­
dile ja elukvaliteedile, saadeti kõigile uuringus osalejatele posti teel küsimustik, 
mis sisaldas peale ülalnimetatud skaalade ka küsimusi demograafiliste andmete, 
majandusliku toimetuleku, hoogude, hoogudega seotud vigastuste, AE ravi 
kõrvaltoimete, raviga rahulolu, ravi muutuste, ravimreziimi järgimise, kaasuvate 
haiguste, tööhõive ja sellega seotud probleemide, stigma tunnetamise ning 
autojuhilubade olemasolu kohta. Täidetud küsimustikud tagastas 78% inimes­
test.
Elukvaliteedi uuringu tulemuste analüüsile eelnes RAND-36 ja QOLIE-31 
küsimustike reliaabluse (usaldatavuse) ja valiidsuse (kehtivuse) kontroll.
Uuringu peamised tulemused
Hoogude sageduse ning valdkondade keskmiste väärtuste vahel ilmnes 
statistiliselt oluline seos: need, kel esines hooge sagedamini, said nii RAND-36 
kui QOLIE-31 kõigis valdkondades vähem punkte (madalam elukvaliteet) 
võrreldes nendega, kel esines hooge harvemini. Samuti oli täheldatav (kuigi 
mitte kõigi valdkondade puhul statistiliselt oluline) seos hoogude tüübi ning 
valdkondade keskmiste väärtuste vahel: patsiendid, kel esinesid general iseeri tud 
toonilis-kloonilised hood, andsid valdkondade hindamisel madalamaid punkte.
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Uuringugrupi keskmine vanus oli 41 aastat. Uuringus osalejad jagati viide 
vanusegruppi: 20-29a. —54 (26.6%), 30-39a. — 42 (20.7%), 40-49a. — 35 
(17.2%), 50-59a. — 28 (13.8%), ning 60a. ja vanemad — 44 (21.7%) inimest. 
Vastanutest 48.8% (99) olid mehed. 82 (40.9%) oli abielus või vabaabielus, 84 
(41.4%) vallalised, 21 (10.3%) lahutatud ja 15 (7.4%) lesed. 90 (44.3%) omas 
algharidust (8 või 9 klassi) ning 113 (55.7%) kesk-või kõrgharidust. 67 (33%) 
töötas täiskohaga, 87 (41.9%) oli alahõivatud või töötud, 49 (24.1%) vanadus- 
või invaliidsuspensionil. Ainult üks vastanutest (0.5%) pidas oma majandus­
likku seisundit väga heaks, 17 (8.5%) — heaks, 119 (59%) — rahuldavaks, 53 
(26.2%) — halvaks, 12 (5.9%) — väga halvaks. 11.3%-1 (23 inimesel) oli juhi­
loa kehtivus katkestatud epilepsia tõttu. Vastanute keskmine vanus epilepsia 
diagnoosimisel oli 26.9 aastat, epilepsia kestus keskmiselt 113  aastat.
84 (41.4%) uuringus osalejal oli esinenud ainult toonilis-kloonilist tüüpi 
hooge, 61 (30%) -  nii toonilis-kloonilisi kui muud tüüpi hooge ning 58 (28.6%) 
ainult muud tüüpi hooge. Viimasel aastal ei olnud hooge esinenud umbes kol­
mandikul (69, 34%), 81 (39.9%) isikul oli hooge harvemini kui kord kuus ja 53 
(26.1%) kord või sagedamini kuus. AE ravi sai 180 vastanut (88.7%), neist 
monoteraapiat 151 (83.9%). Enamus neist, kes said monoteraapiat, tarvitas 
karbamasepiini (113, 74.8%), ülejäänuid raviti valproaadi, primidooni, fenü- 
toiini, fenobarbitaali ning bensobarbitaaliga. AE ravi kõrvaltoimeid kaebas 153 
(75%) vastanut, neist enamusel (113, 73.9%) esines kolm või enam sümptomit. 
Kõige sagedamini esinevad kõrvaltoimed olid mittespetsiifilised: mäluprob- 
leemid (31%), väsimus (25%), unisus (20%), peavalu (20%) ja närvilisus 
(20%). Enam kui pooltel nendest, kel oli viimase aasta jooksul hooge esinenud 
(134 patsienti), oli esinenud ka neist tingitud vigastusi: 19 (14%) tõsisemaid 
vigastusi (põletusi, sügavaid sisselõikeid, luumurde), 51 (38%) pea vigastusi, 29 
(22%) kergemaid vigastusi või peavalu. Vigastusi ei esinenud ligikaudu viien­
dikul (28, 21%) vastanutest. Suurema tõenäosusega esines hoogudega seotud 
vigastusi neil, kel oli hooge kord või sagedamini kuus (%2=11.89, df=2, 
p=0.001), ja neil, kel esinesid generaliseeritud toonilis-kloonilised või segatüüpi 
hood (x2=9.94, df=2, p=0.009). Oma hooge hindas väga rasketeks 15 (7.4%) 
vastanut, 61 (30%) rasketeks, 84 (41.4%) keskmisteks ja 43 (21.2%) kergeteks. 
Esines statistiliselt oluline korrelatsioon hoogude raskuse subjektiivse hinda­
mise ja hoogudega seotud vigastuste vahel (%2= 15.24, df=4, p=0.003). Enamus 
AE ravi saavatest vastanutest (142 isikut ehk 78.8%) oli oma praeguse raviga 
täielikult või enam-vähem rahul, 38 (21%) oli ravi suhtes rahulolematu. Kahel 
viiendikul (74 vastanul ehk 41.1%-1) neist, kes said ravi, oli seda viimase aasta 
vältel muudetud: 51 juhul (68.4%) oli muudetud üks kord, 17 (22.8%) kaks ja 6 
(8.8%) kolm või enam korda. Neist, kelle ravi viimase aasta jooksul oli muude­
tud vähemalt korra, oli 59 (79.3%) seda tehtud ravi ebapiisavuse ja 15 (20.7%) 
kõrvaltoimete tõttu. Ravimrežiimi järgimine: 101 patsienti (56%) ei olnud kor­
dagi unustanud AE tablette võtta, 41 (23%) unustas umbes korra kuus, 25 
(14%) umbes korra nädalas ja 13 (7%) sagedamini kui korra nädalas. Kaasuvaid
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kroonilisi haigusi esines 36 (17.7%) vastanul ja 24 (11.8%) tarvitasid nende 
tõttu ka pidevalt ravimeid. Kõige sagedasemad kaasuvad kroonilised haigused 
olid südamehaigused — neid esines 14 isikul (39%) ning luu- ja liigeshaigused
— 12 vastanul (33%).
Hoolimata sellest, et 78.8% patsientidest oli enam-vähem rahul oma prae­
guse raviga, oli stigmatiseeritute üldprotsent (52.4) ja raskelt stigmatiseeritute 
protsent (24.7) siiski kõrge. Stigma tunnetamise raskus sõltus hoogude tüübist 
ja sagedusest: need, kel hooge esines sagedamini (x2=23.57, df=6, p<0.0001) ja 
neil, kel esinesid segatüüpi hood (%2= 20.65, df=6, p<0.009), tunnetasid stigma 
suurema tõenäosusega, samuti olid nad suurema tõenäosusega raskelt stigmati- 
seeritud. Stigmatiseeritust esines rohkem nende hulgas, kes omasid kesk-või 
kõrgharidust (%2= 12.89, df=6, p<0.05). Täiskohaga töötas kolmandik vasta­
nutest. Neist, kes olid tööga alahõivatud või töötud, pidas 54 (62%) inimest 
selle peamiseks põhjuseks epilepsiat. Viimase kahe aasta jooksul oli töökohta 
vahetanud 47 (29%) vastanut. Pisut vähem kui pooled uuringus osalenutest (74 
isikut, 44%) tunnistasid, et neid on nende haiguse tõttu tööle võtmisel või töö 
juures koheldud ebaõiglaselt. Hoogude sageduse ja tööga alahõivatuse ning 
töötuse vahel leiti positiivne korrelatsioon. Statistiliselt oluline seos esines ka 
täiskohaga töötamise ja haridustaseme vahel: mida kõrgemat haridust isik omas, 
seda suurema tõenäosusega töötas ta täiskohaga (x2=12.12, df=6, p=0.04). Täis­
kohaga töötavate ja alahõivatute protsent oli käesolevas uuringus 64, töötuid oli 
11%. Mujal maailmas tehtud analoogiliste uuringutega võrreldes oli täiskohaga 
töötavate ning alahõivatute epilepsiaga inimeste protsent kõrgem (Jacoby et al., 
1996). Samal ajal uskusid enam kui pooled uuringus osalenutest, et neil on 
nende haiguse tõttu probleeme tööhõivega.
Nii RAND-36 kui QOL3E-31 analüüsimisel osutusid mõlemaid kirjeldavad 
näitajad erinevate valdkondade puhul väga headeks kuni rahuldavateks. 
Reliaabluse näitajad olid üle 0.70. Konstruktiivvaliidsust toetasid tulemused, 
mille järgi need, kel esinesid sagedased hood hindasid valdkondi madalamalt 
kui need, kel hood esinesid harvem. Samasuunaline tendents esines seoses 
hoogude tüübiga: need, kel esinesid generaliseeritud toonilis-kloonilised hood 
hindasid valdkondi madalamalt kui need, kel seda tüüpi hooge ei esinenud. 
Uuringus osalejad said võrreldes kontrollgrupiga kõigis RAND-36 valdkon­
dades vähem punkte, mis näitab, et nad pidasid oma tervist ja sellest tulenevat 
elukvaliteeti halvemaks. Suurimad erinevused ilmnesid nelja valdkonna puhul: 
sotsiaalne tegevus, füüsilisest tervisest tingitud piirangud, emotsionaalsetest 
probleemidest tingitud piirangud, üldine tervis. RAND-36 erinevate valdkon­
dade hindamist mõjutavatest näitajatest osutusid olulisteks hoogude sagedus, 
hoo tüüp, vanus epilepsia diagnoosimisel, epilepsia kestus, stigmatiseeritus, 
stigma raskus, isiku vanus ja tööhõive. QOLIE-31 erinevate valdkondade 
keskmised näitajad olid seotud hoogude sageduse, hoo tüübi, AE ravi tüübi, AE 
kõrvaltoimete esinemise, vanusega epilepsia diagnoosimisel, epilepsia kestuse, 
stigmatiseerituse, stigma raskuse, haridustaseme, perekonnaseisu ja tööhõivega. 
Kui QOLIE-31 abil saadud tulemusi võrreldi USA-s (Devinsky et al., 1995),
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Hispaanias (Torres et al., 1999) ja Ungaris (Lam et al., 2001) sama küsimustiku 
abil läbiviidud uuringute andmetega ilmnes, et Eesti andmed olid kõige enam 
samased Ungari vastavate tulemustega. Tulemused olid madalamad, kui USA-s 
ja Hispaanias läbiviidud uuringutes. Antud uuringus osalejad hindasid üldist 
elukvaliteeti iseloomustavat valdkonda oluliselt madalamalt kui teiste maade 
vastanud, samas oli ravi mõju käsitlevat valdkonda iseloomustav keskmine 
väärtus oluliselt kõrgem kui sama näitaja USA ja Hispaania uuringutes.
Järeldused
1. Uuring toimus aastatel 1997-1998 ning hõlmas 203 epilepsiaga isikut vanu­
ses 20-72 aastat Tartust ja Viljandimaalt. Kõik Tartust pärit uuringus osale­
jad ning probleemsemad Viljandimaalt pärit patsiendid olid uuringu käigus 
kontrollitud hoogude tüübi suhtes, mis välistas juhud, mille korral oli tege­
mist provotseeritud või ägedate sümptomaatiliste epileptiliste krambihoogu­
dega.
2. Uuringu küsimustike (RAND-36 ja QOLIE-31) kasutusele võtmisele ning 
tulemuste interpreteerimisele eelnes nende põhjalik tõlkimisprotsess ja 
hindamine. Mõlemad küsimustikud osutusid antud populatsiooni seisundi 
kirjeldamisel usaldusväärseiks ning valiidseiks.
3. 74%-l uuringus osalejatest esines hooge harvemini kui kord kuus, 34% olid 
viimase aasta jooksul olnud hoovabad. 78% olid rahul oma praeguse AE 
raviga. Sellele vaatamata oli nii stigmatiseeritute üldprotsent (52.4) kui ras­
kelt stigmatiseeritute protsent (24.7) kõrged. Vaatamata sellele, et uuringu- 
grupp ei olnud väga suur ning saadud tulemused võivad peegeldada vaid 
teatud osa epilepsiahaigete arvamust, saab üsna kindlalt väita, et stigmati- 
seeritus on Eestis üheks epilepsiaga inimeste peamiseks probleemiks.
4. Kuigi täiskohaga töötavate ja alahõivatud inimeste osakaal ei olnud antud 
uuringu andmetel madalam kui rahvastikus üldiselt, arvas üle poolte osale­
jatest, et neil on epilepsia tõttu probleeme tööhõivega. Pisut alla poolte 
tunnistas, et neid on nende haiguse tõttu tööl koheldud ebaõiglaselt.
5. Haiguse ja selle raviga seotud kliinilisi aspekte kirjeldavad näitajad ei 
erinenud üldiselt teistes maades läbiviidud uuringute andmetest. Statistiliselt 
olulisi erinevusi ei ilmnenud ka perekonnaseisu ning haridustaseme osas.
6. Epilepsiaga inimesed said kõigi RAND-36 valdkondade hindamisel mada­
lama keskmise väärtuse võrreldes kontrollgrupiga. Kuigi uuringus osalejate 
emotsionaalne seisund ei erinenud palju kontrollgrupi omast, oli nende sot­
siaalne tegevus oluliselt häiritud ning emotsionaalsetest probleemidest tingi­
tud piirangud enam väljendudnud. Kuigi hoogude sagedus osutus kõige 
olulisemaks faktoriks, omasid RAND-36 valdkondade keskmiste väärtuste 
hindamisel tähtsust ka mõningad demograafilised näitajad — vanus ja töö­
hõive. Haigusega seotud näitajatest osutusid peale hoogude sagedusega
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arvestamist olulisteks vanus esimese epileptilise hoo ajal, epilepsia kestus ja 
hoo tüüp.
7. Elukvaliteedi hindamisel QOLIE-31 abil osutus hoogude sagedus samuti 
kõige olulisemaks faktoriks. Lisaks sellele olid olulised ka epilepsiaga seo­
tud näitajad — hoo tüüp, AE ravi tüüp, AE ravi kõrval toimed, vanus esimese 
epileptilise hoo ajal ning epilepsia kestus. Demograafilistest näitajatest olid 
olulised haridus, stigmatiseeritus, stigma raskus, perekonnaseis ja tööhõive. 
Valdkondade keskmiste alusel otsustades andsid Eesti epilepsiaga inimesed 
kõige madalamaid punkte üldist elukvaliteeti puudutavatele küsimustele, 
oodatust mõnevõrra kõrgemalt hinnati ravi mõju. Võrreldes QOLIE-31 vald­
kondade tulemusi mujal maailmas läbiviidud uuringutega ilmnes, et kesk­
mised olid üldiselt madalamad kui arenenud maades (USA, Hispaania), kuid 
samased teises Ida-Euroopa riigis (Ungari) läbiviidud uuringu tulemustega.
8. Antud uuringutulemused kinnitavad, et epilepsiaga kaasnevad olulised 
psühhosotsiaalsed probleemid, mis alandavad elukvaliteeti.
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Appendix 1
ELUKVALITEET EPILEPSIA KORRAL
Kuupäev.................
Nimetähed:................................. Haridus:...............................................
Sünniaeg:....................................  Amet:..................................................
Vanus:....................
Sugu: M N
Perekonnaseis....................................
1. Hoogude sagedus: a) kord või sagedamini kuus
b) harvemini kui üks kord kuus
c) pole esinenud viimase aasta jooksul
2. Hoogudega seotud vigastused viimase aasta jooksul:
a) tõsisemad vigastused: põletused, suuremad marrastused, 
sügavad sisselõiked, luumurrud
b) keelde hammustamine, hammaste vigastused või tugev peavalu
c) kergemad vigastused (kergemad marrastused, verevalumid jne) 
või kerge peavalu
d) muud vigastused..................................................................
e) vigastusi pole esinenud
3. Kui hoog tingib teadvusekaotuse, kas enne seda esineb nn hoiatavaid nähte, mis 
võimaldavad Teil end vigastuste eest kaitsta? (Kui teadvusekaotust ei esine või hood 
tekivad ainult magades, märkige c))
a) mitte iialgi
b) mõnikord
c) peaaegu alati või alati
4. Kui sageli olete hoo korral kukkunud maha?
a) peaaegu alati või alati
b) sageli
c) vahete-vahel
d) mitte iialgi
5. Kui kaua võtab peale hoogu aega, kuni Te olete jälle teadvusel ja aktiivne?
a) alla 1 min
b) 1-10 min
c) 10 min -1 tund
d) 1-3 tundi
e) üle 3 tunni
6. Palun iseloomustage lühidalt oma hooge (mis juhtub Teiega hoo ajal -  mida Te ise 
tunnete, kuidas on Teie hooge kirjeldanud pealtnägijad):.............................................
7. Kui vana Te olite, kui Teil hood esmakordselt tekkisid? ....
8. Millal esines viimane hoog (märkige ligikaudne kuupäev)?
9. Kas Teil on hoo ajal esinenud uriinipidamatust?
a) peaaegu alati või alati
b) sageli
c) vahete-vahel
d) mitte kunagi
10. Kas hoo ajal on esinenud järgmisi nähte:
a) ümbritsevaid inimesi tõsiselt häirivat automaatset tegevust (nt. karjumine, sihitult 
ringi hulkumine, lahti riietumine)
b) kergeid automaatseid liigutusi või võpatusi
c) pole esinenud
11. Kuidas Te ise hindaksite oma hooge: a) väga rasked b) rasked c) keskmised
d)kerged
12. Milliseid epilepsiavastaseid ravimeid Te praegu tarvitate (nimi + annus):
13. Kas Teil on viimase kuu ajajooksul esinenud epilepsiavastaste ravimite 
tarvitamisest tingitud kõrvalnähte? Kui on, siis palun märkige kõrvaltoime taha ka 
number, mis näitab, kui sageli antud kõrvaltoime on esinenud: 1 -  kogu aeg või 
peaaegu kogu aeg, 2 -  mõnikord, 3 -  harva.
pearinglus... b) väsimus... c) tasakaaluhäired... d) iiveldus, oksendamine...e) 
nahasügelus, -lööve... f) kõhulahtisus...g) unisus... h) unetus... 
i) meeleolumuutused... j) närvilisus, ärevus... k) rahutus... 1) peavalu... m) käte 
värisemine... n) kõrvetised... o) kehakaalu muutused... p) isu muutused... r) 
tursed... s) kaebused südame poolt... t) surenenud karvakasv... u) juuste 
väljalangemine... v) kontsentreerumishäired... õ) mäluprobleemid... ä) raskusi 
selgelt mõtlemisega... ö) raskusi rääkimisel... ü) kahekordne või hägune nägemine...
x) muud kõrvalnähud..........................................................................................................
y) kõrvalnähte pole esinenud
14. Kuidas Te olete rahul oma praeguse raviga (nii hoogude kontrolli kui 
kõrvaltoimete talutavuse osas): a) täielikult rahul
b) enam-vähem rahul
c) pisut rahulolematu, võiks olla parem
d) ei ole rahul
15. Kas Teie epilepsiavastast ravi on viimase aasta vältel muudetud? a) jah b) ei 
Kui jah, siis mitu korda? .....
Kas ravi muudeti selle ebapiisavuse või kõrvaltoimete tõttu? (Palun tõmmake joon 
õigele vastusele alla)
16. Kui regulaarselt olete Te viimase kuu ajajooksul tarvitanud epilepsiavastaseid 
ravimeid? a) pole kordagi unustanud tablette võtta
b) olen unustanud võtta tablette umbes korra kuus
c) olen unustanud võtta tablette umbes korra nädalas
d) olen unustanud võtta tablette sagedamini kui korra nädalas
17. Kaasuvad kroonilised haigused (juhul, kui neid esineb):
18. Teised pidevalt tarvitatavad ravimid:
19. Kas Te töötate täiskohaga? a) jah b) ei
Kui Te olete töötu või tööga alakoormatud, kas selle põhjuseks on ka epilepsia?
a)jah b) ei
20. Kas Te olete viimase kahe aasta jooksul vahetanud töökohta?
a)jah b) ei
21. Kas Teid on Teie epilepsia tõttu kunagi tööle võtmisel või tööjuures koheldud 
ebaõiglaselt? a) jah b) ei
22. Majanduslik toimetulek: a) väga hea
b) hea
c) rahuldav
d) halb
e) väga halb
23. Juhiload: a) pole kunagi olnud
b) kehtivus katkestatud epilepsia tõttu
c) on
24. Kas Teil on vahel tunne, et Teie epilepsia tõttu:
- teised inimesed tunnevad end Teiega ebamugavalt? a) jah b) ei
- teised inimesed on kohelnud Teid alaväärsetena? a) jah b) ei
- teised inimesed on eelistanud Teid vältida? a) jah b) ei
25. Umbes mitu korda olete Te viimase aasta jooksul käinud arsti juures? (märkige 
arv).....Sellest mitu korda epilepsia tõttu?......
26. Milliseid ja mitu korda järgnevatest analüüsidest ja uuringutest on Teile viimasel 
aastal tehtud: a) vere analüüs....b) EEG.... c) kompuutertomograafia....
d) magnetresonantstomograafia... .Neist milliseid ja mitu korda epilepsia tõttu?
27. Umbes mitu korda olete viimase aasta jooksul arsti poole pöördunud hoogudest 
tingitud vigastuste tõttu? (märkige arv) .... Kui Teil on esinenud tõsisemaid vigastusi, 
palun märkige ära protseduurid, mis Teiega on tehtud (nt. haavapuhastus, -õmblus, 
luumurru lahastamine, tekkinud tüsistused, ka haiglaravi ja selle päevade arv).
28. Sellele küsimusele vastamine ei ole kohustuslik.
Teie arvamus nii selle kui ülejäänud küsimustike kohta (kas küsimused olid 
arusaadavad, kas Teil tekkis vastamisega mõnele neist probleeme). Kui Teil on 
esinenud muid probleeme seoses epilepsiaga, mida eelnevad küsimused ei kajastanud 
piisavalt, võiksite neid siin kirjeldada. Rõhutame veelkord, et uuring on mõeldud 
epilepsiaga inimeste probleemide välja selgitamiseks ning vastuste analüüsimisel on 
Teie anonüümsus tagatud.
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QUALITY OF LIFE IN EPILEPSY
Date
Initials:........
Date of birth:
Age:............
Sex: M F 
Marital status
1. Seizure frequency status: a) once or more in a month
b) less often than once a month
c) not at all in the past year
2. Injuries associated with seizures during the past year:
a) serious injuries: seizure-related bums or scalds, large excoriations, deep cuts, 
fractures
b) bitten tongue, dental injuries or severe headaches
c) milder injuries (small excoriations, suffusions, etc) or mild headaches
d) any other injuries..............................................................................................
e) no injuries
3. If the seizure causes loss of conciousness, is there a warning long enough for you 
to protect yourself? (If there is no loss of conciousness or seizures occur only while 
asleep, mark c)
a) never
b) sometimes
c) nearly always or always
4. How often have you fallen to the ground during a seizure?
a) nearly always or always
b) often
c) occasionally
d) never
5. How long is it until you are really back to normal consciousness and active after 
the seizure?
a) less than 1 minute
b) between 1 and 10 minutes
c) between 10 minutes and 1 hour
d) between 1 and 3 hours
e) more than 3 hours
6. Please, characterise briefly your seizures (what happens with you during a seizure
-  what do you feel, how have your seizures been characterised by the eyewitnesses):
7. How old were you at the time of the first seizure?.......................
8. When did you have the last seizure (approximate d ate)? ............
9. How often have you been incontinent of urine during a seizure?
a) nearly always or always
Education:
Profession:
2b) often
c) occasionally
d) never
10. Do the following events have occurred during a seizure:
a) seriously disruptive automatisms (e.g. shouting, wandering, undressing)
b) mild automatisms or focal jerking
c) none
11. How would you rate your seizures: a) very severe b) severe c) medium
d) light
12. What kind of antiepileptic drugs are you taking ? (name + dose):
13. Have you experienced any of the symptoms associated with the antiepileptic drug 
treatment during the past month? Please, mark behind the side-effect you have had 
the number showing how often the symptom has been a problem: 1 -  always or often,
2 -  sometimes, 3 -  infrequently.
a) dizziness... b) tiredness... c) unsteadiness... d) nausea, vomiting...
e) skin itch, rash... f) diarrhoea... g) sleepiness... h) insomnia... i) mood changes... 
j) nervousness, agitation... k) restlessness ... 1) headache... m) shaky hands... 
n) heartburn.... o) weight changes... p) changes in appetite... r) oedemas... 
s) heart problems... t) increased growth of hair... u) loss of hair... 
v) difficulty in concentrating... õ) memory problems... ä) difficulty in thinking 
clearly... ö) slurred speach... ü) double or blurred vision... x) other symptoms 
 y) side-effects have not occurred
14. How satisfied are you with your current treatment (also with the control of the 
seizures and the tolerance of the side-effects):
a) absolutely satisfied
b) almost satisfied
c) a little bit unsatisfied, could be better
d) not satisfied at all
15. Has your antiepileptic treatment been changed during the past year? a) yes b) no 
If yes, then how many times? .....
Has the treatment been changed because of its insufficiency or side-effects? 
(Please, underline the right answer)
16. How regularly have you been taking your antiepileptic drugs during the last 
month? a) I have never missed taking my antiepileptic drugs
b) I have missed to take them less than once a month
c) I have missed to take them less than once a week
d) I have missed to take them more often than once a week
17. Additional chronical illnesses (in case you are having any):
18. Other constantly used medication(s):
19. Do you work full-time? a) yes b) no
If you are un- or underemployed, do you consider epilepsy as a reason for it?
a) yes b) no
20. Have you changed a job during the last two years?
a) yes b) no
321. Have you been treated unfairly at work or when applying for a job because of 
epilepsy? a) yes b) no
22. Economical and financial status:
a) very good
b)good
c) satisfactory
d) moderately bad
e) very bad
23. Driving-license:
a) never had one
b) invalidated because of epilepsy
c) having a driving license
24. Have you felt that because of your epilepsy:
- other people have been uncomfortable with you? a) yes b) no
- other people have treated you as inferior? a) yes b) no
- other people have preferred to avoid you? a) yes b) no
25. About how many times during the past year have you visited your doctor? (mark 
the num ber).......  Of this, how many times because of epilepsy?........
26. What kind of and how many of the following analyses have been done to you
during the last year: a) blood test.... b) EEG.... с) C T .... d) MRI...... Of them, which
ones and how many times because of epilepsy?
27. About how many times have you visited your doctor because of the seizure-
related injuries during the last year? (mark the number)..... If you have had serious
injuries, please, mark the procedures that have been done to you (e.g. cleaning of the 
wound, suture of the wound, application of a splint due to fracture, complications, 
also hospital treatment and the number of days)
28. Answering to this question is not obligatory.
We would like to know your opinion about this as well as about the other 
questionnaires (were the questions understandable, did you have problems in 
answering to any of the questions, your opinion about the importance of the study). In 
case you have had any other problem related to your epilepsy that were not 
sufficiently covered with the questions, you could describe them here. We would 
emphasise once more that the study is meant to explore the problems of the people 
with epilepsy and when analysing the answers your anonymity is guaranteed.
Appendix 2
RAND 36-küsimuseline tervisliku seisundi ülevaade, versioon 1.0
Küsimustik
1. Üldiselt öeldes, kas Teie tervis on:
tõmmake ring ümber ainult 
ühele vastusevariandi numbrile
Suurepärane 1
Väga hea 2
Hea 3
Rahuldav 4
Halb 5
2. Milline on Teie tervislik seisund praegu võrreldes olukorraga aasta 
tagasi?
tõmmake ring ümber ainult 
ühele vastusevariandi numbrile
Palju parem kui aasta tagasi 1
Mõnevõrra parem kui aasta tagasi 2
Umbes sama kui aasta tagasi 3
Veidi halvem kui aasta tagasi 4
Palju halvem kui aasta tagasi 5
2ft 1
Alljärgnevalt on toodud igapäevased füüsilist koormust pakkuvad 
tegevused. Kas Teie praegune tervislik seisund piirab Teil nende 
toimingute sooritamist? Kui jah, siis kui palju?
tõmmake igas reas ainult ühele 
vastusevariandi numbrile ring ümber
Jah, piirab 
palju
Jah,
piirab
veidi
Ei, 
üldse 
ei piira
3. Suurt füüsilist koormust pakkuvad 
tegevused nagu jooksmine, raskete 
esemete tõstmine, pingeline 
sporditegevus
1 2 3
4. Keskmist füüsilist koormust
pakkuvad tegevused nagu söögilaua 
liigutamine, tolmuimeja kasutamine, 
kerge võimlemine, lehtede riisumine
1 2 3
5. Poekottide tõstmine või kandmine 1 2 3
6. Mitme trepivahe üles kõndimine 1 2 3
7. Uhe trepivahe üles kõndimine 1 2 3
8. Painutamine, põlvitamine, 
kummardumine
1 2 3
9. Rohkem kui 1 kilomeetri
kõndimine
1 2 3
10.500 m kõndimine 1 2 3
11.100 m kõndimine 1 2 3
12.Enda pesemine ja riietumine 1 2 3
Kas Teil on viimase nelja nädala jooksul ette tulnud allpool loetletud 
probleeme oma töö või muude igapäevaste toimingute juures tingituna 
Teie kehalisest tervisest?
tõmmake igas reas ainult ühele 
vastusevariandi numbrile ring ümber
Jah Ei
13.Olite sunnitud vähendama töö ja teiste toimingute jaoks 
planeeritud aega?
1 2
14.Saavutasite vähem kui Teile oleks meeldinud? 1 2
15.Olite võimeline sooritama ainult teatud töid ja 
toiminguid?
1 2
16.Oli raskusi töö ja  teiste toimingute tegemisel (näiteks 
seetõttu, et see nõudis lisapingutust) ?
1 2
Kas Teil on viimase nelja nädala jooksul ette tulnud oma emotsinaalse
seisundi (näiteks olite depressioonis või ärevil) tõttu tööl või muude 
igapäevaste toimingute juures allpool loetletud probleeme?
Jah Ei
17.Olite sunnitud vähendama töö ja  teiste toimingute jaoks 
planeeritud aega?
1 2
18.Saavutasite vähem kui Teile oleks meeldinud? 1 2
19.Ei teinud oma töid või toiminguid nii hoolikalt kui 
tavaliselt?
1 2
20.Kui palju viimase nelja nädala jooksul on Teie kehaline tervis või 
emotsionaalsed probleemid häirinud Teie normaalset seltskondlikku 
tegevust perekonna, sõprade, naabrite või kolleegidega?
tõmmake ring ümber ainult 
ühele vastusevariandi numbrile 
Üldse mitte 1
Veidi 2
Mõõdukalt 3
Üsna palju 4
Väga palju 5
21.Kui palju füüsilist valu tundsite Te viimase nelja nädala jooksul?
tõmmake ring ümber ainult 
ühele vastusevariandi numbrile 
Üldse mitte 1
Väga vähe 2
Vähe 3
Mõõdukalt 4
Palju 5
Väga palju 6
22.Kui palju segas valu viimase nelja nädala jooksul Teid oma 
igapäevase tööjuures (nii väljaspool kodu kui ka koduste tööde 
juures)?
tõmmake ring ümber ainult 
ühele vastusevariandi numbrile 
Üldse mitte 1
Veidi 2
Mõõdukalt 3
Üsna palju 4
Väga palju 5
3
Järgnevad küsimused puudutavad Teie enesetunnet ja seda, kuidas Teil 
on läinud, viimase nelja nädala jooksul.
Igale küsimusele andke vastus, mis kõige täpsemalt kirjeldab, kuidas Te 
ennast tundsite.
Kui tihti Te viimase nelja nädala jooksul...
tõmmake igas reas ainult ühele 
vastusevariandi numbrile ring ümber
Kogu
aeg
Suurema 
osa ajast
Sageli Vahel Harva Uldse
mitte
23 ....tundsite end 
särtsakalt?
1 2 3 4 5 6
24....olite väga 
närviline?
1 2 3 4 5 6
25....olite nii suures 
masenduses, et miski 
ei suutnud Teid 
lohutada?
1 2 3 4 5 6
26... .olite rahulik? 1 2 3 4 5 6
21... .tundsite ennast 
täis energiat?
1 2 3 4 5 6
28... .olite rõhutud ja 
kurb?
1 2 3 4 5 6
29... .olite kumatud? 1 2 3 4 5 6
30....olite õnnelik? 1 2 3 4 5 6
31... .olite väsinud? 1 2 3 4 5 6
32.Kui suure osa ajast viimase nelja nädala jooksul segasid kehaline 
tervis või emotsionaalsed probleemid Teie seltskondlikku tegevust 
(nt. sõprade ja  sugulaste külastamist jms.)?
tõmmake ring ümber ainult 
ühele vastusevariandi numbrile
Pidevalt 1
Suurema osa ajast 2
Vahel 3
Harva 4
Üldse mitte 5
4
Kui suurel määral on iga järgnev väide Teie suhtes ÕIGE või VALE?
tõmmake igas reas ainult ühele 
vastusevariandi numbrile ring ümber
Väga
õige
Enamasti
õige
Ei tea Enamasti
vale
Väga
vale
33.Mulle näib, et ma jään 
haigeks kergemini kui 
teised inimesed
1 2 3 4 5
34.Ma olen niisama terve 
kui teisedki
1 2 3 4 5
35.Ma arvan, et mu tervis 
halveneb edaspidi
1 2 3 4 5
36.Minu tervis on 
suurepärane
1 2 3 4 5
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1. In general, would you say your health is:
(Circle One Number)
Excellent.............................................. ..1
Very good........................................... ..2
Good................................................... ..3
Fair....,................................................. ..4
Poor.......................................... ............5
2. Compered to one year ego, how would you rate your health in general now?
(Circle One Number)
Much better now than one year ago..........................................  1
Somewhat better now than one year ago.............................. 2
About the same........................................................................... 3
Somewhat worse now than one year ago.................................. 4
Much worse now than one year ago..........................................  5
The following items are about activities you might do during a typical day. Does your health now limit 
you in these activities? If so, how much?
(Circle One Number on Each Line)
Yes. Yes, No,
Limited Limited Not Limited 
a Lot a Uttie at Ай
3 ViQonwie act&tsiee, such as running, Siting heavy 
objecte , pcrHdpeang in strenuous sports............................ 2 3
4. Moderate activtUet, such as moving a table, pushing 
a vacuum cleaner, bowing, or playing golf......................... 2 3
5. Lifting or carrying groceries.................................. .............. 2 3
6 CImbing w a u l flights of stairs.......................................... 2 3
7. Clmbing one fight of stairs................................................ 2 3
8. Bendng, kneeing, or stooping........... ................... ........ 2 3
9 Wcfcing more than a mMe....................................... .......... 2 3
10. WalWng eavera* blocks............... 2 3
11 Walking one block.............................................................. 2 3
12 Bathing or dressing yourself................................................... 2 3
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During the рем 4 weeks, have you had any of th» following problems with your work or other regular 
daily activities as с result of your physical health?
(Circle One Number on Each Line)
le i  tki
13. Cut down the amount of time you spent on work or
other activities.....................................................................  1 2
14. Aceomp&afted less than you would like............................  1 2
15. War# Srnüed in the kind of work or other activities.............  1 2
16. Had dffflcufty performing the work or other activities
(for example, It took extra effort).........................................  1 2
During the past 4 weeks, have you had any of the following problems with your work or other regular 
daily activities as a result of any emotional problems (such as feeling depressed or anxious)?
(Circle One Number on Each Line)
Iss. Uü
17. Cut down the amount of tfcne you spent on
work or other activities........................................................  1 2
16. AccompUsfted less man you would like...........................  1 2
13. Didn't Co work or other activities as carefully as usual...... 1 2
20. During th# past 4 weeks, to what extent has your physical health or emotional problems interfered 
with your rsormal social activities with family, friends., neighbors, or croups?
(Circle On* Number)
Not at all........................................... -  1
Sfightiy ...............................................  2
Moderately.........................................  3
Quite a bit...........................................  4
Extremely................. ........................ 5
21. How much bodily pan have you had during the pest 4 weeks?
(Circle One Number)
None................................................... ..1
Very mild....................... ..................... ..2
Mild.................................................... ..3
Moderate............................................ ..4
Severe................................................ ..5
Very severe...................................... ..... ..6
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22. During the paat 4 wM ki, how much did pain interfere with your normal work (including both work 
outside the home and housework)?
(Circle One Number)
Not at all................................................  1
A little bit ............................................ . 2
Moderately............................................ 3
Quite a bit.............................................. 4
Extremely.............................................  5
These questions are about how you feel and how things have been with you during the past 4 weeks. 
For each question, please give the one answer that comes closest to the way you have been feeling.
How much of the time during the past 4 weeks
(Circle One Number on Each Line)
AH
of the 
Time
Most 
of the 
Tima
A Good 
Bit of 
tofiJime
Some 
of the 
Time
A Little 
of the 
lim e
Nc 
of I 
Hi
23. Did you feel fuH of pep?............................. 1 2 3 4 5 8
24, Have you been a ve*у  nervous person?.... 1 2 3 4 5 6
25. Have you re* so down in the dumpe that 
nothing could cheer you up?.... .................. 1 2 3 4 5 6
26 Have you felt calm and peaceful?.............. 1 2 3 4 с 6
27. Did have a lot of energy?.................... 1 2 3 4 5 S
28 Have you fe» downhearted and blue?.... 1 2 3 4 5 6
29. Did you Seei worn out?................................ 1 2 3 4 5 6
30. Have you been a happy person?............... 1 2 3 4 5 в
31. Did you feel tired?........ 1 2 3 4 5 6
32. During the past 4 weeks, how much of the time has your physical health or emotional 
problems interfered with your sodal activities (like visiting with friends, relatives, etc.)?
(Circle One Number)
AH of the time.......................................  1
Most of the time...................................  2
Some of the time................................ 3
А Wtte of th e  time................................. 4
None of the time....................  .......... 5
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How TR U E or FALSE )s each of the following statements tor you?
(CJreie One Number on Each Line)
Definitely Mostly Don't Mostly Definitely
True True Know False
33. I seem to get sick a ittte easier than 
other people........................................
34. I am as healthy as anybody I know. ..
35. I expect my health to get worse.........
36. My health is excellent............... .........
False
5
5
5
5
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Appendix 3
ELUKVALITEET EPILEPSIA KORRAL 
OOLIE-31 (Versioon 1.0)
KÜSIMUSTIK PATSIENDILE
Kuupäev__/ __ / __ /
päev kuu aasta
Nimi...........................
SISSEJUHATUS
Selles küsimustikus esitatakse Teile küsimusi Teie tervise ja igapäevaste tegevuste kohta. 
Palun vastake igale küsimusele, märkides ära vastav number (1, 2, 3, ...)•
Kui Te ei ole päris kindel, kuidas küsimusele vastata, andke sobivaim ligilähedane vastus 
ja kiijutage lehe servale selgitav märkus.
Kui vajate küsimustiku lugemisel või täitmisel kellegi kõrvalabi, paluge, et keegi Teid 
aitaks.
1. Kuidas Te hindate oma elukvaliteeti laias plaanis?
(Märkige alloleval skaalal üks arv)
10 9 8 7  6 5 4  3 2 1  0 
I______ I______ I_____I______ I_____I_____I______ 1_ I I______ !
Parim võimalik Halvim võimalik
elukvaliteet elukvaliteet
(sama halb või halvem 
oleks olla surnud)
Neis küsimustes käsitleme seda, kuidas Te end TUNNETE ja kuidas Teil on läinud 
viimase 4 nädala jooksul. Palun andke igale küsimusele vastus, mis Teie seisundile 
kõige enam vastas.
Kui tihti viimase 4 nädala jooksul ...
(Märkige igas reas üks arv ringiga)
Kogu Suurema Sageli Mõnikord Harva Üldse
aeg osa
ajast
mitte
2. ... tundsite end särtsakalt? 1 2 3 4 5 6
3. ... olite Te väga närviline? 1 2 3 4 5 6
4. ... olite nii löödud, et
miski ei suutnud Teid
lohutada? 1 2 3 4 5 6
5. ... olite Te rahulik ja 
tasakaalukas? 1 2 3 4 5 6
6. ... olite Te täis energiat? 1 2 3 4 5 6
7. ... olite Te tujutu ja kurb? 1 2 3 4 5 6
8. ... olite Te kurnatud? 1 2 3 4 5 6
9. ... olite Te õnnelik? 1 2 3 4 5 6
10. ... olite Te väsinud? 1 2 3 4 5 6
11. ... olite Te mures järgmise 
hoo tekkimise pärast? 1 2 3 4 5 6
12. ... oli Teil raskusi prob­
leemide kallal töötamisel 
või nende lahendamisel (nt. 
plaanide tegemisel, otsuste 
vastu võtmisel, uute asjade
õppimisel)________________ 1_______ 2________3_______4_______ 5 6
13. ... olite Te oma tervisliku 
seisundi tõttu piiratud sot­
siaalse tegevuse ja ette­
võtmiste osas (nt. sõprade
või lähedaste külastamine)_____1_______ 2_______ 3 4 5 6
14. Milline oli Teie ELUKVALITEET 
viimase 4 nädala jooksul (s.t. 
kuidas Teil on läinud)?
Väga hea: 
parem ei saagi olla
Üsna hea
Nii hea kui halb
Üsna halb
Väga halb: 
halvem ei saagi olla
Märkige 
üks arv 
ringiga
29
Järgmine küsimus puudutab MÄLU.
(Märkige ringiga üks arv)
Jah, palju Jah, Ainult Ei, 
mõningal vähesel üldse 
________ ___________________________________ määral_____ määral____ mitte
15. Kas Teil on olnud viimase 4
nädala kestel probleeme mäluga? 1 2  3 4
Märkige üks arv, iseloomustamaks seda, kui sageli viimase 4 nädala jooksul on Teil 
olnud probleeme meenutamisega või kui sageli on probleemid mäluga seganud Teie 
normaalset tööd või elu.
Alati Enamasti Kaunis Mõnikord Harva Mitte 
_________________________________________ sageli_________________ kunagi
16. Oli Teil probleeme 
meenutamaks asju, mida Teile
oli öeldud? 1 2 3 4 5 6
Järgmised küsimused käsitlevad võimalikke probleeme, mis Teil võivad esineda seoses 
KONTSENTREERUMISEGA. Märkige üks arv, iseloomustamaks seda, kui sageli 
viimase 4 nädala jooksul on Teil olnud probleeme kontsentreerumisega või kui sageli 
on need probleemid seganud Teie tööd või elu.
Alati Enamasti Kaunis 
sageli
Mõnikord Harva Mitte
kunagi
17. Oli Teil probleeme lugemisele 
kontsentreerumisega? 1 2 3 4 5 6
18. Oli Teil probleeme kontsent­
reerumisega ühe asja tegemisele 
korraga? 1 2 3 4 5 6
Järgmised küsimused puudutavad probleeme, millised võivad olla seotud kindlate 
TEGEVUSTEGA. Märkige üks arv, iseloomustamaks seda, kui palju on Teie epilepsia 
või epilepsiavastased ravimid viimase 4 nädala jooksul põhjustanud Teile probleeme 
järgmiste tegevuste juures.
Väga
palju
Palju Veidi Väga
vähe
Üldse
mitte
19. Vaba aja veetmine (nt. 
hobid, väljas käimine) 1 2 3 4 5
20. Auto-, mootorratta juhtimine 1 2 3 4 5
(Märkige igas reas ringiga üks arv) 
Suur hirm Mõõdukalt Vähe hirmu Üldse mitte
Järgmised küsimused püüavad välja selgitada Teie SUHTUMIST oma hoogudesse.
hirmu hirmu
21. Kui suur on Teil hirm
hoo tekke ees järgneva kuu
jooksul 1 2 3 4
Muretsen Vahete-vahel Ei muretse
palju muretsen üldse
22. Kas Te muretsete selle pärast, 
et võite end hoo ajal vigastada? 1 2 3
Väga mures Mõõdukalt Pisut Üldse mitte
mures mures mures
23. Kui mures Te olete selle üle, 
et hoog järgmise 4 nädala jooksul 
asetab Teid piinlikku olukorda või 
tekitab Teile kaaskodanikega 
muid probleeme? 1 2 3 4
24. Kui mures Te olete selle üle, 
et kui Te pidevalt tarvitate epilepsia- 
vastaseid ravimeid, võivad need Teie 
tervisele halvasti mõjuda? 1 2 3 4
Märkige iga järgneva probleemi kohta skaalal 1 kuni, 5 Uks arv, mis näitab, kui väga Te
selle all kannatate, kusjuures 1 = ei kannata üldse ja 5 = kannatan väga (erakordselt).
25. Haigushood 1 2 3 4 5
26. Mäluprobleemid 1 2 3 4 5
27. Piirangud töös 1 2 3 4 5
28. Piirangud sotsiaalsetes suhetes 1 2 3 4 5
29. Epilepsiavastaste ravimite
kehalised körvaltoimed 1 2 3 4 5
30. Epilepsiavastaste ravimite
psüühilised körvaltoimed 1 2 3 4 5
31. Kui heaks või halvaks hindate Te oma tervist? Allpool kujutatud skaalal on parim 
kujuteldav terviseseisund 100 juures ja halvim kujuteldav terviseseisund 0 juures. 
Palun märkige skaalal ristiga, kuidas Te oma tervist hindate. Sellele küsimusele 
vastates palun hinnake epilepsiat osana oma üldisest tervisest.
100 = parim kujuteldav 
terviseseisund
90 
80 
70 
60 
50 
40 
30 
20
10
0 = halvim kujuteldav 
terviseseisund
14. How has the QUALITY OF YOUR LIFE been during the paat 4 weeks (that is, how 
have things been going for you)?
(Circle
one
number)
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The following question is about MEMORY.
(Circle one number)
Yes, a Yes, Only No, 
great deal somewhat a little not at all
15. In the past 4 weeks, have 
you had any trouble with 
your memory?
1 2 3 4
Circle one number for how often in the past 4 weeks you have had trouble 
remembering or how often this memory problem has interfered with your normal 
work or living.
All Most 
of the of the 
time time
A good Some 
bit of of the 
the time time
A little 
of t he 
time
None
of the 
time
16. Trouble remembering 
things people tell you 1 2 3 4 5 6
The following questions are about CONCENTRATION problems you may have. 
Circle one number for how often in the past 4 weeks you had trouble concentrating 
or how often these problems interfered with your normal work or living.
Ail Most 
of the of the 
time time
A good Some 
bit of of the 
the time time
A little 
of the 
time
None 
of the 
time
17. Trouble concentrating 
on reeding 1 2
3 4 5 6
18, Trouble concentrating 
on doing one thing 
at a time
1 2 3 4 5 6
The following questions are about problems you may have with certain ACTIVITIES. 
Circle one number for how much during the post 4 weeks your epilepsy or 
antiepileptic medication has caused trouble with. ..
A great
deal A lot Somewhat
Only 
a little
Not 
at all
19. Leisure time 
(such as hobbies, 
going out)
1 2 3 4 5
20. Driving 1 2 3 4 5
Do Not
Write in
This Spac<
CopyrigM 1993. BAND. All fight* raiafvad The OCM.IE-31 wu d nM pad in coopafaiion with Рго(в*»юл»1 Postgr*Ou«le Sarv.cas,
a division Ы Phyaiciani Wortd Communicatlona Group. and Iha QOLIE Oavatopmanl Group.
The following questions relate to the way you FEEL about your aetame.
(Circle one number on each line)
Not Not
Very Somewhat very fearful
fearful fearful fearful at all
21. How fearful are 
you of having a 
seizure during the 
next month?
1 2 3 4
Worry 
a lot
Occasionally
worry
Don’t worry 
at all
22. Do you worry 
about hurting 
yourself during 
a seizure?
1 2 3
Very
worried
Somewhat
worried
Not
very
worried
Not 
at all 
worried
23. How worried are you 
about embarrassment or 
other social problems 
resulting from having a 
seizure during the 
next month?
1 2 3 4
24. How worried are you 
that medications you 
are taking will be bad 
for you if taken for 
a long time?
1 2 3 4
For each of these PRO*LEMS, circle one number for hew much they bether you 
on a scale of 1 to 5 where 1 =  Not at all bothersome, and 5 =  Extremely bothersome.
Not at ail Extremely 
bothersome bothersome
25. Seizures 1 2 3 4 5
26. Memory difficulties 1 2 3 4 5
27. Work limitations 1 2 3 4 5
28. Sociai limitations 1 2 3 4 5
29. Physical effects of antiepMeptic 
mecfcation 1 2 3 4 5
30 Mental effects of antiepileptic 
medication 1 2 3 4 5
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31. How good or bad do you think your health is? On the thermometer scale below, the 
best imaginable state of health is 100 and the worst imaginable state is 0. Please 
indicate how you feel about your health by circling one number on the scale. Ploaae 
consider your epilepsy aa part of your health whan you answer thla question.
О
100 = Best Imaginable 
Health State
90
80
70
60
50
40
30
20
10
0 -  Worst Imaginable 
Health State
Do Not
Write In
This Space
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PUBLICATIONS
QUALITY OF LIFE IN EPILEPSY 
QOLIE31 (Version 1.0)________
Patient Inventory
Today'll Date__ I__ /__
Pattenft Nam*________________________________________________
Patient* ID#__________
G to r tfe r  □  M a le  □  F em e*#  W r t h d f ____ / ____ I
INSTRUCTIONS__________________________________________________________
This survey asks about your health and daily activities. Answer every queeMon by circling 
the appropriate number (1, 2, 3 ..
If you are unsure about how to answer a question, please give the best answer you can and 
write a comment or explanation in the margin.
Please feel free to ask someone to assist you if you need help reading or marking the form.
1. Overall, how would you rate your quality of life?
(Circle one number on the scale below)
8 7 6 5 4 3 2 1 0
Worst Possible 
Quality of Life
(as bad as or 
worse than 
being dead)
Copyright 1993 RAND. AN right» raaarvad Tha QOLIE-31 m  developed in cooperation with Prctfeaatonal Poalgraduata Services
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Best Possible 
Quality of Life
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These questions are about how you FEEL and how things havetf>een for you during 
the past 4 weeks. For each question, please indicate the one answer that comes 
closest to the way you have been feeling.
How much of the time during the past 4 weeks. ..
(Circle one number on each line)
Alt Most A good Some A little None 
of the of the bit of of the of the of the 
time time the time time time time
2. Did you feel 
full of pep? 1 2 3 4 5 6
3. Have you been 
a very nervous 
person?
1 2 3 4 5 6
4. Have you felt so 
down in the dumps 
that nothing could 
cheer you up?
1 2 3 4 5 6
5. Have you felt 
calm and peaceful? 1 2 3 4 5
6
6. Did you have 
a lot of energy? 1 2 3 4 5 6
7. Have you felt 
downhearted 
and blue?
1 2 3 4 5 6
8. Did you fee! 
worn out? 1 2 3
4 5 6
9. Have you been 
a happy person? 1 2 3
4 5 6
10. Did you feel 
tired?
1 2 3 4 5 6
11. Have you worried 
about having 
another seizure?
1 2 3 4 5 6
12. Did you have 
difficulty reasoning 
and solving problems 
(such as making 
plans, making 
decisions, learning 
new things)?
1 2 3 4 5 6
13. Has your health 
limited your social 
activities (such as 
visiting with friends 
or close relatives)?
1 2 3 4 5 6
Do Not
Writ* In
TNs Space
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M. Rätsepp, А. Õun, S. Haldre, A.-E. Kaasik. 
Täiskasvanute elukvaliteet epilepsia korral. 
Eesti Arst 1998; 6: 529-533 (in Estonian).
Täiskasrvanute 
elukvaliteet epilepsia 
korral
M u ju R it ie p p  Andre õ u n  Sulev Haldre 
Ain-Etm ar l ü u u i k
epilepeia, stigma, hoo raakue, terviaega seotud 
elukvaliteet, elukvaliteedi hiadamiae vahen­
did, elukvaliteedi uuringud
Inimesi, kellel eeineb epilepsia, on läbi 
aegade peetud "ebasoovitavalt erineva­
teks" (an undetirtd differtntnesa) (15). 
Epilepeia ei ole pidev seisund. See on hai­
gus, mille korral normaalse neuroloogili­
se funktsiooniga perioodid vahelduvad 
harvade lühikeste hoogude-perioodidega. 
Mitme kroonilise haiguse puhul esinev 
haiguenAhtu de avaldumise ootamatus, 
mis tekitab inimeses pideva kindlusetus- 
tunde, on epilepsia puhul eriti ilmekalt 
väljendunud.
Haiguse raskus ja  prognoos on variee­
ruvad ning hood eelle välise ilminguna et­
tearvamatud. Epilepeia tõttu suuremal 
või vähemal määral esile kerkivad peüh- 
hcsotsiaaised probleemid kaaluvad sageli 
üies hoogude ja  nende raviga seotu. Klii­
niliste nähtude ja  sotsiaalse tähenduse 
tõttu võib epilepeia inimese elukvaliteedi­
le avaldada märkimisväärset mõju (2, 3).
Stigma olemus. E. Goffman defineerib 
stigma (kr. stigma — arm, märk) sisemi­
se häbitundena, mis võib muuta inimese 
iseloomu nii, et tal tekivad tõsised suhtle­
misprobleemid, mis omakorda tekitavad 
raskusi ja  langetavad motivatsiooni toi­
metulekuks ühiskonnas (15). Stigma ku­
junemisel näevad nii E. Goffman kui ka 
H. Becker olulist osa ühiskonnas valitse­
val üldisel suhtumisel inimestesse, kee on 
millegi poolest erinevad, ning nende suh-
E©*ti Ar*t, 191)8, 6, 529—633
M a r ju  R ä ts e p p , A n d r e  õ u n ,  S u le v  H a ld re ,  
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tee kehtestatud reeglites ja  piirangutes (4, 
15). Kuid nagu väidavad mitmed autorid, 
on stigma tekkeks eelkõige vajalik see, et 
inimene tunneks, et ta on mingil põhjusel 
sunnitud Ühiskondliku arvamusega ar­
vestama, s.t. selle teataval määral omaks 
võtma (27).
E. Goffman leiab, et stigma väljendub 
erinevalt inimestel, kelle haigussümpto- 
mid on kõigile nähtavad ja esinevad pide­
valt, võrreldes nendega, kelle haigus aval­
dub episoodiliselt ning võib neid asetada 
ootamatutesse olukordadesse. Viimati 
mainitute puhul tekitab neile enim prob­
leeme see, et nad peavad pidevalt kontrol­
lima, mida, millal ja  kellele oma seisun­
dist rääkida ja mida vaijata (15). Selline 
olukord võib tekitada pideva ärevus- ja 
stressiseisundi. G. L. Albrecht ja  kaas­
autorid väidavad, et kord juba tekkinud 
stigmast ei olegi täielikult võimalik vaba­
neda ning seetõttu peavad nad seisundit 
pöördumatuks (1). G. Scambler rõhutab 
stigma olemasolu just epilepeia korral 
(24).
Uuringutega on esile tõstetud mitmeid 
erilist tähelepanu väärivaid valdkondi (6, 
8, 16). Epilepsiaga isikutel on tihti vähe­
nenud enesest lugupidamine (5), sageda­
mini kui rahvastikus keskmiselt eeineb 
neil ärevust ja  depressiooni (7). Nende 
hulgae tuleb suhteliselt sageli ette töötust 
või tööga alahõivatust (14), samuti on 
suurem sotsiaalne isolatsioon ja  väiksem 
abielus olevate inimeete protsent (2, 12).
Epidemioloogilised uuringud on näida­
nud, et 70—80%-l epilepeiahaigeteet allu­
vad hood hästi epilepeia vastasele ravile 
(23), ning on tõendeid, et nende puhul epi­
lepeia otseselt elukvaliteeti ei alanda (17). 
Ülejäänud 20—30% puhul, kelle hood on 
kroonilised ja ravile raskesti alluvad, on 
olukord tunduvalt komplitseeritum. Siia­
ni tehtud uuringud on selgelt näidanud, 
et suhe epilepeia raskuse ja  tema mõju va­
hel elukvaliteedile on kompleksne ning 
selle hindamisel tuleb arvesse võtta erine­
vaid tegureid, kaasa arvatud patsiendi
529
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enda arvamus, tema haiguse raskus ja 
selle mvi <22).
Tervisega seotud elukvaliteet. Ter­
vis on Maailma Tervishoiuorganisatsiooni 
defineeri tuna täieliku füüsilise, vaimse ja 
sotsiaalse heaolu seisund, mitte lihtsalt 
haiguse puudumine (11). H Schipper ja 
kaasautorid on kirjeldanud tervisega seo­
tud elukvaliteeti {health-related quality of 
life) krooniliste haiguste korral kui haigu­
se ja  selle mvi funktsionaalset efekti pat­
siendile, tunnetatuna tema enda poolt 
(26). Mõiste on laiem kui üksikute selle 
alla kuuluvate komponentide summa, 
sest sellega tähistatakse sünergiat erine­
vate valdkondade vahel ja erinevusi, mis 
on tingitud olukordadest ja petsiendipooi- 
sest suhtumisest. Definitsioone kombi­
neerides võib öelda, et meditsiin püüab li­
sada elule aastaid, samal $jai kui inimloo­
mus tahaks lisada aastatele elu. Leitakse, 
et elukvaliteedi uurimisel tuleks peatähe­
lepanu koondada sellele, kuidas inimene 
ise oma sekundit hindab, arvestamata, 
mida näitavad kliinilised uuringud ja 
analüüsid (11).
Elukvaliteedi uuringud epilepsia 
korral. Üks esimesi, koe uuris elukvali­
teedi spetsiifilisi aspekte epilepsia korral, 
oli J. Collings (3). Ta hindas patsientide 
eneseväärikust, eluga rahulolu, sotsiaal­
seid ja isikutevahelist suhteid, üldist ter­
vist, probleemide üle muretsemise määra 
ja üldist heaolu, kasutades erinevaid 
psühhomeetriiisi vahendeid. Tuleimiaed 
näitasid märkimisväärseid enesehinnan­
gu vasturääkivusi, Kui remissioon viis 
mvi lõpetamiseni, siis peühhosotsia&lne 
seisund mõningal määral paranes. A. Ja­
coby ja kaasautorid, kasutades viit stan­
dardset psühhomeetrilist testi, hindasid 
patsiente, kellel ei olnud hooge tekkinud 
mitme aasta vältel. Nad leidsid, et neil, 
kelle epilepsiavastane ravi jätkus, esines 
märgatavalt rohkem stressi kui neil, kel­
le ravi oli lõpetatud (19).
G, Scambler ja A. Hopkins, hinnates
piiranguid sotsiaalsetes suhetes, kiEelda­
sid erinevust tõelise ja tunnetatud stigma 
vahel (25). Patsiendi enesehinnang leiti 
olevat heas korrelatsioonis üldise tervise­
ga seotud elukvaliteediga. Epilepsiahai- 
gad said märgatavalt vähem punkte ene­
seväärikuse, eluga rahulolu, sotsiaalsete 
probleemidega toimetuleku, füüsiliste 
sümptomite ning murede ja emotsioonide 
tasakaalustamise osas kui kontrollrühma 
patsiendid. Hoogude esinemissagedus ei 
olnud kõige tähtsam sotsiaalse stressi 
näitaja, kuigi parem kontroll hoogude üle
oli korrelatsioonis üldise heaoluga (25).
Nii arst kui ka patsient koondavad oma 
tähelepanu tavaliselt hoogude sagedusele 
ja raskusele. Eesmärk pärast diagnoosi 
määramist ja mvi alustamist on hoogu­
dest vabanemine. Kahjuks korduvad need 
70%-l komplekssete partsiaalsete hoogu­
dega täiskasvanuist ravile vaatamata 
(20). Komplekssed partsiaalsed hood on 
epileptilised hood, mille aluseks olsv aju 
bioelektrilise aktiivsuse ülemäärane tõus 
algab hemisfääri ühee osas. Need hood 
kulgevad teadvushäiretega, miile väljen­
duseks on reageerimatus välistele ärrita­
jatele ja automatismide avaldumine (näi­
teks suu matsutamine, huuite lakkumine, 
sõrmede keerutamine, vahel ka eesmär­
gistatud tegevus). Kuigi isik on hoo ajal 
ärkvel, eeineb tai toimunu suhtee hiljem 
tihti amneesia.
Edasi sõltub ravi korrigeerimine suu­
resti patsiendist endast. Arst võib ravi 
muuta vastusena selle patsiendi ohtrate­
le kaebustele, kel esinevad harvad hood, 
kuid mitte muuta ravi teise sama hoogu­
de arvuga patsiendi puhul, kes peab oma 
seisundit rahuldavaks. Sageli hindavad 
sama tüüpi epilepsiahoogudega isikud, 
kellel hood alluvad ka ravile samaselt ja 
kes taluvad ka ravi kõrvaltoimeid sama­
selt, epilepsia mõju oma igapäevaelule 
täiesti erinevalt, sõltuvalt sellest, mida 
kumbki enda jaoks piiranguna tunnetab 
(11).
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Epilepsia korral põhineb haiguae raskuse 
hindamine tavaliselt hoogude sageduse 
arvestamisel, kuid hoogude arvu ja nende 
tagajärgede vahel ei pruugi olla selget 
vastavust. Isikutel, kellel esineb refrak- 
taame (ravile allumatu) epilepsia, võtb 
hoogude raskus olla tähtsam psühhosot- 
aiaalse heaolu determinant kui hoogude 
segadus. Samal fi^ al, kui isiku puhul, kel­
lel esinevad kerged hood, võib suurimaks 
probleemika olla hoopis epilepsia diag­
noos ise (23). Samuti ei pruugi hoogude 
tüüp haiguse raskust рт^вкЫа.
Näiteks võib lihtne partsiaalne hoog 
(epilepeiahoog, mille aluaeks edev aju 
bioelektriliae aktiivsuse ülemäärane tõus 
algnh hesniiftkri Qhee oaas nmg mk ei 
põlyueta teadvushäiret) nähtava ja kont­
rollimatu motoorse komponendiga olla 
inimesele subjektiivselt häirivam kui ker­
ge teadvuse hägunemise ja а£ммаада kul­
gev kompleksne partsiaalne hoog, mis 
jääb kõrvalseisjaile märkamatuks (9).
Hoo raskuse hindamine annab lisain­
formatsiooni ka neil juhtudel, kui sama 
hoogude sai^duse juures muutub nende 
.kvaliteet, näiteks ilmnevad muutused 
automatismide (sihipäratu, kontrollima­
tu, tahtliku juhtimiseta toimuv (auto­
maatne) liigutus või liigutuste kompleks) 
raskuses, esineb fftfeam kukkumisi ja vi 
g*sfe«et hoo «да!, kiire® taastumine vms. 
(21).
Boofttäe r&sšmm jm. efeJkvaMSeedä 
кЫ аавке' riaw hd. Hoogude rsakuae 
hindamiseks oa kasutatud erinevaid 
skaalasid, kuid laiaklaaeit ei oie neist le­
vinud ükski. Iga skaala abil on võimalik 
koguda teatav punktisumma, mille abil 
hinnatakse seisundit secsas hoogude sa- 
gpthmttgn kindlaks määratud perioodi väi- 
tel. Ameerika Ühendriikides riiklikult fi- 
aanteeeritavsi sõjaveteranide tervš»- 
homorganiaaitskxmi epilepeaauuringute 
grupi poolt väljatöötatud hoogude sagedu­
se ja raskuse hindamise skaala (The Vete­
ran» Affair» (VA) Seizure Frequency and 
Severity Seale) on kasutusel kliinilistee 
katsetes, et dokumenteerida nii hoogude 
arvu kui ka tüüpi.
Inglismaalt pärit Chalfimdi hoogude 
skaala (The Chalfoni Seizure Scale) ning 
selle lühendatud ja  lihtsustatud variant 
— NHS3 (The National Hoepited Seizure 
Severity Scale) — koondavad tähelepanu 
hoogude objektiivsete parameetrite re­
gistreerimisele. Neid skaalaaed täidab 
arat, kes küsitleb pftisieoti ja  võõaalrae 
korral ka hoogu peaknäinud isikut. Liver- 
pooli skaala (The Liverpool Seale) kujutab 
endast küsimustikku, mis põhineb pat­
siendi tunnetatud epilepsia mõju ning 
hooaegnte ja  -järgsete nähtude arvesta­
misel (21).
Küllaltki laialdaselt kasutusel olev 36 
punktiline ükiise tsmsega seotud dukva- 
liteedi hindamise küsimustik SF-36 (The 
RAND 36 Item Health Survey (Short 
Form-Эв)) on tuletatud pikemast uurimis- 
vahendist, mille on vftjja tõõtanud Amee­
rika Ühendriikide (Santa Monks.. CA) 
RAMD-i instituudi teadksed. See vahend 
hõlmab küsimusi, mis puudutavad sellt- 
ssid valdkondi nagu sotäa&lne tegevus, 
depressiooni olemasolu ja sügavus» füüsi­
lise aktiivsuse tase jne., et peeg^kJjssla 
igapäersast toimetulekut (11). O. Devinsky 
ja  kaasautorid on aelle põhjal välja tööta­
nud uue küsimustiku, mis võimakkb hin­
nata patsientide seisundit pärast epilep­
sia tõttu rakendatud kirurgilist mvi (13).
1990-ndate aastate algu! äIus&žss 
RAND-i epiieptoloogidest ja  sotsioloogi­
dest koosnev uuriauemeeskond (The 
QOLIE (Quality ofUfe in Epüepey) Deve­
lopment Group) uue, laiahaardelisema 
epilepsiaapetsüiiUee umimisvahendt 
väljatöötamist. Тбб tulemusena valmis 
kolm küsimustikku, mida esmakordselt 
tutvustati Ameerika Epilepsia Ühingu 
(The American Epilepsy Society) koosole­
kul 19Ö2. aastal. Need küsimustikud cm; 
QOLIE-89 (hõlmab 17 valdkonda, mis si­
531
saldavad 89 küsimust), QOLIE-31 (7 vald­
konda, 31 küsimust) ja  QOLIE-IO (10 kü­
simust). Kaks esimest küsimustikku on 
mõeldud ravimite või kirurgilise ravi 
mõju hindamiseks ning erinevate patsien- 
tiderühmade võrdlemiseks, kolmas on 
mõeldud kasutamiseks kliinilises prakti­
kas, et valgustada probleeme, mis ei pruu­
gi veetluse käigus ilmsiks tulla (10).
QOLIE-31 küsimustik on kasutusel ka 
TÜ Närvikliinikus käimasolevas Tartu 
linna täiskasvanud epilepeiahaigete elu­
kvaliteedi uuringus. Selle vahendi abil on 
võimalik hinnata järgmisi valdkondi: ül­
dine elukvaliteet, energia, emotsionaalne 
heaolu, mure hoogude pärast, kontsent­
ratsiooni võime, töö ja  sotsiaalse tegevuse­
ga toimetulek, mälu, ravi mõju igapäeva­
elule ja üldine tervis (13).
Suuremad maailmas läbiviidud 
epilepeiahaigete elukvaliteedi uurin­
gud. 15 Euroopa riigis, millest suurima 
vastajate arvuga olid Suurbritannia, 
Prantsusmaa, Madalmaad ja Saksamaa, 
esines uuringu andmeil 5200 täiskasva­
nud epilepaiahaigeet rohkem kui ühel kol­
mandikul hooge kord või sagedamini 
kuus. Viiendik tundis, et nende hood ei ol­
nud raviga hästi kontrollitud. 38%-l ei ol­
nud viimasel aastal hooge esinenud. Epi- 
lepeiavastast ravi sai 96%, 47% monote- 
raapiana (neist 53% karbamasepiini, 33% 
valproaati, 25% fenütoiini ja  14% fenobar- 
bitaali). 36% tarvitas kahte preparaati, 
13% kolme või enamat ravimit. Ravist tin­
gitud kõrvaltoimeid esines palju, sageda­
mateks olid väsimus, mäluprobleemid ja 
kontsentreerumisraskueed. Kõrvaltoi­
meid ei esinenud 12%-1. Umbes pooled 
tundsid end epilepsia tõttu stigmatiseeri- 
tutena. Küsimusele, kui väga nad oma 
epilepsia pärast muret tunnevad, vastas 
48%, et nad muretsevad väga palju või 
palju; üldse ei muretsenud 15% (3).
Võrdlusena toodud meie poolt Tartu lin­
na 30 epilepeiahaige hulgas korraldatud 
pilootuuringu andmeil esines hooge kord
või sagedamini kuus 27%-l; viimase aasta 
jooksul ei olnud hooge esinenud 33%-l. 
Kõikidest vastanutest sai epilepeiavas- 
tast ravi 93%, neist monoteraapiana 77%; 
kaks preparaati 7%, kolm või enam pre­
paraati 10%. Erinevusi ilmnes konkreet­
sete ravimite tarvitamise osas: monote­
raapiana sai karbamaaepiini 65%, valp­
roaati 9%, primidooni 22% ja  bensonaaii 
4%. Kõrval toimetena toodi kõige enam 
esile peavalu, unisust ja  südamekaebusi. 
Pooled vastanuist tundsid väga või mõõ­
dukalt muret selle üle, et kui nad kestvalt 
tarvitavad ravimeid, siis võivad need nei­
le halvasti mõjuda.
Pisut varem Suurbritannias ligikaudu 
1000 epilepeiahaige hulgas korraldatud 
uuring näitas, et kui isikute hulgas, kelle 
epilepeia oli remissioonis, esines ärevust 
13%-1 ja  depressiooni 4%-l* siis sagedate 
hoogudega isikute hulgas vastavalt 44% 
ja 21%. Sagedate hoogudega isikud (need, 
kellel esines hooge kord või sagedamini 
kuus) hindasid epilepsia mõju igapäeva­
elule väga suureks või suureks 2—3 kor­
da sagedamini. 62% tundis end epilepeia 
tõttu stigmatiseerituna, võrreldes 40%- 
ga, kel esines hooga harvemini kui kord 
kuus, ja 25%'ga, kellel viimase aasta jook­
sul hooge ei ole esinenud. Psühhoeotsiaal- 
aele staatusele kõige tugevamat mõju 
avaldavaks näitajaks oli hoogude sage­
dus.
Ärevuse astmega korreleerusid epilep­
sia keetus ja naissugu, depressiooniga 
epilepsia kestus, vanus epilepeia avaldu­
misel ja praegune vanus. Stigmat tunne­
tasid oluliselt rohkem need, kellel epilep­
sia oli alanud vanemas eas. Mis puutus 
haiguse remissiooni ja psühhoeotsiaal.se 
staatuse suhtesse, siis kõik peühhoeot- 
siaalset staatust iseloomustavad näitajad, 
v.a. rahulolu materiaalse kindlustatuse 
üle, olid paremad neil, kellel epilepeia oli 
remissioonis (18).
Meie pilootuuringu andmeil tegid hoo­
gudest tingitud sotsiaalsed probleemid
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väga või mõõdukalt muret 57%-le küsitle­
tuist. Piirangute tõttu sotsiaalsetes suhe­
tes kannatas 63%, samal ajal kui epilep­
sia mõju vaba aja veetmisele pidas suu­
reks või väga suureks ainult 13%.
Üksikasjalikumaid järeldusi tegemata 
võib öelda, et ka meie ühiskonnas on prob­
leemid selles valdkonnas suured ning va­
javad esmalt täpsemat väljaselgitamist. 
Uuringute alusel tehtud kokkuvõtetes rõ­
hutatakse aeda, et epilepsiahaigete elu­
kvaliteedi parandamise võtmeks on hoo­
gude üle parema kontrolli saavutamine ja 
samal ajal epilepsiavastaseet ravist tingi­
tud kõrvaltoimete vähendamine, samuti 
epilepsia tSttu tunnetatud stigma vähen­
damine nii epilepsiaga isikute kui ka 
ühiskonna teadlikkuse tõstmise kaudu (3, 
18).
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Summary
The quality of life of adults in  case of 
epilepsy. Epilepeia is a stigmatising disorder 
and available evidence suggests that i t s  d i a ­
gnosis can have important psychosodal con­
sequences and severely reduce the quality o f  
an individual’s everyday life. This is a  review 
of the literature of the nature of stigma and 
the quality of life in epilepsy. Different scales 
to  evaluate the seizure severity and health-re­
lated qualify of life are described. Also brief in­
formation about the findings from the recent 
largest studies investigating the quality of life  
in epilepsy a s  compared to the results o f  th e  
pilot-study we conducted is  g iven .
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M. Rätsepp. Epilepsia mõju isiku psühhosotsiaalsele adaptatsioonile. 
Haigestumist ja tervenemist soodustavad psühhosotsiaalsed tegurid.
Tallinn: TPÜ kirjastus 1999; 49-56 (in Estonian).
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EPILEPSIA MÕJU ISIKU PSÜHHOSOTSIAALSELE 
ADAPTATSIOONILE
Marju Rifsepp
Tartu Ülikooli närvikliinik
Epilepsia piirdub suuremal osal juhtudest harvaesinevate, lühiaegsete, iselõppe- 
vate hoogudega. Sellele vaatamata tunnevad seUe haigusega inimesed end iga­
päevaelus stigmatiseeritutena (ehk “ märgistatutena” ). Käesoleva uuringu üheks 
eesmärgiks oli epilepsia mõju hindamine isiku psühhosotsiaalsele adaptatsioonile 
Uuring haiaras 90 Tartu linnas elavat epilepsiaga isikut. Umbes kolmandikul vas­
tanutest esines hooge kord või sagedamini kuus. Üle poolte tunnistasid, et neid on 
nende haiguse tõttu tööle võtmisel või tööjuures koheldud ebaõiglaselt. Üle poolte 
tundsid end epilepsia tõttu stigmatiseeritutena. Uuring näitas, et epilepsia mõju 
oma igapäevaelule hindasid suurimaks need, kel esinesid sagedased hood, ja need, 
kel esinesid generaliseeritud toonilis-kloonilised hood koos mingit muud tüüpi 
hoogudega. Parema psühhosotsiaalse adaptatsiooni ja toimetuleku saavutamisel on 
meditsiinilisest seisukohast oluline eelkõige parema kontrolli saavutamine hoogu­
de üle. Lisaks on oluline nii ühiskonna teadlikkuse kui epilepsiaga isikute enese­
teadvuse tõstmine.
SISSEJUHATUS
Termin “ epilepsia” tuleneb kreeka sõnast, mis tähendab “ kinni haarama” , “ oma 
valdusesse võtma” või “ ülemvõimu omama” . Antiikkreeklased viitasid epilep­
siale kui “ pühale haigusele” ning pidasid seda põdevaid inimesi jumala poolt 
väljavalituiks. Hiljem on suhtumine epilepsiasse muutunud, epilepsiahoogudes on 
nähtud deemonliku hõlmatuse väljendust. Tänaseni on see haigus paljudes ühis­
kondades jäänud suures osas valesti mõistetuks (13). Epilepsia on haigus, mille 
korral normaalse neuroloogilise funktsiooniga perioodid vahelduvad harvade, lühi­
keste hoogude-perioodidega. Mitmete krooniliste haiguste puhul esinev haigus- 
nähtude avaldumise ootamatus, mis tekitab inimeses pideva kindlusetustunde, on 
epilepsia puhul eriti ilmekalt väljendunud. Haiguse raskus ja prognoos on variee­
ruvad ning hood selle välise ilminguna ette ennustamatud. Epilepsia on oma ole­
muselt stigmatiseeriv, mis tähendab, et sellega kaasnevad psühhosotsiaalsed 
probleemid kaaluvad sageli üles kliinilised probleemid. Goffman defineerib
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stigma (kr. stigma -  arm, märk) sisemise häbitundena, mis võib muuta inimese 
iseloomu nii. et tal tekivad tõsised suhtlemisprobleemid, mis omakorda tekitavad 
raskusi ja langetavad motivatsiooni toimetulekuks ühiskonnas (11). Stigma kuju­
nemisel näevad nii Goffman kui Becker olulist rolli ühiskonnas valitseval üldisel 
suhtumise! inimestesse, kes on millegi poolest erinevad, ning nende suhtes kehtes­
tatud reeglites ja piirangutes (3, 11). Scambler rõhutab stigma olemasolu just 
epilepsia korral (18). Uuringutega on esile tõstetud mitmeid erilist tähelepanu 
väärivaid valdkondi (5, 7, 12). Epilepsiaga isikutel on tihti vähenenud enesest 
lugupidamine (4). sagedamini kui rahvastikus keskmiselt esineb neil ärevust ja 
depressiooni (6). Nende hulgas tuleb suhteliselt sageli ette töötust või tööga aia- 
hõivatust (10), samuti on suurem sotsiaalne isolatsioon ja madalam abielus olevate 
inimeste protsent (1, 9). Epidemioloogilised uuringud on näidanud, et 70-80%-! 
epilepsiaga inimestest alluvad hood hästi antiepileptilisele raviie (17) ning nende 
puhul ei tohiks epilepsia otseselt ebikvaliteeti alandada (13). Goodridge ja Shor- 
von leidsid oma uuringus, et ainult 20%-l patsientidest esines krooniline, ravim- 
resistentne epilepsia. Jacoby jt, hinnates patsiente, kelle! ei olnud hooge esinenud 
mitme aasta vältel, leidsid, et neil, kelle epilepsiavastane ravi jätkus, esines 
märgatavalt rohkem stressi võrreldes nendega, kelle ravi oli lõpetatud (i5). Nii 
arst kui patsient koondavad oma tähelepanu tavaliselt hoogude sagedusele ja 
raskusele. Eesmärk pärast diagnoosi püstitamist ja ravi alustamist on hoogudest 
vabanemine. Kuid sageli hindavad isikud sama tüüpi hoogudega, mis alluvad ka 
raviie sarnaselt, ja kes taluvad ravi kõrvaltoimeid sarnaselt, epilepsia mõju oma 
igapäevasele elule täiesti erinevalt, sõltuvalt sellest, mida kumbki isik tunnetab 
enda jaoks piiranguna (8).
UURINGU EESMÄRK
Meie poolt läbiviidava uuringu üheks eesmärgiks oli uurida epilepsia ja selle ravi 
mõju epilepsiaga isikute üldisele elukvaliteedile, sealhulgas ka psühhosotsiaalsele 
adaptatsioonile.
MEETODID
Uuring hõlmas 90 Tartu ünnas elavat epilepsiaga isikut vanuses 16-89 eluaastat, 
kes omasid vähemalt algkooli tasemel lugemis-ja kirjutamisoskust. Algandmed 
patsientide kohta pärinesid eelnevalt läbi viidud epidemioloogilise uuringu mater­
jalidest. Antud uuringusse kuuluvatei isikutel oli esinenud vähemalt 2 provot­
seerimata hoogu, neist vähemalt üks ligikaudu viimase viie aasta jooksu!. Uuringu 
käigus täitsid kõik selles osalejad küsimustiku hoogudesse puutuvate kliiniliste 
näitajate ja demograafiliste andmete kohta kas neuroloogi vastuvõtule tulles või 
kodus, vastates posti teel saadetud ankeedile. Stigma tunnetamise hindamiseks 
kasutasime 3-küsimuseiist skaalat, mille igale küsimusele sai anda “jah” või '‘ei"
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vastuse. Stigma olemasolu ja raskust hindasime “jah” -vastuste summa alusel Pat­
sientidel tuli vastata järgmistele küsimustele: kas Teil on vahel tunne, et Teie 
epilepsia tõttu teised inimesed tunnevad end Teiega ebamugavalt; on kohelnud 
Teid alaväärsetena; on eelistanud Teid vältida.
TULEMUSTE ANALÜÜS
Uuringus osalejate demograafilised ja kliinilised näitajad (tabel 1, 2).
Tabel 1. Vastanute tähtsamate demograafiliste näitajate võrdlus.
PARAMEETER %
OSALEJAD
Vanus (keskmine) 42;5 а
M/N 41/49 45,6/54,4
Perekonnaseis:
abielus/vabaabielus 39 43,3%
vallaline 33 36,7%
lahutatud 1 1 12.2%
iesk 7 7.8%
Tdöfeõive:
töötab täiskohaga 30 33,3%
töötu või alahõivatud ■ 32 35,6%
pensionil 9 10,0%
invaliidsuspensioni! 14 21,1%
Igr 1 3.4%
II gr 24 82,8%
Iil gr 4 13.8%
Haridus:
alla 8 klassi 5 5.6%
8 või 9 klassi 29 32,2%
kesk- või keskeriharidus 45 50,0%
kõrgem 11 12,2%
Autojuhiload
olemas 12 13%
kehtivus katkestatud epilepsia tõttu 1 1 12%
ei ole 67 75%
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Tabel 2. Vastanute tähtsamate hoogudega seotud näitajate võrdlus.
PARAMEETER UURINGUS
OSALEJAD
%
Vanus epilepsia diagnoosimisel (keskmine) 26,9 a
Epilepsia kestus (keskmine) 17,2
Hoogude sagedus viimase aasta jooksul:
pole esinenud 29 32,60%
harvemini kui 1 kord kuus 32 36,0%
kord või sagedamini kuus 28 31,5%
Epilepsia diagnoositud
kuni 5a tagasi 19 21,30%
kuni 10a tagasi 14 15,70%
kuni 20a tagasi 22 24,70%
üle 20a tagasi 34 38,30%
Vanus esimese hoo ajal
kuni 10a 8 9%
11-20a 30 33,70%
21-30a 20 22,50%
31-40a 12 13,50%
41-50a 9 10,10%
üle 50a 10 11,20%
Neist, kes viimase aasta jooksul olid olnud 
hoovabad, esines viimane hoog
kuni 2a tagasi 29 32,10%
2-5a tagasi 51 57,10%
üle 5a tagasi 10 10,70%
Oma hooge hindas ise väga rasketeks 10%, rasketeks 31,1%, keskmisteks 37,8% 
ja kergeteks 21,1%. Ilmnes statistiliselt oluline seos: need, kel esines hooge sage­
damini, pidasid neid ka raskemateks.
Kõikidest vastanutest sai antiepileptilist ravi 88,9%, neist ühte ravimit tarvitas 
76,7%.
Tööhõive ja sotsiaalne seisund
Neist, kes olid tööga alahõivatud või töötud, pidas 63% selle põhjuseks ka epilep­
siat. Statistiliselt oluline seos ilmnes siin hoogude sagedusega. Viimase kahe aasta 
jooksul oli töökohta vahetanud 32% vastanutest. Ka siin ilmnes oluline seos hoo­
gude sagedusega. Küsimusele, kas neid on kunagi epilepsia tõttu tööle võtmisel
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või tööjuures koheldud ebaõiglaselt, vastas jaatavalt 55,4%. Statistiliselt oluline 
seos ilmnes täiskohaga töötamise ja hoogude sageduse vahel: need, kel esines hoo­
ge sagedamini, töötasid väiksema tõenäosusega täiskohaga. Samuti ilmnes oluline 
seos hariduse ja täiskohaga töötamise vahel: mida kõrgem oli haridus, seda suure­
ma tõenäosusega töötas isik täiskohaga.
Stigma tunnetamine
51% vastanutest tundis end epilepsia tõttu stigmatiseerituna, 14% vastas “jah" 
kõigile kolmele küsimusele, mis näitab, et nad tunnetasid seda väga tugevalt. 
Stigma tunnetamine sõltus hoogude tüübist: suurema tõenäosusega tundsid end 
stigmatiseerituna need, kel esinesid generaliseeritud toonilis-kloonilised hood koos 
mingit muud tüüpi hoogudega, samuti tunnetasid nad suurema tõenäosusega 
stigma tugevamini. Statistiliselt olulist seost hoogude sagedusega tõestada ei õn­
nestunud, kuid ilmnes selge tendents stigma tunnetamise tõenäosuse suurenemi­
sele sagedamini esinevate hoogude korral (tabel 3).
Tabel 3. Stigma tunnetamine hoogude sageduse alusel.
Parameeter 0
Tunnetatud stigma 
1 2 3
Hoogude sagedus:
kord või sagedamini kuus (%) 41.2 36,7 16,6 5,5
harveminii kui kord kuus (%) 50,0 15,0 10,0 25,0
pole esinenud viimase aasta jooksul (%) 57,9 15,8 15,8 10,5
Kõik vastanud (%) (=100%) 49 23 14 14
Stigmat tunnetasid suurema tõenäosusega enam need, kes hindasid oma hooge ras­
keteks või väga rasketeks; lisaks võis täheldada statistiliselt olulist seost mitmete 
teiste näitajatega (tabel 4). Stigma tunnetamise raskus sõltus ka epilepsia kestu­
sest: kui neist, kes tundsid end stigmatiseeritutena ja kellel epilepsiat oli diag­
noositud kuni 5a tagasi ning kuni 10a tagasi, vastas kolmele stigma tunnetamist 
näitavale küsimusele “jah” 0%. siis nende gruppides, kellel epilepsiat oli diagnoo­
situd 20a ja üle 20a tagasi, olid need protsendid vastavalt 25 ja 46 (p=0,03).
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Tabel 4. Stigma tunnetamise seos erinevate näitajatega.
Näitaja P*
Stigma
Subjektiivne hinnang hoogudele 0,03
Hirm järgmise hoo ees järgneva 4 nädala 
jooksul
Mure hoo tõttu piinlikku olukorda sattumise
<0,001
pärast järgneva 4 nädala jooksul
Mure ravimite ebasoovitavate kõrvaltoimete
<0,001
avaldumise pärast kestval kasutamisel 
Arvamus, et töötuse või tööga alakoormatuse
0,01
põhjuseks on ka epilepsia
Arvamus, et epilepsia tõttu on neid kunagi tööle
0,009
võtmisel või tööjuures koheldud ebaõiglaselt 0,03
*Seoste olulisuse tõenäosuse leidmisel on kasutatud hii-ruutu.
DISKUSSIOON
Antud uuring käsitles epilepsia mõju inimeste psühhosotsiaalsele adaptatsioonile. 
Et kõik uuringus osalejad olid epidemioloogilise uuringu käigus juba eelnevalt läbi 
vaadatud, siis on põhjust arvata, et vastasid eelkõige need, kes tunnetasid oma hai­
gusest tulenevaid probleeme kõige tugevamini ning seega peegeldab uuring eel­
kõige nende seisukohti. Monoteraapiat sai 76,7%, mis on tunduvalt kõrgem võr­
reldes mujal läbi viidud uuringutega (2, 14, 16). kuid ilmselt oli see tingitud 
sellest, et valitud uuritavate gruppi oli tihti spetsialistide poolt läbi vaadatud ning 
ravi korrigeeritud. On rõhutatud, et kroonilist haigust põdevate inimeste puhul on 
oluline mitte ainult see, et nad oleksid sümptomitevabad, vaid et nad elaksid nii 
normaalset elu kui võimalik (19). Meie poolt uuritud isikutest 32,6%-t ei olnud 
viimase aasta jooksul hooge esinenud ja 36%-l tuli neid ette harvemini kui kord 
kuus. Seega tuleb arvesse eeskätt toimetulek ravist tingitud probleemide ja epilep­
siast põhjustatud psühhosotsiaalsete probleemidega. Epilepsia mõju oma igapäeva­
sele elule hindasid suurimaks need, kel esinesid sagedased hood, ja need, kel esi­
nesid generaliseeritud toonilis-kloonilised hood koos mingit muud tüüpi hoogu­
dega. End rohkemal või vähemal määral stigmatiseeritutena tundis 51% vasta­
nutest. Nende isikute hulgas, kel generaliseeritud hooge ei esinenud, ja nende, 
kel viimase aasta jooksul hooge ei olnud esinenud, oli end stigmatiseeritutena 
tundvate isikute protsent väikseim. Stigma tunnetamisega kaasnes suurema hirmu 
tundmine ootamatute hoogude ees ja hirm sattuda seetõttu piinlikku olukorda ning 
muretsemine selle üle, et kestval tarvitamisel võivad antiepileptiIised ravimid 
halvasti mõjuda. Kõige halvemaks hindasid oma elukvaliteeti 41-50-aastased al la
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8 kl haridusega lahutatud või lesestunud isikud, kel hood esinesid kord või sage­
damini kuus. Üksikuid inimesi (vallalised, lahutatud või lesed) oli kokku 56,7%. 
Töötuid või tööga alahõivatuid oli 35,6%, neist 63% pidas selle põhjuseks ka 
epilepsiat. Üle poolte märkisid, et neid on nende haiguse tõttu tööle võtmisel või 
töö juures koheldud ebaõiglaselt. Tulemuste alusel võib väita, et parema psühho- 
sotsiaalse adaptatsiooni saavutamisel on oluline hoogude sageduse langetamine, mil­
le aluseks on korrigeeritud antiepileptiline ravi võimalikult minimaalsete kõrval- 
toimetega. Hoogude vähenemisega on otseselt seotud stigma tunnetamise nõrge­
nemine ja toimetulek probleemidega. Rõhutamist väärib aga see, et võrdselt olu­
line on nii ühiskonna teadlikkuse kui epilepsiaga isikute eneseteadvuse tõstmine.
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This article examines the impact o f epilepsy and its treatment on employment status and the extent o f stigma among patients 
with epilepsy.
Clinical and demographic data concerning patients examined during a recent epidemiological survey were obtained from 
medical notes and postal self-completed questionnaires.
Information was collected from 90 patients aged 16-70 years. A third of the respondents had been seizure-free during the last 
year. Thirty-nine percent were working full-time, 24% were working part-time and 11% were unemployed. Sixty-three percent 
from those working part-time or unemployed considered their epilepsy to be a significant reason for this. Overall, 55.4% 
beiieved they had been treated unfairly at work or when trying to get a job. Fifty-one percent of respondents felt stigmatized by 
epilepsy, 14% of them highly so.
The level of employment among epileptic people was not lower than in the general population. The percentage o f stigmati 
zation in general and the percentage of the severely stigmatized was as high or even higher than in other studies. Occurrence of 
stigma and its severity depended first and foremost cn the type of seizures. H ie frequency of seizures was not clearly related to 
this.
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INTRODUCTION
Several investigators have discovered psychological 
and social problems among people with epilepsy. Liv­
ing with epilepsy necessitates paying attention to more 
than seizures. Though being episodic, they impact on a 
wide range of daily activities and feelings. The misun­
derstanding and the resulting social stigma surround­
ing epilepsy can often cause more suffering than the 
seizures themselves. Patients with epilepsy often feel 
stigmatized by their condition1-3. Felt stigma has been 
described as the shame associated with being epileptic 
and a source of unhappiness3. Different authors have 
stressed that in order for stigma to exist, individuals 
must accept their devaluation4. A person’s own reac­
tion to having a seizure disorder is even considered the 
most significant factor in adjustment5. The perception 
of stigma can reduce motivation for work and social 
activity6. Nowadays, it has become relatively common 
to have patients make a judgement about their medical
1059-1311ЛХУ080394 + 06 $35.00/0
care7. It means they must have the courage to express 
their opinion and to show their dissatisfaction. Individ­
uals with epilepsy often have problems with employ­
ment8'9, although there is evidence that when seizures 
are well-controlled and uncomplicated by any other 
handicap they do not generally experience problems10. 
Part-time employment and unemployment have been 
identified as two very serious problems among peo­
ple with epilepsy5, being closely connected to overall 
well-being11, К  Many investigators have studied the 
problems accompanying epilepsy, however data from 
Eastern European countries are scarce.
Estonia is a newly independent state, re-established 
after the collapse of the Soviet Union which geo­
graphically is positioned in Eastern Europe on the 
Baltic Sea coast. Today, of the 1.5 million people who 
live in Estonia, 64.6% are ethnic Estonians. Among 
other nationalities, Russians represent the largest fig­
ure (about 28.5%). The Russian-speaking population 
is not evenly distributed throughout the counfty13.
©  2CC0 BEA Trading Ltd
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Southern Estonia is focused on Tartu, the historic uni­
versity town and the country’s second largest city. Be­
ing the intellectual and educational centre of Estonia, 
Tartu demonstrates quite typical demographic charac­
teristics for Estonia with the exception that the per­
centage of the Russian-speaking population is lower 
than in Estonia in general.
The present report is a preliminary study and the first 
in its fieid in our country. The aim of the study was 
to examine the impact of epilepsy and its treatment 
on employment status and the extent of stigma among 
individuals wish epilepsy, focusing on the following 
questions: What is the current treatment status? How 
many people feel stigmatized by their epilepsy? What 
is the relationship between feelings of stigma and the 
main clinical characteristics describing seizures? Do 
the feelings of stigmatization make it more difficult 
to perceive the psychosocial problems connected to 
epilepsy and employment status? What is the current 
employment status of the respondents? To what extent 
is it affected by their disease? Had there been any oc­
casions when people had been treated unfairly at work 
because of their epilepsy?
S U B JE C TS  AND M ETH O D S
The research took place between 1997 and 1998 and 
followed an epidemiological survey of epilepsy in the 
city of Tartu. Estonia. The epidemiological survey in­
cluded persons who were residents of Tartu and were 
aged 19 and over, and had before or within the course 
of 01/01/1991-01/01/1996 had at least two unpro­
voked epileptic seizures, at least one of them within 
the previous 5 years. Data collection for epidemio­
logical study consisted of two parts: data registration 
from a multi-source medical register review and data 
registration from a personal case re-examination. Case 
records of patients treated in the University Hospital, 
Outpatients’ Clinics, physicians offices, emergency 
rooms and the electroencephalograpic laboratory with 
a diagnosis of epilepsy, convulsions, syncope, amnes­
tic attacks and abnormal involuntary movements were 
reviewed and invitations for re-examination were sent 
to the suitable persons. Over the last 2 years, all the 
patients were re-examined at least once by a neurolo­
gist to specify the type of their seizures. This present 
study was based on the analysis of data collected from 
a sample of 90 patients, in the 16-70 year age group. 
The patients were picked out randomly from the pre­
liminary lists of the epidemiological study leaving out 
the people who were not capable o f  understanding Es­
tonian (mostly the Russian-speaking people) because 
there were not any sufficiently well translated and val­
idated questionnaires available for them. All patients 
gave their consent to participate in the research and
Stigmatization and emptoymant probtam* in apllapsy
the project was approved by the Ethics Committee of 
the University of Tartu. All of the respondents had at 
least a basic education level with sufficient ability to 
read and write, and were capable of understanding and 
completing the questionnaires. Clinical information, if 
needed, was abstracted once again from medical notes 
and during the personal re-examination of subjects. 
Abstracted information used in the study related to 
the etiology of epilepsy, classification of seizure type 
and current antiepileptic drug (AED) therapy. To eval­
uate the impact of epilepsy on employment status and 
perceived stigma, the patients were sent a question­
naire through the mail. Following the example of other 
quality-of-life studies conducted among epileptic peo­
ple10, 14_16, the questionnaire employed a combination 
of open questions together with a previously translated 
and validated scale (The Stigma of Epilepsy Scale). 
In addition, single items were included which referred 
specifically to feelings of stigmatization in the areas 
of employment (Table 1). The questionnaire contained 
a number of questions covering the following issues. 
(1) Demographic characteristics: information was ob­
tained about subjects’ sex, age, marital and employ­
ment status, and education level. (2) Economical and 
financial status: patients were asked to state whether 
they considered it to be 'very good’, ‘good’, ‘satis­
factory’, ‘moderately bad’, or ‘very bad’. (3) Seizure 
frequency: patients were asked whether they had had 
one or more seizures in a month, less than one a 
month, or not at all in the past year. (4) Previous re­
search has shown that patients’ perception of the sever­
ity of their seizure disorder may be more important 
than seizure frequency in determining their psycholog­
ical and social well-being17. Therefore, subjects were 
asked to assess their seizures as ‘very severe’, ‘severe’, 
‘medium’, or ‘light’. (5) AED treatment and side ef­
fects: patients were asked about the AED they were 
taking and about the experienced side effects during 
the past month, as well about the satisfaction with the 
current treatment and about the changes in AED med­
ication in the past year. (6) Compliance with medica­
tion: patients were asked to state whether they never 
missed taking their AEDs, missed less than once a 
month, missed less than once a week, or missed more 
than once a week. According to other studies, correla­
tions between patient reports and objective methods 
has been shown to be high14. (7) Perceived stigma 
was measured with a three-item Stigma Scale, devel­
oped originally for stroke18, which was adapted for 
epilepsy and is already used in other quality-of-life 
studies14,15. Respondents with epilepsy had to state 
whether they; (a) felt that other people were uncom­
fortable with them, (b) treated them as inferior, or 
(c) preferred to avoid them. Each of the three items 
required a yes/no response. An individual’s score was 
the sum of the ‘yes’ responses and the higher the score,
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the greater the perception of stigma was. The scale 
was translated into Estonian by two independent na­
tive Estonian speakers with an excellent knowledge of 
English. The translators then met to discuss and agree 
upon a common version of the questionnaire. Subse­
quently, the common version was evaluated by another 
native Estonian speaker in terms of conceptual equiv­
alence, linguistic performance and clarity. The agreed 
upon Estonian form was then backtranslated into En­
glish and rated. If modifications were necessary, the 
re-formulation id the Estonian version was performed. 
The internal consistency of the scale was examined 
using Cronbach’s alpha and found to be acceptable 
(a =  0.71)19. The evidence for the construct validity 
of the scale was supported by the data received follow­
ing the hypotheses that patients with frequent seizures 
and mixed seizure types would score poaitively on 
the scale. (8) The impact of epilepsy on employment 
history—those currently in part-time employment or 
unemployed—were asked whether the reason for it 
was their epilepsy, whether they had changed jobs in 
the preceding 2 years because of epilepsy and whether 
they had been treated unfairly at work because of 
epilepsy. Each of the items required a yes/no response.
When analysing the data, the unemployed and part- 
time employed were counted together because it is 
not common in our country to work part-time since 
it causes serious financial difficulty in coping with ev- 
eiyday life. Patients were divided into three groups by 
seizure type (as having only tonic-clonic, only other 
types, or both tonic-clonic and other types) and fre­
quency (based on seizure occurrence occurring once 
or more a month, less than once a month, or not at all 
in the past year).
Statistical methods
The data were analysed using the statistical analysis 
package SPSS Professional Statistics™ 7.520. Tests 
of significance were x 1 (chi-squared) and Spearman’s 
rank correlation. Attention is drawn to results where 
differences were significant at the 5% level or less 
(P  < 0.05). To test the reliability of the Stigma scale, 
Cronbach’s alpha was used19.
Response to the study
Questionnaires to be completed individually were 
mailed to 110 patients, of whom 78 replied—a 
response rate of 71%. After sending a reminder, 
16 patients returned their questionnaires. From all the 
questionnaires returned, 19 appeared to be unusable: 
in six of them more than 10% of the questionnaire was 
left unanswered, three were sent back with a note that
the person was dead, five with a note that die person 
no longer lived at the address, five because the persons 
were not capable of understanding the questions due to 
mental disability. The rest of the questionnaires were 
considered usable and were included in the study. In 
addition, 15 patients filled in the questionnaires while 
visiting their neurologist at the Outpatients’ Clinic.
RESULTS
Demographic and clinical characteristics of the 
study population
The study included 90 persons with epilepsy. Socio­
demographic characteristics of the sample are pre­
sented in Table 2. Of the sample, 45.6% (41 per­
sons) were men. The median age of respondents was 
42.5 years. Forty-three point three percent (39) were 
married or cohabiting, 36.7% (33) reported being sin­
gle, 12.2% (11) were divorced and 7.8% (7) widowed. 
Thirty-eight point nine percent (35) were working full­
time, 24% (22) were working part-time and 11% (10) 
were unemployed. Fifteen point six percent (14) were 
receiving disablement pension. Twenty-two percent 
(20) of respondents were aged 60 years or older and 
10% (9) were receiving the state pension. Five point 
six percent (5) had less than primary education (lower 
than the 8th level), 32.2% (29) had primary education 
(8th or 9th level), 50% (45) had high school educa­
tion (11 th or 12th level) and 12.2% (11) had graduated 
from university.
Table 1: Coverage of the questionnaire.
1. Demographic details
Sex and age 
Marital status 
Employment status 
Educational level
2. Self-»»sc*ted economical and financial status
3. Disease characteristics
Seizure frequency
4. Self-assessed seizure severity
5. Anti epileptic treatment
Current medication 
Associated side effects 
Changes in AED medication
6. Compliance with medication
7. Perceived stigma
Stigma of Epilepsy Scale
8. Impact of epilepsy on employment history
Part-time employment or unemployment 
A job change 
Unfair treatment
Stigmatization and employment problems In epMepay
Tabte 2: Socio-demographic characteristics of respondents.
Parameter
Study
respondents %
Age (median) 42.5 years
Sex (male) 41 45.6
Marital status
miHMd/cobabiüag 39 43.3
single 33 36.7
divorced 11 12.2
widowed 7 7.8
Employment status
full-time 35 38.9
part-time 22 24.0
unemployed 10 11.0
retired 9 10.0
receiving disablement pension 14 15.6
Education
less than primary (lower than 8 th level) 5 5.6
primary (8th or 9th level) 29 32.2
high school (11th or 12th level) 45 50.0
university 11 12.2
Taüie 3: D isease characteristics of respondents.
Parameter
Study
respondents %
Duration of epilepsy (median) 17.2 years
Seizure type
tonic-clonic only 36 40.0
toei-c-clooic a»d others 36 40.0
o4hears ooly 18 20.0
Setгаге irssjucacy status Id the last year
Beisure-frts 30 33.3
< 1 seizure t  month 32 35.6
> 1 seizure a month 28 31.1
Seizure onset
5 years 19 21.3
10 years sgc 14 15.7
up to 20 years ago 22 24.7
more than 20 years ago 35 38.3
Medication
free from medication 1! 12.2
on AED treatment 79 87.7
For thote receiving AED medication
on moootherapy 61 77.2
receiving 2 AEDs 5 6.3
receiving >3 AEDs 13 16.5
Type of drug on monotherapy
carbamazepine 49 80.0
valproate 5 8.2
primidone 5 8.2
bensobarbital 2 3.3
The results of the underlying epidemiological study 
are as yet not fully published. Therefore, we found it 
necessary to give more detailed information about the 
clinical characteristics of the epilepsy of the study re­
spondents. The main disease characteristics are pre­
sented in Table 3.
Twenty-two persons (24.4%) reported some other 
chronic disease in addition to epilepsy, 12 per­
sons (13.6%) constantly used medications because 
of their condition. One point one percent (2) de­
scribed their economic and financial status as very 
good; 6.7% (6), good; 51.7% (46), satis factor}'; 30.3% 
(27), quite bad; 10.2% (9), very bad. Subjectively, 
10% of respondents considered their seizures very 
severe, 31.1% severe, 37.8% medium, and 21.1% 
light. There was a significant interaction between the 
severity of seizures and seizure type: those experi­
encing generalized tonic-clonic seizures were more 
likely to evaluate their seizures severe or veiy severe 
(X 2 =  12.8, P  =  0.04). A significant interaction be­
tween the seizure frequency and seizure severity was 
revealed: the more frequently the seizures occurred, 
the more severe they were considered (x2 — 6.02, 
P — 0.03). Of all subjects receiving AEDs 27.8% 
reported no side effects. Compliance with medication 
was quite good: 52% (43) of respondents said they 
never missed taking AEDs, 21% (17) reported miss­
ing on an average once a month, 17% (14) reported 
missing once a week, and 10% (8) more than once a 
week.
Twenty-five point five percent of respondents were 
completely satisfied with the current treatment, 51% 
were fairly satisfied, 17.6% were somewhat unsatis­
fied, and 5.9% stated that the level of control was 
unsatisfactory. There was a weak statistically signifi­
cant relation with the seizure frequency (Spearman’s 
rho — —0.34, P — 0.02): those having seizures more 
often were more likely to feel dissatisfaction.
Foury-three point one percent of all respondents had 
changed their AED medication in the past year: 47% 
had changed it once, 31.3% twice, and 7,8% three or 
more times. Sixty-six point five percent had changed it 
because their seizures were poorly controlled, 19.5% 
because of associated side effects.
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Perceived stigma
Of the respondents, 51% felt stigmatized by their 
epilepsy: 14% answered ‘yes’ to all three items and 
this shows that they were highly stigmatized. The per­
ception of stigma depended on seizure type: persons 
having tonic-clonic and other types of seizures were 
more likely to feel stigmatized ( x 2 =  5.02, P  =  
0.05); in addition, they were more likely to score 
highly on the stigma scale (x2 =  4.27, P =  0,04). We 
could not point out a statistically significant interac­
tion between perceived stigma and seizure frequency 
(P  -  0.3) but there was a clear tendency to a higher 
significance of feeling stigmatized when having more 
frequent seizures. However, the severity of stigmatiza­
tion was not related to this (Table 4).
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Table 4: Raporteid stigma by seizure type and frequency.
Parameter
Score on stigma scale
0 1 2 3
Seizure type
Tonic-clonic only (n =  36) 47.8% 30.4% 8.7% 13.0
Tonic-clomic and other (я — 36) 40.9% 18.2% 18.2% 22.7%
Other only (n =  18) 66.7% . 16.7% 16.7% 0
X =  3.02, P =  0.05
Seizure frequency
One or moife a month (я =  28) 41.2% 41.2% 12.1% 5.5%
Lea* than one a month (л =  32) 50.0% 15.0% 10.0% 25.0%
None in p u t year (n =  30) 57.9% 15.8% 15.8% 10.5%
X =  4.07, P  =  0.3
Figure* in bracket* are the numbers oa which percentages are calculated.
Those who considered their seizures to be more se­
vere had a greater likelihood of feeling stigmatized 
(X2 r= 6.7, P =  0.03). In addition, those people 
who had more fear of having a seizure during the 
next month (x2 = 18.4, P < 0.001), worry more 
about embarrassment resulting from having a seizure 
(x2 =  16.3, P < 0.001), and also about the adverse 
effects of AED medication if taken for a long time 
(x2 =  8.0, P  — 0.01) were more likely to feel stigma. 
The same features concerned those who believed that 
epilepsy was one of the main reasons of their part- 
time employment or unemployment (x2 =  7.0, P = 
0.009), and that they had been treated unfairly when 
seeking a job or at work (x2 =  4.5, P =  0.03).
Employment and social status
A third of all respondents were working full-time. 
From those being in part-time employment or unem­
ployed, 63% believed the significant reason for this 
was their epilepsy. Respondents with frequent seizures 
were more likely to believe this (Spearman’s iho =  
0.5, P  — 0.003). During the last 2 years, 32% of 
respondents had changed their jobs (meaning chang­
ing their working place, not a change of speciality or 
losing a job). In this situation, the respondents with 
frequent seizures were more likely to do this (Spear­
man’s rho =  0.6, P  =  0.05). Fifty-five point four per­
cent said that they had been treated unfairly at work 
or when applying for a job. There was a significant 
interaction between employment status and seizure 
frequency: those having frequent seizures were more 
likely to be in part-time employment or unemployed 
(Spearman’s rho =  0.3, P =  0.02) (Tfcble 5). There 
was also a significant interaction between full-time 
working and education: the higher the education was, 
the more likely the person would be working full-time 
(X 2 =  13.3, P — 0.03). To explore the correlation 
we reassessed the role of seizure characteristics and
stigma after adjustment for levels of education. How­
ever, since we found no significant interactions at the 
5% level, we are unable to construct a corresponding 
model.
DISCUSSION
The aim of the study was to describe some aspects 
of the psychosocial status of epileptic patients and to 
analyse how they are affected by their disease. Despite 
the relatively small sample size, the findings from this 
study give preliminary information and further out­
lines for investigation about the situation of people 
with epilepsy in a country in transition, such as Es­
tonia at the current moment of time. On 1 January,
1996, the estimated crude prevalence ratio of active 
epilepsy in Tartu was 4.1 per 100021. When compar­
ing the percentages of sex and age structure of the 
epileptic people of the present study with the epilep­
tic people of Tartu and the general population of the 
city there were no significant differences so we would 
consider our study consecutive (Table 6). The clini­
cal characteristics were similar to most other series of 
prevalence cases of epilepsy22-24. Most of the study 
respondents had generalized seizures with or without 
other seizure types and were predominantly on carba­
rn azepine monotherapy. The average duration of the 
disease was 17 years. Of the respondents, 68.9% had 
been seizure-free during the last year or had had less 
than one seizure a month which points to a rather effi­
cient antiepileptic drug control. Compared with other 
studies, the disease status was quite satisfactory and 
the number of patients receiving monotherapy was 
higher10,14’15,25. The explanation is that all of them 
were earlier consulted by an epileptologist which of­
ten resulted in a correction of medication. To review 
the economical and financial status of the respondents, 
their own opinion was asked. According to this, 59.5% 
valued it as very good, good or satisfactory, and 40.5%
3K
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Table 4: Reported stigma by seizure type and frequency.
Parameter
Score on stigma scale
0 1 2 3
Seizure type
Tonic-clonic only (n =  36) 47.8% 30.4% 8.7% 13.0
Tonic-clonic and other (n =  36) 40.9% 18.2% 18.2% 22.7%
Other only (n =  18) 66,7% . 16.7% 16.7% 0
X =  5.02. P =  0.05
Seizure frequency
One or more a month (л =  28) 41.2% 41.2% 12.1% 5.5%
Less than one a month (л =  32) 50.0% 15.0% 10.0% 25.0%
None in peat year (л =  30) 57.9% 15.8% 15.8% 10.5%
X =  4.07. P =  0.3
Figures in brackets are the numbers on which percentages are calculated.
Those who considered their seizures to be more se­
vere had a greater likelihood of feeling stigmatized 
(X2 — 6.7, P  =  0.03). In addition, those people 
who had more fear of having a seizure during the 
next month (x 2 =  18.4, P < 0.001), worry more 
about embarrassment resulting from having a seizure 
(X 2 =  16.3, P  < 0.001), and also about the adverse 
effects of AED medication if taken for a long time 
(X2 — 8.0, P — 0.01) were more likely to feel stigma. 
The same features concerned those who believed that 
epilepsy was one of the main reasons of their part- 
time employment or unemployment (x2 =  7.0, P =  
0.009), and that they had been treated unfairly when 
seeking a job or at work (x 2 =  4.5, P  =  0.03).
Employment and social status
A third of all respondents were working full time. 
From those being in part-time employment or unem­
ployed, 63% believed the significant reason for this 
was their epilepsy. Respondents with frequent seizures 
were more likely to believe this (Spearman’s rho =
0.5, P  — 0.003). During the last 2 years, 32% of 
respondents had changed their jobs (meaning chang­
ing their working place, not a change of speciality or 
losing a job). In this situation, the respondents with 
frequent seizures were more likely to do this (Spear­
man’s rho =  0.6, P  =  0.05). Fifty-five point four per­
cent said that they had been treated unfairly at work 
or when , applying for a job. There was a significant 
interaction between employment status and seizure 
frequency: those having frequent seizures were more 
likely to be in part-time employment or unemployed 
(Spearman’s rho — 0.3, P — 0.02) (Table 5). There 
was also a significant interaction between full-time 
working and education: the higher the education was, 
the more likely the person would be working full-time 
(X 2 =  13.3, P — 0.03). To explore the correlation 
we reassessed the role of seizure characteristics and
stigma after adjustment for levels of education. How­
ever, since we found no significant interactions at the 
5% level, we are unable to construct a corresponding 
model.
DISCUSSION
The aim of the study was to describe some aspects 
of the psychosocial status of epileptic patients and to 
analyse how they are affected by their disease. Despite 
the relatively small sample size, the findings from this 
study give preliminary information and further out­
lines for investigation about the situation of people 
with epilepsy in a country in transition, such as Es­
tonia at the current moment of time. On 1 January, 
19%, the estimated crude prevalence ratio of active 
epilepsy in Тагш was 4.1 per 100021. When compar­
ing the percentages of sex and age structure of the 
epileptic people of the present study with the epilep­
tic people of Tartu and the general population of the 
city there were no significant differences so we would 
consider our study consecutive (Table 6). The clini­
cal characteristics were similar to most other series of 
prevalence cases of epilepsy22"24. Most of the study 
respondents had generalized seizures with or without 
other seizure types and were predominantly on carba­
mazepine monotherapy. The average duration of the 
disease was 17 years. Of the respondents, 68.9% had 
been seizure-free during the last year or had had less 
than one seizure a month which points to a rather effi­
cient antiepileptic drug control. Compared with other 
studies, the disease status was quite satisfactory and 
the number of patients receiving monotherapy was 
higher10' 14,13’25. The explanation is that all of them 
were earlier consulted by an epileptologist which of­
ten resulted in a correction of medication. To review 
the economical and financial status of the respondents, 
their own opinion was asked. According to this, 59.5% 
valued it as very good, good or satisfactory, and 40.5%
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Table 5: Reported problems with employment by seizure frequency.
One or more a 
month
Seizure frequency 
Less than one a 
month
None in past 
year
Believed the significant reason for being in part-time 45% (9) 35% (9) 20% (4)
employment or unemployed was their epilepsy n =  20
Had changed Ibeir job n =  29 52% (15) 27% (8) 21% (6)
Part-time unemployment or unemployed n =  32 50% (16) 31% (10) 19% (6)
Figure* in brackets lire the numbers on which percentages are calculated.
Table 6: Comparison of ten  and ag e  structure Ы Tartu epileptic people and epUepUc people of the present study.
Among epileptic people of Among epileptic people of
Parameter ■ftctu the present study
n % n % P
Sex
male 172 55.7 41 45.6 0.09
female 137 44.3 49 54.4
Age group*
16-19 years 2 2.2
20-29 years 53 17.2 23 25.6 0.08
30-39 years 74 23.9 15 16.7 0.15
40-49 years 70 22.6 17 18.9 0.46
50-59 years 54 17.5 13 14.4 0.49
>60 years 58 18.8 20 22.2 0.51
Total 309 100.0 90 100.0
as bad or very bad. Correspondingly, more than half 
of the study population copes with everyday needs. 
This pattern is presumably similar to that of the gen­
eral population. The present study did not confirm the 
fact that the rates of marriage are significantly lower 
among people with epilepsy than in general which 
has been reported11,14,26. Despite the fact that more 
than 75% of the patients confirmed being satisfied with 
the current treatment, the percentage of stigmatization 
in general and the percentage of severely stigmatized 
was as high or even higher than in other studies10,14. 
Fifty-one percent of the respondents felt stigmatized 
by their epilepsy, 14% of them highly. The perception 
of stigma depended on seizure type: persons having 
tonic-clonic and other types of seizures were more 
likely to score high on the stigma scale. Of subjects 
reporting frequent seizures, 58.3% felt stigmatized by 
their epilepsy, as compared with 50% of those hav­
ing seizures less ithan once a month and with 42% of 
those having none in the past year. This is much higher 
compared with the work of Jacoby e t  a l .15 who found 
corresponding percentages of 62, 40 and 25, and with 
the study by Baker e t  a l .14 who reported on their re­
sults as 67%, 48% and 37%. We speculate that the 
higher percentage: of stigmatization could be a char­
acteristic of Eastern European countries and could be 
the result of a general lack of knowledge and indiffer­
ence, as due to their complicated political status, an
individual’s health and well-being was not valued for 
a long period. The finding also confirms the fact that 
the feeling of stigma was not clearly related to seizure 
frequency. Several authors have shown how epilepsy 
affects people’s perceptions of themselves and their 
overall Well-being4,11. In our study, a very clear rela­
tionship between stigmatization and problem percep­
tion was found. This emphasizes the importance of re­
ducing stigma in order to improve the overall health- 
related quality of life.
In Estonia, the pension age (age for retiring) is 
65 years. But it is very common to continue working to 
obtain the same salary as it makes it easier financially 
to cope with life. In our study, only nine persons stated 
they were retired, meaning that they were only receiv­
ing the state pension. The percentage of full-time and 
part-time employed people in the present study was 
62.9, 11% were unemployed. Compared to the find­
ings of a UK study by Jacoby15, who found that the 
percentage of unemployed people was 10 and that of 
employed people was 35, the results indicate that the 
condition of our epileptic people is better. The employ­
ment status of the study respondents was compared 
with the published data on the inhabitants of Tartu27. 
According to the data of the labour force surveys of the 
Statistical Office of Estonia, on 1 January, 1998, the 
percentage of employed people (including those em­
ployed part-time) among inhabitants of Tbrtu aged 20
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Epilepsy in Estonia: A Quality-of-Life Study
Marju Herodes, Andre Õun, Sulev Haldre, and Ain-Elmar Kaasik
Department o f  Neurology and Neurosurgery, Faculty o f Medicine, University o f Tartu, Tartu, Estonia
S m m r y :  Purpose: To study the impact of epilepsy and its 
treatment on people with epilepsy in Estonia and to analyze 
how it ii affected by the characteristics of epilepsy .
Methods: Clinical sod demographic data about patients were 
obtained from ямкЬса! notes and mailed talf-compteied ques­
tionnaires (including the RAND 36-Items Health Survey 1.0 
(RAND-36)).
Results: Information was collected from 203 patients aged 
20-74 years, who all had active epilepsy. A third of the re­
spondents had been seizure free during the laet year. Eighty- 
four percent wen: receiving monotherapy. More than half of 
respondents felt stigmatized by epilepsy, 24.7% of them highly 
so. A third were working full-time. 31.9% were underemployed 
workers, and 11%, unemployed. Sixty-two percent of these 
same unemployed or underem ployed workers considered their 
epilepsy to be a significant reason for this situation. Overall,
44% believed they had been treated unfairly at work or when 
trying to get a job. Study respondents scored lower in all do­
mains on the RAND-36 than did persons from the control 
group. The biggest differences were found in five domains. 
Social functioning. Role limitatkms-physical, Role limitation- 
s-emotional. General health, and Vitality.
Conclusions: The clinical characseriatics of this study were 
similar to thoee of moat other scries o f prevalence cases of 
epilepsy. The level of employment among persons with epi­
lepsy was not lower than that in the general population. The 
percentage of stigmatization was high. There were significant 
differences in the way respondents scored on the stigma scale 
and on the RAND-36 domains when measuring their health 
status, depending above all on seizure frequency and type. Key 
Word*: Epilepsy— Quality of life—Stigmatization—-RAND- 
36— Estonia.
A lthough it is a universal brain disorder, epilepsy is 
often m isunderstood. It is now widely acknowledged that 
people w ith  eptlep ty  are as likely to  be distrcaaed by 
social and cultural problem s as they are by continuing 
seizures, and tha t epilepsy has profound physical, psy­
chological, and social consequences (1). Although cur­
rent seizure frequency is one o f  the most important 
predictors show ing the efficacy o f  treatm ent, it is not the 
only m easure, especially  from the patien t's viewpoint, 
com m only used in  clinical studies o f  new  andepileptic 
drugs (A ED s) (2). T he effect o f  any disease is deter­
mined by several factors, including underlying biology, 
as well as host factors, and available m edical interven­
tions, but also by the attitudes and reactions o f the sur­
rounding society (3). Several studies have used health- 
related quality o f  life in epilepsy as an outcom e measure 
and have also used it to  give a broader measure o f  the 
burden o f the d isease (4). Quality o f life is difficult to 
define but m ight tie said to  reflect functions in three main 
areas: physical, social, and psychological ( I ). Devinsky 
and C ram er (S) slatted that the essence o f  quality o f  life
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is the balance between patients’ perceived and desired 
status. It also is defined by how well one is able to 
function and how  one feels about o n e’s daily life (6), on 
the assum ption that aspects o f functional health  status 
have an im pact on quality o f  life. A lthough no definitive 
consensus has been reached concerning the essential na­
ture o f  quality o f  life, there is som e agreem ent that gen­
eral health status is one o f its m ain com ponents (7). A 
variety o f  instrum ents are available to  evaluate the per­
ception of health in the general population O ne o f  these, 
which also is am ong the m ost w idely used question­
naires, is the RA ND  36-Item H ealth Survey 1.0. It is a 
brief and intensively tested instrum ent that w as derived 
from longer instrum ents developed by RAND research­
ers (Santa M onica, CA, U.S.A .) for the M edical O ut­
com e Study (M O S) and the H ealth Insurance Experim ent 
(8) to assess health status. The purposes and m ethods o f 
the RAND study have been fully sum m arized (9,10). The 
RA ND  36-Item H ealth Survey 1.0 items are identical to 
the MOS 36-item  short-form  health survey (M OS SF-36) 
described  by W are and Sherbourne (9). T hey  w ere 
adapted from longer instrum ents com pleted by patients 
participating in the M OS ( I I ) .  The conceptual fram e­
work is based on the m ultidim ensional W orld Health 
O rganization definition o f health (12) A lthough the
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RAND version has a slightly different scoring method, it 
allows users of the MOS SF-36 and RAND-36 to relate 
their findings (9).
Because of the emphasis on the phenomenologic ex­
perience of the individual, it is necessary' that quality of 
life be determined from the patient’s subjective view­
point, the physician’s viewpoint being deliberately ex­
cluded, as self-reports are the primary method of 
assessing it (6) because, with very few exceptions, evalu­
ations conducted by physicians tend to concentrate pri­
marily on seizure management, Leaving all else as 
secondary features (13). It has become relatively com­
mon to have patients make a judgment about their medi­
cal care (14). This means they must have the courage to 
express their opinion and show their dissatisfaction. 
There is a growing awareness of the psychosocial impli­
cations of epilepsy. People with epilepsy face social dis­
advantages not shared by those with other chronic 
diseases. Psychiatric problems, particularly anxiety, de­
pression, and loss of self-esteem are common among 
people with epilepsy (15-26). Most patients feel that a 
prospective employer’s knowledge of a diagnosis of epi­
lepsy will make it more difficult for them to get a job 
(27). Information on these issues has come mainly from 
developed countries (26,28-33). Very few studies origi­
nate from developing countries (34-37). and there is 
clearly a lack of documented evidence regarding the im­
pact of epilepsy in Eastern Europe (38,39).
Estonia, which is located in Eastern Europe on the 
coast of the Baltic Sea, regained its independence after 
the collapse of the Soviet Union. Today 64.6% of the 1.5 
million people living in Estonia are ethnic Estonians. 
Among other nationalities, Russians represent the largest 
group (-28.5%). The Russian-speaking population is not 
evenly distributed throughout the country (40). Southern 
Estonia revolves around Tartu, the historic university 
town and the country’s second largest city. Tartu, the 
intellectual and educational center of Estonia, demon­
strates relatively typical demographic characteristics for 
Estonia, with the exception that the percentage of the 
Russian-speaking population is lower than that in Esto­
nia as a whole. Viljandi County, with a population of 
62,336 (41), is considered to be first in the country in 
terms of the level of development of agriculture, and is 
located in south-central Estonia. The administrative cen­
ter of the county is the town of Viljandi, which is situated 
81 kms from Tartu.
This report is a comprehensive study of what it is like 
to have epilepsy in our society. It was conducted to pur­
sue the following objectives: (a) to describe the quality 
o f life for epilepsy patients on the grounds of perceived 
health status and possible stigma accompanying epilepsy 
and to analyze how it is affected by the characteristics of 
epilepsy; and (b) to analyze how quality of life is affected
by the sociodemographic characteristics of epilepsy pa­
tients, with emphasis on their current employment status.
METHODS
Design and study sample
The research took place in 1997 through 1998 and 
followed an epidemiologic survey of epilepsy in the city 
of Tartu, Estonia. The epidemiologic survey included 
persons who were residents of Tartu, were aged 20 years 
and older, and had before or during the period from 
January 1, 1991, through January I, 1996, had at least 
two unprovoked epileptic seizures, at least one of them 
within the previous 5 years. Data collection for the epi­
demiologic study consisted of two parts: data registration 
from a multisource medical register review and data reg­
istration from a personal case reexamination. Case re­
cords of patients treated at the University Hospital, 
Outpatients’ Clinics, physicians’ offices, emergency 
rooms, or the electroencephalographic laboratory with a 
diagnosis of epilepsy, convulsions, syncope, amnestic at­
tacks, or abnormal involuntary movements were re­
viewed, and invitations for reexamination were sent to 
the relevant persons. During the last 2 years, all the pa­
tients were reexamined at least once by one of the au­
thors to specify the types of their seizures.
Our study focused on the analysis of data collected 
from a sample of 203 patients in the 20- to 74-year age 
group. The patients were selected at random from the 
preliminary lists of the epidemiologic study conducted in 
Tartu, excluding people who were not capable of under­
standing Estonian (mostly Russian speakers) because no 
sufficiently well translated and validated questionnaire 
was available. In Viljandi, primary information about 
people with epilepsy was gathered through the local epi­
lepsy support group, and clinical information was ab­
stracted from medical notes held in the County Hospital 
and Outpatients’ Clinic register. To evaluate the accu­
racy of diagnoses, the problematic cases were investi­
gated by one of the authors and reexamined if necessary. 
All patients gave their consent for participation in the 
research, and the project was approved by the Ethics 
Committee of the University of Tartu. In addition, a  con­
trol group of 200 healthy subjects corresponding in age, 
sex, and educational level was randomly selected from 
among the patients receiving treatment from dentists at 
the University’s Dental Clinic. All of the respondents 
possessed at least a basic education with sufficient ability 
to read and write, and were capable of understanding and 
completing the questionnaires.
Measures
Clinical information, if needed, was abstracted, once 
again, from medical notes and during the personal reex­
amination of subjects. Abstracted information used in ins 
study related to the etiology of epilepsy, classification of
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seizure type, and current AED therapy. To evaluate the 
impact of epilepsy on employment status and perceived 
stigma, the patients were sent a questionnaire by mail. 
Following the example of other quality of life studies 
conducted among persons with epilepsy (26,42-44), the 
questionnaire used a combination of open questions with 
two previously translated and validated scales (The 
Stigma of Epilepsy Scale and the RAND 36-Item Health 
Survey 1.0). In addition, single items that referred spe­
cifically to feelings of stigmatization in the area of em­
ployment were used. The questionnaire contained a 
number of scales and questions covering the following 
issues:
1. Demographic characteristics: information was ob­
tained about subjects’ sex, age, marital and em­
ployment status, and educational level;
2. Economic and financial status: patients were 
asked to state whether they considered it to be 
“very good,” “good,” “satisfactory,” “moderately 
bad, or “very bad”;
3. Seizure frequency: patients were asked whether 
they had had seizures once or more in a month, 
less often than once a month, or not at all in the 
past year;
4. Injuries associated with seizures: subjects who 
had had at least one seizure in the past year were 
asked whether they had had a burn or scaid, a head 
injury, milder injuries (including dental injuries), 
any other injuries (unspecified), or no injuries;
5. History of the epilepsy: patients were asked about 
age at first attack;
6. Previous research has shown that patients‘ percep­
tion of the severity of their seizure disorder may 
be more important than seizure frequency in de­
termining their psychological and social well­
being (45). Therefore subjects were asked to 
assess their seizures as “very severe,” "severe.” 
“medium,” or “light”;
7. AED treatment and side effects: patients were 
asked about the AED they were taking and about 
the experienced side effects during the past 
month, as well as about satisfaction with the cur­
rent treatment and about changes in AED medi­
cation in the past year;
S. Compliance with medication: patients were asked 
to state whether they never missed taking their 
AEDs, missed less often than once a month, 
missed less often than once a week, or missed 
more often than once a week. According to other 
studies, correlations between patient report and 
objective method have been shown to be high 
(43);
9. Perceived stigma was measured with a three-item 
scale developed originally for stroke (46), adapted
for epilepsy and already used in other quality-of- 
life studies (26,43). Respondents with epilepsy 
stated whether they felt that other people (a) were 
uncomfortable with them, (b) treated them as in­
ferior, or (c) preferred to avoid them. Each of the 
three items required a yes/no response. An indi­
vidual’s score was the sum of the “yes” responses, 
and the higher the score, the greater was the per­
ception of stigma. The scale was translated into 
Estonian by two independent native Estonian 
speakers with an excellent knowledge of English. 
The translators then met to discuss and agree on a 
common version of the questionnaire. Subse­
quently the common version was evaluated by an­
other native Estonian speaker in terms of 
conceptual equivalence, linguistic performance, 
and clarity. The agreed Estonian form was then 
translated back into English and rated. If modifi­
cations were necessary, reformulation was per­
formed in the Estonian version. The internal 
consistency of the scale was examined using 
Cronbach’s alpha and found to be acceptable (al­
pha *= 0.71) (47). The evidence for the construct 
validity of the scale was supported by the data 
received following the hypotheses that patients 
with frequent seizures and mixed seizure types 
would score positively on the scale;
10. The impact of epilepsy on employment history: 
those currently un- or underemployed were asked 
whether this was caused by their epilepsy, wheth­
er they had changed jobs in the preceding 2 years 
because of epilepsy, and whether they had been 
treated unfairly at work because of epilepsy. Each 
of the items required a yes/no response. Patients 
were divided into three groups by seizure type (as 
having only tonic-clonic, only other types, or both 
tonic-clonic and other types) and frequency 
(based on seizure occurrence once or more a 
month, less often than once a month, or not at all 
in the past year);
11. Health status: respondents were asked to complete 
a comprehensive generic health status measure, 
the RAND 36-Item Health Survey 1.0 (RAND- 
36) (48), which consisted of eight multiitem vari­
ables: physical functioning (PF), 10 items; social 
functioning (SF), two items; role limitations due 
to physical problems (RP), four items; role limi­
tations due to emotional problems (RE), three 
items; mental health (MH): five items; energy and 
vitality (VT), four items; bodily pain (BP), two 
items; and general perception of health (GH), five 
items. There is a further unsealed single item on 
changes in respondents' health over the past year 
(CHG). The scale was translated into Estonian as 
described in the Stigma scale. The RAND-36
V.il 42, N o К  W H
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questionnaire took -5  min to complete. As indi­
cated in standard RAND-36 scoring algorithms, 
for each variable item scores were coded, 
summed, and transformed onto a scale from 0 
(worst possible health state measured by the ques­
tionnaire) to 100 (best possible health state). 
Missing value rates for the items were low and did 
not exceed 1.5% for any item of the eight scales. 
Interna]-consistency reliabilities (Cronbach’s al­
pha) met the level acceptable for group compari­
sons (>0.70) across all scales ranging from 0.75 to 
0.92. Scaling assumptions were tested in two 
ways. Corrections, between items and hypoth­
esized scales, were substantial within each scale 
and reached the level of >0.40 in ail instances, 
supporting the reliability of the RAND-36 scales 
in both groups. In the epilepsy group, the lowest 
median item-total correlation was 0.53 for general 
health, and the highest, 0.84 for bodily pain. Dis­
criminant validity was considered acceptable 
when these correlations exceeded all correlations 
between items and other scales. All of the eight 
scales in both groups passed this test level. The 
validity of the RAND-36 was assessed using dis­
criminant techniques. The RAND-36 ability to 
distinguish between a high and a low symptom 
load was determined through assessment by sei­
zure type and frequency. Discriminative power 
was examined by comparing the RAND-36 score 
profiles of the healthy respondents and respon­
dents with epilepsy. A subsequent methodo logic 
article will examine in detail the psychometric 
properties of the RAND-36 in this sample of 
people with epilepsy.
Statistical methods 
The data were analyzed using the statistical analysis 
package SPSS Professional Statistics 7.5 (49). Tests of 
significance were x 2 (chi square) and one-way analysis 
of variance (ANOVA). Attention is drawn to results in 
which differences were significant at the 5% level or less 
(p s  0.05). To examine the correlations between differ­
ent characteristics concerning employment and stigma, 
we performed a multivariate analysis of the data, but 
because we found no significant interactions at the 5% 
level, we were unable to construct corresponding mod­
els. Cron bach’s alpha was used to test the reliability of 
the scales. To assess the influence of patient character­
istics on quality of life (RAND-36) domains, the effects 
of the clinical variables (seizure frequency, type of sei­
zures, age at onset, duration of disease), stigmatization 
and its severity, and sociodemographic variables (age, 
sex, educational level, employment status, marital status) 
on each domain total score were studied, using multifac- 
tor ÄNOVA models. Preliminary analyses were carried
out to investigate which of the clinical variables pre­
dominated. At each stage, factors found to be no longer 
significant after adjusting for the remainder were ex­
cluded. The final model includes only the factors that 
contributed significantly in predicting the domain score. 
To determine significant differences between pairs of 
groups, the Tukey HSD procedure or Bonferroni’s 
method was used (50).
Response to the study
In Tartu, questionnaires to be completed individually 
were mailed to 110 patients, of whom 78 replied, a re­
sponse rate of 71%. After sending a reminder, 16 more 
patients returned their questionnaires. Of all the ques­
tionnaires returned, 19 appeared to be unusable: in six 
cases, >10% of the questionnaire was left unanswered; 
three were sent back with a note that the person was 
deceased; five, with a note that the person no longer lived 
at the address; five, because the person was incapable of 
understanding the questions because of mental disability. 
The remaining questionnaires were considered usable 
and were included in the study. In addition, 15 patients 
completed the questionnaires while visiting their neu­
rologist at the Outpatients’ Clinic. One hundred twenty- 
two of the questionnaires appeared usable.
In Viijaadi, questionnaires were mailed to 120 pa­
tients, of whom 85 replied. After being sent a reminder, 
10 more patients returned their questionnaires. Eighty- 
one of the returned questionnaires appeared usable.
RESULTS
Sociodemographic characteristics of sample
The median age of the study population was 41 years 
(25th and 75th percentiles 29 and 57). The respondents 
of the study were divided into five age groups: 20-29 
years. 26.6%; 30-39 years, 20 7%; 40-^9 years, 17.2%; 
50-59 yean, 13.8%; and 60 years and older, 21.7%. Men 
accounted for 48.8%. Of the respondents, 40.9% were 
married or cohabiting, 41.4% were single, and 10.3% 
were divorced; 44.3% had less than primary (lower than 
eighth grade) or primary education (eighth or ninth 
grade), and 55.7%, high school (11th or 12th grade) or 
university education. Thirty-three percent were w orking 
full-time, and 41.9% were un- or underemployed; 0.5% 
described their economic and financial status as very 
good; 8.5%, as good; 59%, as satisfactory; 26%, as mod­
erately bad; 6%, as very bad (Table 1).
The median age of the control group was 40 (25th and 
75th percentiles 27 and 56) years. Forty-nine percent 
were men. Eight percent had less than primary education 
(lower than eighth grade level), 32% had primary edu­
cation (eighth or ninth grade level), 49% had a high 
school education, and 11% had graduated from univer­
sity.
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TABLE 1. Sociodemographic characteristics o f respondents
Parameter
Swdy
respondents %
Age (median) 41 yr
Sex (M/F) 991104 48.8/SI.2
Martial alatus
Marriadfcohabiting 82 40.9
Single 84 41.4
Divorced 21 10.3
Widowed IS 7.4
Employment status
Full-time 67 33.0
Uademeptoyed 65 31.9
Uacteplnyad 22 lt.0
Retired or receiving disability pension 49 24.1
Citarnian
beat titan primary (lower than 8th grade) 22 10.8
Primary (Mi or 9th grade) 68 33.5
High school (1 lift or 12th grade) 93 45.8
Uni vanity 20 99
Миме characteristic* of the sample
The median age of the oniet of epilepsy was 26.9 
years, and the median duration of epilepsy was 11.3 
years (25th and 75th percentiles 5.8 and 22.4). Patients 
were divided into five groups by duration of the disease 
and into six groups by age at onset of the epilepsy. Of 
patients, 41.4% reported having only tonic-clonic sei­
zures, 30% reported having both tonic-clonic and ocher 
types of seizure», and 28.6% reported having only other 
types of seizures. Almost a third (34%) had been seizure 
free in the last year; 39.9 had less than one seizure a 
month; and 26.1 % had one or more seizures a month. Of 
those who had had at least one seizure in the past year 
(134 patients), 14% reported having serious injuries 
(bum, scald); 38%, head injuries; 22%, milder injuries or 
headache; and 5%. other injuries. More than a fifth 
(21%) had not experienced any injuries. Those having 
seizures once or more in a month (x2 =  11.89; df = 2; 
p =  0.001) anti thoae having multiple or generalized 
tonic-clonic seizure types (x2 *  9.94; df =  2; p = 
0.009) were more likely to report a seizure-related injury. 
Of these, 7.4% described their seizures as very severe; 
30%, as severe; 41.4%, as moderate; and 21.2%, as light. 
There was a significant correlation with the subjective 
assessment about the severity of the seizures (those as­
sessing their seizures as very severe or severe and those 
considering them moderate or light were counted to­
gether) with reported seizure-related injuries (x2 -  
15.24; df = 4; p = 0.003). Of the 88.7% who were 
receiving AED treatment, 83.9% were receiving mono­
therapy. The majority (74.8%) of those receiving mono­
therapy were receiving carbamazepine (CBZ). The most 
commonly experienced side effects were memory prob­
lems (3 1 %), tiredness (25%), sleepiness (20%), headache 
(20%), and nervousness (20%). A third (33%) of subjects 
reported no side effects. The majority of respondents 
(78%) receiving AED treatment described their epilepsy
as very or fairly well controlled by this; 21% stated that 
the level of control was unsatisfactory. Almost two fifths 
(41.3%) of those receiviag medication had changed it at 
least once in the past year; 68.4% had changed it once: 
22.8%, twice; and 8.8%, three or more times. Of those 
who had changed their medication once in the past year, 
79.3% had changed it because of unsatisfactory control 
and 20.7% because of side effects. For compliance with 
medication, 56% of respondents said they never missed 
taking AEDs, 23% reported missing on average once a 
month, 14% reported missing once a week, and 7%, 
more than once a week. Some (17.7%) had some other 
disease or health problem in addition to epilepsy; 11.8% 
were receiving medical treatment because of these. The 
most common additional diseases were diseases of the 
heart (39%) and joints (33%). The results of the under­
lying epidemiologic study conducted in Tartu have not 
yet been published in full. We therefore found it neces­
sary to provide more detailed information about the clini­
cal characteristics of the epilepsy of the study 
respondents. The main disease characteristics are pre­
sented in Table 2.
TABLE 2. Disease characteristics o f respondents 
Study
Parameter respondents %
Duration of epilepsy (median)
SI yr
11.3 yr
li 5.4
2-5 yr 45 22.2
6-10 yr 46 22.7
11-20 yr 44 21.7
>20 yr 57 28.1
Age at on**i
<10 yr 20 9.9
11-20 yr 68 33.3
21-30 yr 38 18.7
31-40 yr 36 17.7
41-50 yr 15 7.4
>50 yr 26 12.8
Seizure type
Tonic-clonic only 84 41.4
Tonic-clonic and others 61 300
Others only 58 28.6
Seizure frequency status in the last year
Seizure free 69 34.0
<1 seizure a month 81 39.9
£1 seizure a month 53 26.1
Medication
Free of medication 23 11.3
AED treatment 180 88.7
Of thoae receiving AED medication
Monotherapy 151 83.9
Receiving 2 AEDs 22 12.2
Receiving 23 AEDs 6 3.3
Type of dn>g
Cwhnmuepine 113 74.К
Valproate 15 9.9
Primidone 12 79
Phenytoin 5 3.4
Phenobarbilal 4 2 7
Ben.subatbiial 2 1.3
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TABLE 3. Reported stigma by seizure type and frequency
Parameter
Score on stigma scale
Seizure type 
Tonic-ctonic only (n « 84) 
Tonic-clonic and ocher (n »  61) 
Other only (n -  58)
X1 -  20.65. p < 0.009 
Seizure frequency 
One or more a month (n = 53) 
L a i  than one a month (n «= 81) 
None in past year (n »  69)
X1 -  23.57. p < 0 0001
46.4%
29.8%
65.4%
25.6%
45.6%
68.8%
27.5% 11.6%
27.7% 23.4%
17.3% 13.5%
27.9% 27.9% 
27.9% 11.8%
17.2% 12.1%
14.5%
19.1%
3.8%
18.6%
14.7%
6.9%
Figures in brackets are the numbers on which percentages are calculated
Perceived stigma
More than half of all respondents (52.4%) felt stigma­
tized by their epilepsy; 24.7% answered “yes” to all three 
items, and this shows that they were highly stigmatized. 
Respondents were more likely to feel stigmatized if they 
had frequent seizures (x2 *  23.57; df = 6; p < 0.0001) 
or mixed seizure types ( \ 2 = 20.65; df = 6; p < 0.009; 
Table 3). At the same time, only 37.4% considered their 
seizures very severe or severe. Those who had experi­
enced seizures during the last year (x2 = 18.63; df = I; 
p < 0.0001) and those who had tonic-clonic type of 
seizures only or together with other seizure types ( \ 2 = 
7.02; df =  1; p < 0.008) were more likely to score highly 
(to give two or three “yes” answers) on the stigma scale. 
Stigmatization was more common among those having 
university or high school education (x2 = 12.89; df *= 6; 
p < 0.05). No differences were found in scores on the 
stigma scale by sex, marital status, or employment status.
Employment
A third of ail respondents were working full-time. Em­
ployment status (working either full-time or being un­
deremployed; those retired or receiving disability 
pension were excluded) was significantly related to age
(X2 =  12.02; df =  4; p =  0.03), seizure frequency (x2 
=  10.81; df = 2; p = 0.004), age at the onset of sei­
zures (x2 =  15.13; df = 5; p = 0.0!) and education (x2 
=  11.38; df =  3; p = 0.01). Sixty-two percent of those
who were un- or underemployed named epilepsy as the 
significant reason for it. Respondents with frequent sei­
zures were more likely to believe it (x2 = 11.03; df = 
2; p =  0.001). During the last 2 years, 29% of respon­
dents had changed jobs (meaning a change of workplace, 
not change of speciality or loss of job). Men (x2 =  7.07; 
df = 1; p < 0.003) and those with frequent seizures (x2 
= 11.79; df =  2; p<0.006) were more likely to do this. 
Forty-four percent said that they had been treated un­
fairly at work or when getting a job. There were signifi­
cant interactions between this opinion and seizure 
frequency, type, and education: respondents with fre­
quent seizures ( \ 2 =  16.26; df =  2; p =  0.0001), re­
spondents having tonic-clonic or multiple seizure types 
(X2 = 8.94; df *= 1; p =  0.002) and respondents who 
had lower than high school education (x2 =  7.32; df =
1; p =  0.007) were more likely to report this. We cannot 
leave unmentioned here that, although it was not asked, 
several respondents commented on the fact that they had 
hidden their diagnosis of epilepsy from employers and 
colleagues because of the fear of discrimination and 
shame. There also was a significant interaction between 
full-time work and educational level (those retired or 
receiving a disablement pension were excluded): the 
higher the person’s education, the more likely he or she 
was to be working full-time (x2 = 12.12; df = 6; p — 
0.04).
TABLE 4. Descriptive statistics and features o f score distributions fo r  the KAND-36 Health Survey by seizure type
Domain
Tonic-clonic only fn = 84) Tonic-clonic and others (n = 61) Others only (n = 58)
p Value"Mean Median Cl SEM Mean Median Cl SEM Mean Median Cl SEM
Physical functioning 74.5 87.5 68.7-804 2.9 74.2 75 67.4-79.0 2.9 83.0 90 77.7-88.4 2.7 0.06
Role-physical 48,5 25 39.1-57.9 4.7 43.9 25 32.5-55.2 5.7 60.8 62.5 51.2-70.3 4.8 0.05
Role-emotional 51.6 33.3 42.5-60.7 4.6 39.9 33.33 29.5-50.3 5.2 53.5 66 66 42.6-64.3 5.4 0.03
Energy/fatigue 46.0 45 40.9-51.2 2.6 45.2 50 39.7-50.6 2.7 52.6 55 47.2-57.9 2.7 0.1
Emotional well-being 60.8 64 56.4-65.1 2.2 55.2 56 49.5-609 2.8 63.2 64 583-68.2 2.5 0.02
Social functioning 67.7 75 61.6-7J.9 3.1 62.5 62.5 55.4-69.6 3.6 79.1 87.5 72.8-85.4 3.1 0.006
Bodily pain 68.4 68.75 62.2-74.6 3.1 60.1 67.5 52.2-67 У 3.9 74.6 77.5 68.1-81.1 3.3 0.04
General health 42.1 40 37.4-46.9 2.4 43.9 40 37.6-50.1 3.1 46.5 45 40.9-52.0 2.8 0.4
Cl. 95% confidence interval; SEM. standard error of Ihe mean.
" Variance betwsen seizure type*. Test of significance wax Kruskal-Wallis one-way analysis of variance.
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TABLE 5. Descriptive statistics and features o f score distributions for the RAND-36 Health Survey by seizure frequency status
in the last year
Domain
г  I seizure/mo (n *  53) <1 seizure/mo (n « 81) Seizure free (n -  69)
p Value"Mean Median Cl SEM Mean Median Cl SEM Mean Median a SEM
Physical functioning 73.0 75 67.3-78.7 2.1 74.3 85 68.5-80.2 2.9 81.9 90 76.3-87.5 2.8 0.07
Rote-physical 33.5 25 23.4-43.6 5.0 49.4 50 40.3-58.5 4.6 65.2 100 55.1-75.4 5.1 0.0001
Rote-emotional 27.0 30 17.7-36.4 4.7 490 33.33 39.9-58.1 4.6 64.7 100 55.0-74.4 4.9 0.0001
Energy/fatigue 45.1 50 39.7-50.5 2.7 43.2 40 38.2-48.2 2.5 54.8 60 49.5-60.1 2.6 0.004
Emotional well-being 55.1 56 49.6-60.6 2.7 58.4 60 53.8-63.0 2.3 65.0 72 60.3-69.8 2.4 0.02
Social functioning 59.2 62.5 51.6-66.8 3.1 69.1 75 63.0-75.3 3.1 77.5 87.5 71.5-83.5 3.0 0.001
Bodily peia 56.2 57.5 4*. 1-64.3 4.0 68 1 77.5 61.8-74.4 3.1 76.1 80 69.9-82.2 3.1 0.0006
General health 39.3 40 33.6-44.9 2* 41.0 40 36.0-45.9 2.5 50.9 50 45.4-56.3 2.7 0.005
Cl, 95% confidence interval; SEM. standard error of the mean.
* Variance between seizure frequencies. Тел of significance was Kruskal-Wallis one-way wialysii of variance.
RAND-36
The correlations between the RAND-36 scales and 
seizure status together with descriptive statistics for the 
questionnaire are given in Tables 4 and S. Variance be­
tween seizure types was statistically significant in five 
RAND-36 domains. The comparisons between groups 
were investigated for each domain using the Tulcey HSD 
test at the 0.05 level. Patients who did not have gener­
alized tonic-c!k>nic seizures or multipie seizure types had 
significantly higher scores in the Role-physical and So­
cial functioning domains. Those who had multiple sei­
zure types had lower scores than did those with only 
tonic-clonic seizure types or those with other types of 
seizures only in the Role-emotional domain. Those who 
experienced multiple seizure types scored significantly 
lower in the Emotional well-being and Bodily pain do­
mains compand with those who did not have generalized 
tonic-clonic seizures (Fig. 1).
Variance between seizure frequency statuses was sta­
tistically significant in seven domains. The differences 
were significant between all three groups in the Role- 
emotional domain. Between those who had not had sei­
zures in the past year and those who had had seizures at 
least once a month or less often than once a month, the 
differences were significant in the Role-physical, En­
ergy/fatigue, and General health domains. Those experi­
encing seizures at least once a month scored significantly
lower in Emotional well-being and Social functioning 
compared with those who had been seizure free in the 
past year, in the Bodily pain domain, the differences 
were significant between those having seizures once or 
more in a month compared with those who had had sei­
zures less often than once a month or had not had them 
in the past year (Fig. 2).
Study respondents scored lower in all domains on the 
RAND-36 than did persons from the control group, 
meaning that they were more dysfunctional (Fig. 3). The 
greatest differences were found in five domains: Social 
functioning. Role limitations-physical, Role limitations- 
e mot tonal. General health, and Energy/fatigue (Table 6).
The results of the final models fitted to each RAND- 
36 domain score, including the factors that remain sig­
nificant after controlling for die others, are shown in 
Table 7. Each multifactor model is a main-effect model 
(no significant interactions were found between the fac­
tors). Pairs of groups of significantly different factors 
were compared using Tukey HSD or Bonferroni's pro­
cedures. Scores of the RAND-36 domains were first 
compared in terms of the clinical variables. Significant 
differences were found for seizure frequency in all do­
mains, except the Physical functioning domain. Seizure- 
free patients scored significantly higher than did patients 
who had experienced seizures during the last year in the 
Role limitations-physical. Energy/fatigue, Bodily pain.
FK2. 1. Companion Ы mean ccorts for 
the RAND-Эв health statue measure by 
seizure type. ’Teat of significance was 
me Krusfcai-Wallls one-way analysis of 
variance.
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RO. 2. Comparison Ы mean scores for 
the RANO-Эв health status measure by 
seizure frequency status. *Teet Ы signifi­
cance was the Kaiskai-Wadts one-way 
analysis of variance.
and General health domains. The difference between 
those who had had seizures once or more in a month 
compared with those having seizures less often than once 
a month or not having seizures during the last year was 
significant in the Rote limitatioofr-emotkmal, Emotional 
well-being, and Social functioning domains.
In the Rote lirmtations-phyrical domain, age, stigma- 
dzation, stigma severity, and age at onset of epilepsy 
became significant after controlling for seizure fre­
quency. Younger people were leas likely to score low in 
this domain, and there were significant differences were 
between die 20-29 and 30-39 age groups compared with 
people who belonged to the 60 years and older age 
group. Mean scores for this domain were significantly 
lower for those who were stigmatized, and for those who 
expressed very strong feelings of stigma (gave three 
“yes" answers on the stigma scale) compared with those 
who expressed less (one “yes” answer). Later age at on­
set was associated with lower scores; differences were 
significant between those for whom epilepsy had been 
diagnosed at the age of 41-50 or older than 50 compared 
with those for whom it had been diagnosed at younger 
than 20 years.
In the Role limitations-emotional domain, mean 
scores were significantly lower for those who were stig­
matized and for those who expressed very strong feelings 
of stigma (gave three “yes” answers on the stigma scale) 
compared with those who expressed themselves less 
strongly (one “yes” answer).
In the Energy/fatigue domain employment status, du­
ration of epilepsy, and age at onset of epilepsy were 
significant. In this domain, mean scores were signifi­
cantly lower for those currently unemployed, in compari­
son to those who were in full-time or underemployed 
work, for those who had had epilepsy for 2 to 5, and 6 to 
10 years compared with those who had epilepsy longer 
and for those whose epilepsy had been diagnosed at the 
age of 41-50 or older than 50 compared with those for 
whom it had been diagnosed at younger than 20 years.
In the Emotional well-being domain, those who were 
stigmatized had significantly lower scores than did those 
who were not and of those who had had epilepsy 2 to 5 
years compared with those who had had epilepsy >20 
years.
In the Social functioning domain, stigmatization, 
stigma severity, employment status, seizure type, and age 
at onset of seizures became significant. Significantly 
lower scores were obtained by those who were stigma­
tized; those who expressed very strong feelings of stigma 
(gave three “yes” answers) compared with those who did 
not feel this so strongly (one “yes” answer), those who 
were currently unemployed compared with those who 
were in full-time employment or underemployed, those 
who experienced either tonic-clonic or multiple seizure 
types compared with those who had only other types of 
seizures, and those for whom epilepsy had been diag­
nosed at the age of 41-50 or older than 50 compared with 
those for whom it had been diagnosed at younger than 20 
years.
In the Bodily pain domain, lower scores were related
BP CHG
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FIG. 3. Discriminative power of RAND- 
36. Comparison of mean scores for the 
RAND-Эв health status measure: people 
with epilepsy and the control group. 'Test 
of significance was the Kruskal-Wallis 
one-way analysis of variance
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TABLI£ i .  Mean scores o f dimensions o f 
HAND-36 questionnaire
Epilepsy Control
Dimension gfOUp (roup p Value*
Physical functioning 76.36 17.20 0.0001
Rote HmttalMMM (physical problems) 50.42 •6.71 0.0001
Rale limitation* (emotional problems) 41.40 69.13 00001
Energy/fatigue 47 .64 65.34 0.0001
Emotional wett-being 59.Ю 67.12 0.001
Social functioning 69.40 17.12 0.0001
Bodily paan 67 .» 78.97 0.0001
General kaakh 43.19 66.83 0.0001
'  VariMce batweia groups. Те*» of significance was Knukal-Wallis 
one-way analysis of variance.
to a shorter (2-5 yean) rather than longer (11-20 and 
>20 yean) duration of epilepsy.
In the General health domain, mean scores were sig­
nificantly lower for those whose epilepsy had been di­
agnosed at the life of 41-50 or at older than 50 years 
compand with those for whom it had been diagnosed at 
younger than 20 yean. Those who were stigmatized also 
scored significantly lower than those who were not. and 
those who expressed very strong feelings of stigma (gave 
three “yes” answers) in comparison to those who did not 
(one “yes" answer).
In the Physical functioning domain, stigmatization, 
age at onset, and current age were found to be significant.
Mean scores in this domain were significantly lower for 
those who were stigmatized compared with those who 
were not and for those aged 60 years or older compared 
with those aged 20-29 years. The overall pattern of 
variation in terms of age at onset was similar to that in 
the General health domain.
DISCUSSION
The importance of measuring quality of life in epi­
lepsy patients has been emphasized (8,13,26,43,44,51- 
54). In dealing with epilepsy, several authors have drawn 
attention to the special importance of considering the 
social aspects. At the same time, recent investigations 
based on community populations suggest that although 
significant social difficulties may be experienced, many 
people with epilepsy cope well in society. However, pa­
tients with poor seizure control, multiple seizure types, 
or associated handicaps have significant social problems 
(55). Our study focused on adults living in the commu­
nity. To give a more extensive and accurate survey, the 
sample for the study was drawn from two Estonian towns 
differing from each other in several respects. One of 
them represented the country's urban society, and the 
other, a mainly provincial and rural population. On Janu­
ary 1, 1996, the estimated crude prevalence ratio of ac-
TABLE 7. Results o f analysis-of-variance models
Domains Factors
Mean square 
ratio p Value
Physical functioning Stigmatization 4.78 0.03
Age at onset 3.65 0.001
Систем age 4.39 0001
Rote limitations (physical problems) Seizure frequency 9.27 0.0001
Current age 3.54 0.02
Stigmatization 8.93 0.003
Stigma severity 4.16 0.02
Age at onset 3.15 0.01
Role limitations (emotional problems) Seizare frequency 13.89 0.0001
Stigmatization 7.91 0.005
Stigma severity 3.47 0.03
Energy/fatigue Seizure frequency 24.20 0.0001
Employment 3.26 0.02
Duration of disease 3.27 0.02
Age at onset 2.66 0.03
Emotional well-being Seizure frequency 3.96 0.03
Stigmatization 4.27 0.04
Duration of disease 3.27 0.02
Social functioning Seizure frequency 11.88 0.0001
Stigmatization 69* 0.0!
Stigma severity 8.83 0 0007
Employment 23.85 0.0001
Seizure type 5 88 0.003
Age at onset 3.34 0.007
Bodily pain Seizure frequency 7.76 0.0006
Duration of disease 2.44 0.05
General health Seizure frequency 5.36 0.005
Age at onset 3.25 0.009
Stigmatization 4.69 0.03
Stigma severity 3.K2 0.03
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TABLE В. Comparison o f sex and age structure o f  Tartu people with epilepsy and 
those included in the present study
Parameter
Among people with 
epilepsy in Tartu
Among people with epilepsy in 
Tartu in the present study
Pn % n %
Sex
Male 172 55.7 56 45.9 0.07
Female 137 44.3 66 54.1
Age groups
20-29 yr 53 17.2 26 21.3 0.3
30-39 yr 74 23.9 27 22.1 0.7
40-49 yr 70 22.6 24 19.7 0.5
50-59 yr 54 17.5 20 16.4 0.8
£60 yr 58 18.S 25 20.5 0.7
Total 309 100.0 122 100.0
live epilepsy in Taitu was 4.1 per 1,000 (56). When 
comparing the percentages of sex and age structure of the 
people with epilepsy in the present study with the same 
data available about the people with epilepsy of Tartu, 
there were no significant differences, and thus we con­
sider our study consecutive (Table 8). The clinical char­
acteristics of the present study were similar to most other 
series of prevalence cases of epilepsy (57-59). Most of 
the study respondents had generalized seizures with or 
without other seizure types, the average duration of the 
disease was 11 years, and patients were predominantly 
receiving CBZ monotherapy. More than half of those 
who had experienced seizures during the last year re­
potted having injuries related to them. Findings regard­
ing the rate and severity of seizure-related injuries were 
slightly higher compared with the results of studies con­
ducted in other countries (43,60). Beran (61) pointed out 
that the purpose of treating epilepsy may not necessarily 
be that of seizure eradication but rather the maximal 
improvement of quality of life for the patient. In com­
prehensive management, the treating physician must 
very seriously consider the influence of the therapy on 
the patients' quality of life (53). Eighty-four percent of 
our study respondents were receiving monotherapy. This 
was higher compared with the other studies (26,43,62). 
The explanation is that all of the patients from Tartu 
were participating in an epidemiologic survey with con­
sultation by an epileptologist, which often resulted in the 
correction of medication. The number of untreated cases 
(11%) was not high and probably reflects insufficient 
compliance. However, AED prescription patterns had 
some distinctive features. CBZ was a much more fre­
quently reported drug than in other studies, whereas the 
percentage of those using valproate (VPA) or phenytoin 
(PHT) was lower. To our surprise, two patients reported 
taking bensobarbital, a drug that is no longer officially 
used in Estonia. The results indicate that treatment strat­
egies in Estonia probably should be modified. Significant 
numbers of study respondents (67%) reported side ef­
fects from the AEDs; the most commonly experienced
side effects were nonspecific. In the past year, 41% of 
respondents had changed their medication; at present, 
78% stated that the level of seizure control was satisfac­
tory.
The problem of stigmatization has been projected as 
one of the most common social problems faced by per­
sons with epilepsy in a number of studies (23,37,63-66). 
Stigmatization seems to vary from region to region, and 
it tends to be more severe outside the developed world 
(67-72). However, despite its changed manner, it is still 
a difficult problem in Western countries. As stigmatiza­
tion is difficult to compare, we collated our results only 
with the results from the European study (43) in which 
the same scale was used for measuring stigma. Accord­
ing to this, the highest proportions of stigmatized persons 
(>60%) were found among the respondents from two 
highly developed countries (i.e., France and Germany). 
The study also included respondents from Poland, the 
Czech Republic, and Hungary, where the percentages of 
stigma were 32, 55, and 52, respectively. In Estonia, the 
levels of stigma among people with epilepsy were also 
high (52%), although 40% of our study's respondents 
had less than one seizure a month, and 34% had been 
seizure free in the last year. The majority of patients 
stated that they were nevertheless satisfied with the cur­
rent treatment, and the percentage of stigmatization in 
general and the percentage of severely stigmatized per­
sons was high. The factors influencing the development 
and maintenance of stigma in different countries are di­
verse, but we speculate that in general, the higher per­
centage of stigmatization could be a characteristic of 
Eastern European countries and could be the result of a 
general lack of knowledge and of indifference, because 
the individual’s health and well-being was not valued, 
for a long period, because of the complicated political 
status. Furthermore, more precise studies from other 
Eastern European countries could perhaps clarify this 
topic. Respondents were more likely to feel stigmatized 
by epilepsy if they had frequent seizures or a combina­
tion of seizure types, findings that were in agreement
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with the results of other studies (26,43,63,65). Stigmati­
zation^ was more common among educated persons.
Unemployment and part-time employment, being 
much more frequent in the epilepsy population than in 
general, have been identified as being among the most 
serious problems facing people with epilepsy (73,74). 
The percentage of people working full-time and part- 
time was 65 in the present study; 11 % were unemployed. 
We do not consider this high because, according to the 
data of the labor force surveys of the Statistical Office of 
Estonia, the percentage of employees (both employed 
and underemployed) residing in Tartu and aged 20 years 
and older on January 1, 1998, was 63%, the unemploy­
ment rate was 9.5%, and 25.5% were pensioners receiv­
ing the state pension (75). At the same time, more than 
half of the study’s respondents believed that their em­
ployment problems were erased by their disease. A little 
fewer than half sutcd that they were being treated un­
fairly at work. Perceived discrimination may not always 
correspond to real discrimination (1). Although the find­
ings of this study do not provide evidence of active dis­
crimination against people with epilepsy, this topic must 
be investigated, in greater depth. Of respondents, 55.7% 
had at least high school education, and problems con­
nected with unemployment or part-time employment 
were not much expressed among this group. Not surpris­
ingly, seizure frequency was positively related to the 
unemployed and underemployed workers, but we could 
not find a relationship with the type of seizure. The find­
ing supports the data of previous research in which lower 
seizure frequency had been related to the greater likeli­
hood of being employed (1,42,76). The results of our 
study showed very clearly that there are a variety of 
reasons for the existence of the stigma. Although it has 
been found that unemployment and employment prob­
lems are on the whole the main source of the stigma 
(17,42,65), the most educated respondents in our study 
who had jobs were even more stigmatized.
To assess general health status, a multidimensional 
instrument, the RAND 36-Item Health Survey 1.0, was 
used. Although they have proven useful in their countries 
of origin, such instruments are not directly applicable 
across nations because of cultural diversity (77). Before 
using it in our study, we performed a thorough transla­
tion and validation process. The construct validity of the 
scale was supported by the findings that those with fre­
quent seizures did poorly compared with those who ex­
perienced infrequent seizures or were currently seizure 
free. This expected finding was in accordance with other 
studies (26,41,62,78,79). Although the differences be­
tween seizure types were not significant in all the 
RAND-36 domains, there was a clear tendency toward a 
greater likelihood of lower scores in the case of patients 
with generalized tonic-clonic seizures. Patients who ex­
perienced both generalized tonic-clonic and other types
of seizures did poorly compared with the others, as was 
to be expected (26,43,78). Discriminant validity was 
highly acceptable. People with epilepsy had significantly 
lower scores than did the controls in all domains. Al­
though the mental health of the study respondents was 
not much worse than that of the control group, their 
social functioning was significantly lower, and limita­
tions due to emotional problems were more expressed. 
The results of the European study had previously drawn 
attention to the fact that it was unclear why respondents 
with epilepsy scored relatively poorly on the domain 
concerned with physical function (43). Although current 
seizure activity remained the most important predictor, 
there was a concomitant importance of sociodemo­
graphic variables (current age and employment status) in 
quality of life. Older people and people who were cur­
rently unemployed were more likely to score lower. The 
other substantial disease characteristics in explaining the 
variation in the scores of several domains after control­
ling for seizure status were age at onset of epilepsy, 
duration of disease, and seizure type. Age at onset be­
came significant in the case of Physical functioning, Role 
limitations-physical. Energy/fatigue, Social functioning, 
and General health. In all those domains, later age at 
onset was associated with lower scores. Dominian et al. 
(80) reported an association between depression and 
older age at onset. Jacoby et al. (26) considered older age 
at onset to be implicated in feelings of depression and 
stigma. Duration of disease was significant in the case of 
Energy/fatigue. Emotional well-being, and Bodily pain. 
Here, a shorter duration of epilepsy was related to lower 
scores. Seizure type became significant in relation to 
Social functioning; those who experienced either tonic- 
clonic or multiple seizure types scored significantly 
lower than did those who had only other types of sei­
zures.
To increase the clinical significance of these tests, it is 
essential to perform repetitive dials. This will be one of 
the subjects of further investigation. As the RAND-36 
was not designed to measure limitations or restrictions 
specifically associated with epilepsy, a disease-specific 
instrument may be more sensitive in evaluating varia­
tions in patient perception (81,82).
We consider the strength of our study to be that epi­
lepsy diagnosis was based on a clinical assessment. A 
profound translation and psychometrical testing phase 
preceded the inclusion of the RAND-36 questionnaire in 
the research. Although we arc aware of the limitations to 
the generalizability of the study in the interpretation of 
the results because of a relatively small and somewhat 
biased sample size, the findings of the study reveal quite 
clearly that one of the main problems of people with 
epilepsy in Estonia is their perception of stigmatization 
The characteristics describing their disease, its medica­
tion, and complications were generally in accordance
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with the data from other countries, and also marital and 
educational status (except when assessing the stigmati­
zation) were not statistically significant. Achieving better 
control of seizures and reducing side effects are essential 
in improving the quality of life of people with epilepsy, 
because this reduces the stigma associated with the con­
dition. We emphasize to doctors the importance of psy­
chological support in the care of patients with epilepsy. 
Unfortunately, the results of our study suggest that, at 
least in our country, many physicians ignore or do not 
recognize this actuality, considering it irrelevant.
In conclusion, the findings of this study confirm that 
psychosocial problems accompany the diagnosis of epi­
lepsy. Although the study demonstrated quality of life 
decreases in subjects with epilepsy, we consider the re­
sults encouraging. No remarkable differences were found 
in terms of medical problems. A further study is required 
in this field within our community to help people with 
epilepsy to better understand their condition, to analyze 
the reasons for stigma, and if it is not possible to elimi­
nate them completely, then to promote adjustment.
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Abstract
The purpose of this investigation was to test, the acceptability, validity, and 
reliability of the RAND-36 and to describe, by it, how quality of life (QOL) is 
affected by patients’ and epilepsy characteristics in an Estonian sample of adults 
with epilepsy. The form was translated with accompanying translation quality 
ratings and pilot tested. It was administered to 203 epileptic patients and to a 
control group of 200 healthy subjects. The RAND-36’s ability to distinguish 
between high and low symptom load was determined assessing by seizure type 
and frequency. All sub-scales passed tests for item-internal consistency and 
item-discriminant validity. Reliability coefficients exceeded 0.40 in all 
instances. QOL was poor for patients with frequent seizures and tonic-clonic or 
multiple seizures. The patients with epilepsy were more dysfunctional in all 
RAND-36 domains than were persons from control group. Though the emotio­
nal well-being of the study respondents was not much worse than that of the 
control group, their social functioning was significantly lower and limitations 
due to emotional problems more expressed. Although current seizure activity 
remained the most important predictor, there was a concomitant importance of 
socio-demographic variables (current age and employment status) and disease 
characteristics (age at onset, duration of epilepsy, and seizure type).
1
Introduction
Quality-of-life issues are most relevant to disorders that are chronic and asso­
ciated with problems beyond the experience of the obvious disease symptoms. 
Epileptic seizures are usually infrequent but antiepileptic drug (AED) therapy, 
side effects, and attendant psychosocial problems are usually chronic [10]. The 
extent to which an individual with a chronic illness feels the impact of his or her 
condition may vary with its course and depend on different factors at different 
stages in its history. Health-related quality of life can be assessed through 
various objective indicators and much empirical data gained through this 
approach are now available regarding various epilepsy populations. However, it 
has been realised for a long time that people act or feel in accordance with their 
perceptions of reality, which may or may not relate directly to their actual 
circumstances or to objective indicators of their medical condition [7]. At the 
same time, it is useful to have a focus on objectivity in research and clinical 
practice. Today many researches agree on the importance of a comprehensive 
view within epilepsy-care [5, 18,43].
A variety of instruments are available for evaluating health-related quality of 
life in the general population. One among the most widely used questionnaires 
is the RAND 36-Item Health Survey 1.0. It is a brief and intensively tested 
instrument that was derived from longer instruments developed by RAND 
researchers (Santa Monica, California) for the Medical Outcome Study (MOS) 
and the Health Insurance Experiment [8]. The purposes and methods of the 
RAND study have been fully summarised [20]. The RAND 36-Item Health 
Survey 1.0 items are identical to the MOS 36-item short-form health survey 
(MOS SF-36) described by Ware and Sherboume [42]. They were adapted from 
longer instruments completed by patients participating in the Medical Outcomes 
Study [19]. The conceptual framework is based on the multidimensional World 
Health Organisation definition of health [44]. Although the RAND version has 
a slightly different scoring method, it allows users of the MOS SF-36 and 
RAND-36 to relate their findings [20]. The RAND 36-Item Health Survey also 
forms the core component of two quality of life measures in epilepsy, the 
Epilepsy Surgery Inventory (ESI-55) [43] and the Quality of Life in Epilepsy 
Inventory (QOLIE-89) [12]. The RAND-36 has a high validity and reliability as 
compared with the Nottingham Health Profile and can discriminate between 
healthy controls and subjects who have mild health problems [16, 39]. It has 
been carefully tested, validated, and extensively used among patients with 
chronic disease [36]. Due to its long developmental history and use in research 
as well as in clinical practice, it provides a rich database enabling researches to 
compare their results. In the international context, thus it is possible research on 
the cultural universality vs. differences in quality-of-life assessment [6]. 
Standard scales are needed to meet the demands of international studies. 
Although proven useful in their country of origin these measures are not directly 
applicable across nations due to cultural diversity. In order to use such instm-
ments in a new national context, a thorough translation and testing phase 
preceding the inclusion of an instrument in a study is necessary. Measures need 
also to be psychometrically tested in a specific cultural context to assure their 
psychometric soundness [6, 21, 29].
The purpose of the present paper was to test the acceptability, validity, and 
reliability of the RAND 36-Item Health Survey 1.0 questionnaire and to analyse 
by means of it how QOL is affected by socio-demographic and epilepsy cha­
racteristics.
Methods
The RAND-36 is a short questionnaire with 36 items which measure eight 
multi-item variables: physical functioning (PF) — ten items, role limitations 
due to physical health problems (RP) — four items, role limitations due to 
personal or emotional problems (RE) — three items, energy/fatigue (EF) — 
four items, emotional well-being (EW) — five items, social functioning (SF) — 
two items, bodily pain (BP) — two items, and general perception of health 
(GH) — five items. It also includes a single item that provides an indication of 
perceived change in health over the past year (CHG). For each variable item 
scores are coded, summed, and transformed on to a scale from 0 (worst possible 
health state measured by the questionnaire) to 100 (best possible health state) 
[31]. The RAND-36 questionnaire takes about five minutes to complete.
Translation
The translation procedure was carried through taking into account the re­
commendations of the developers of the Nottingham Health Profile, the 
Sickness Impact Profile, The Quality of Well-Being Scale, etc. [2] and the 
Intemationail Quality of Life Assessment (IQOLA) — translation group [1]. The 
items and responses of the original American RAND-36 questionnaire were 
translated into Estonian independently by two native Estonian speakers with 
excellent knowledge of English. The translators then met to discuss and agree 
upon the common version of the questionnaire. Subsequently the common 
version was evaluated by another native Estonian speaker in terms of 
conceptual equivalence, linguistic performance and clarity. The agreed upon 
Estonian form was then translated back into English and rated. If modifications 
were necessary, the reformulation in the Estonian version was performed.
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The Estonian questionnaire was given for self-assessment to 15 epilepsy 
patients who visited their neurologist at the University’s Outpatients’ Clinic. 
During individual interviews, each item and response choice was carefully 
discussed as to its meaning and connotations with the responders. As a result 
the wording of five questions was altered slightly. Then the questionnaire was 
mailed by post to 15 epilepsy patients. The goal of this administration was to 
detect problems with the forms in terms of missing data, inconsistent answers 
and ease of administration.
No respondent found the questionnaire either difficult or too personal.
Subjects
Our results are based on data gained from a sample of 203 patients, in the 20-70 
age group. The research took place in 1997-98. The QOL data was collected 
from respondents with epilepsy living in two towns of Estonia — Tartu and 
Viljandi. Tartu, with a population of 100 977 [35] is the country’s second 
largest city. Southern Estonia revolves around Tartu which is the intellectual 
and educational centre of Estonia. Viljandi County, with a population of 62 782 
[35], is located in south-central Estonia. The administrative centre of the county 
is the town of Viljandi, the country’s sixth largest town by its population, which 
is situated 81 kilometres from Tartu. In Tartu, the study followed an an epi­
demiological survey of epilepsy in the town of Tartu. The patients for the 
present study were selected at random from the preliminary lists of the 
epidemiological study. The epidemiological survey included persons who were 
residents of Tartu and were aged 20 and over, and had before or within the 
course of 01.01.1991-01.01.1996 had at least two unprovoked epileptic 
seizures, at least one of them within the previous five years. Data collection for 
the epidemiological study consisted of two parts: data registration from a multi­
source medical register review and data registration from a personal case re­
examination. Case records of patients treated in the University Hospital, 
Outpatients’ Clinics, physicians’ offices, emergency rooms, the electroencepha- 
lographic laboratory with a diagnosis of epilepsy, convulsions, syncope, amnes­
tic attacks, abnormal involuntary movements were reviewed and invitations for 
re-examination were sent to the suitable persons. During the last 2 years, all the 
patients were re-examined at least once by a neurologist to specify the type of 
their seizures. In Viljandi, primary information about people with epilepsy was 
gathered through the local epilepsy support group, and clinical information was 
abstracted from medical notes held in the County Hospital and Outpatients’ 
Clinic register. To evaluate the accuracy of diagnoses, the problematic cases 
were investigated by one of the authors and re-examined if necessary. The 
present study excluded the Russian-speaking people because there were not any
Piloting
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sufficiently well translated questionnaires available for them. All patients gave 
their consent to participate in the research and the project was approved by the 
Ethics Committee of the University of Tartu. All of the respondents had a basic 
education level with sufficient ability to read and write, and were capable of 
understanding and completing the questionnaires. Clinical information, if 
needed, was abstracted once again from medical notes and during the personal 
re-examination of subjects. Abstracted information used in the study related to 
the aetiology of epilepsy, classification of seizure type and current AED the­
rapy. All the patients were sent a questionnaire by mail that employed a combi­
nation of open questions together with two previously translated and validated 
scales (the Stigma of Epilepsy Scale and the RAND 36-Item Health Survey). 
Information was obtained about subjects' sex, age, marital and employment 
status, and educational level. To evaluate seizure frequency, patients were asked 
whether they had had seizures once or more in a month, less often than once a 
month, or not at all in the past year. Also patients were asked about age at first 
attack. Perceived stigma was measured with a three-item scale (Cronbach’s 
alpha = 0.71), which Estonian translation and validation has been described
[33]. Respondents with epilepsy had to state whether they (a) felt that other 
people were uncomfortable with them, (b) treated them as inferior, or (c) 
preferred to avoid them. Each of the three items required a yes/no response. An 
individual’s score was the sum of the “yes” responses and the higher the score, 
the greater was the perception of stigma.
In addition, a control group of 200 healthy subjects corresponding in age, 
sex, and educational level was randomly selected among the patients visiting the 
dentist at University’s Dental Clinic.
Response to the study
Questionnaires were sent to the identified individuals by post, with a covering 
letter from the study conductors, explaining the purpose of the study. To those 
who did not respond to the initial questionnaire a reminder was sent about three 
to six weeks later. Questionnaires, to be completed individually, were mailed to 
290 patients, of whom 225 replied — a response rate of 78%. From all the 
questionnaires returned, 22 appeared to be unusable and the rest of 203 
questionnaires were included in the study.
Statistical analysis
The data were analysed using statistical analysis package SPSS Professional 
Statistics™ 7.5 [34]. Test of significance was one-way analysis of variance 
(ANOVA). Attention is drawn to results which differences were significant at 
the 5% level or less (p<0.05). The RAND-36 was evaluated using the data
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completeness at an individual item and scale level, correlations between items 
and hypothesised scales, correlations between items and other scales, average 
inter-item correlation, intemal-consistency reliability (Cronbach’s alpha [9]) 
and score distributions (floor and ceiling effects, skewness and kurtosis). 95% 
confidence intervals (Cl) were computed to define the range of variation around 
the mean.
Construct validity, showing the extent to which the questionnaire supports 
predefined hypotheses [24] and the main requirement of any measuring tool [4], 
was assessed in connection with seizure frequency and seizure type. This 
followed the hypothesis that patients with frequent seizures and patients with 
tonic-clonic or multiple seizure types would have poorer health status. To test 
for such comparisons between groups, Tukey’s studentized range test was used 
for each variable. To assess the influence of patient characteristics on quality of 
life (RAND-36) domains, the effects of the clinical variables (seizure frequency, 
type of seizures, age at onset, duration of disease), stigmatisation and its seve­
rity, and socio-demographic variables (age, sex, educational level, employment 
status, marital status) on each domain total score were studied, using multifactor 
analysis of variance models. Preliminary analyses were first carried out to 
investigate which of the clinical variables predominated. At each stage, factors 
found to be no longer significant after adjusting for the remainder were exclu­
ded. The final model includes only the factors, which contributed significantly 
in predicting the domain score. To determine significant differences between 
pairs of groups, Tukey HSD procedure or Bonferroni’s methods were used [38].
Results 
Characteristics of respondents
The main characteristics of respondents are given in table 1. The median age of 
the study epilepsy sample was 41 (25th and 75th percentiles 29 and 57) years. 
The respondents of the study were divided into five age groups: 20-29 years — 
26.6%, 30-39 years — 20.7%, 40-49 years — 17.2%, 50-59 years — 13.8%, 
and 60 years and older — 21.7%. Median age of the onset of epilepsy was 26.9 
years, and the median duration of epilepsy was 11.3 years (25th and 75th 
percentiles 5.8 and 22.4). Patients were divided into five groups by duration of 
the disease and into six groups by age at onset of their epilepsy. 88.7% were 
receiving AED treatment. From those, 83.9% were receiving monotherapy. 
From those on monotherapy, the majority (74.8%) were receiving carbama­
zepine. 52.4% felt stigmatised by their epilepsy. From those, 24.7% answered 
“yes” to all three items, 27.8% to two and 47.5% to one item showing their 
stigmatisation.
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Table 1. Characteristics of respondents.
Parameter Study respondents %
Age (median) 41 years
Sex (M/F) 99/104 48.8/51.2
Marital status
married/cohabiting 83 40.9
single 84 41.4
divorced 21 10.3
widowed 15 7.4
Employment status
full-time 67 33.0
underemployed 65 31.9
unemployed 22 11.0
retired or receiving disablement pension 49 24.1
Education
less than primary (lower than 8th level) 22 10.8
primary (8th or 9th level) 68 33.5
high school (1 1th or 12th level) 93 45.8
university 20 9.9
Duration of epilepsy (median) 11.3 years
until 1 year 11 5.4
2-5 years 45 22.2
6-10 years 46 22.7
i 1-20 years 44 21.7
over 20 years 57 28.1
Age at onset
under 10 years 20 9.9
11 -20 years old 68 33.5
21-30 years old 38 18.7
31 -40 years old 36 17.7
41-50 years old 15 7.4
over 50 years old 26 12.8
Seizure type
tonic-clonic only 84 41.4
tonic-clonic and others 61 30.0
others only 58 28.6
Seizure frequency status in the last year
seizure free 69 34.0
<1 seizure a month 81 39.9
>1 seizure a month 53 26.1
Medication
free from medication 23 11.3
on AED treatment 180 88.7
The median age of the control group was 40 (25th and 75th percentiles 27 and 
56) years. 49% were men. 8% had less than primary education (lower than 8th
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grade), 32% had primary education (8th or 9th grade), 49% had high school 
education and 11 % had graduated from university.
Data completeness
The distribution of responses of the respondents from epilepsy group to the 36 
items, as well as the number and percentage of patients missing each of the 36 
items is given in Table 2. Missing value rates for the items were low and did not 
exceed 1.5% for any item. The total number of omitted items per questionnaire 
was 8.3%. 92% completed all 36 items.
Table 2. Item frequency distributions — the epilepsy sample.
Item Nr
Item Missing %
nr
PF1 202 40.1% 33.7% 26.2% 1 0.5
(81) (68) (53)
PF2 202 6.9% 26.7% 66.3% 1 0.5
(14) (54) (134)
PF3 202 10.9% 24.3% 64.9% 1 0.5
(22) (49) (131)
PF4 202 16.3% 34.7% 49.0% 1 0.5
(33) (70) (99)
PF5 202 2.5% 18.8% 78.7% 1 0.5
(5) (38) (159)
PF6 202 17.3% 31.2% 51.5% 1 0.5
(35) (63) (104)
PF7 202 16.3% 20.3% 63.4% 1 0.5
(33) (41) (128)
PF8 202 5.9% 15.4% 78.7% 1 0.5
(12) (31) (159)
PF9 202 3.5% 9.0% 87.5% 2 1.0
(7) (18) (176)
PF10 202 2.5% 9.4% 88.1% 1 0.5
(5) (19) (178)
RPl 202 43.1% 56.9% 1 0.5
(87) (115)
RP2 202 54.5% 45.5% 1 0.5
(110) (92)
RP3 202 49.5% 50.5% 1 0.5
(100) (102)
RP4 202 50.0% 50.0% 1 0.5
(101) (101)
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Item Nr
Item Missing
nr
%
1 2 3 4 5 6
REl 202 45.1% 55.0% 1 0.5
(91) (111)
RE2 202 61.4% 38.6% 1 0.5
(124) (78)
RE3 202 47.0% 53.0% 1 0.5
(95) (107)
EF1 201 16.9% 29.9% 22.4% 18.9% 10.5% 1.5% 2 ...1.0
(34) (60) (45) (38) (21) (3)
EF2 202 21.8% 20.3% 27.2% 19.3% 7.9% 3.5% 1 0.5
(44) (41) (55) (39) (16) (7)
EF3 202 2.5% 9.4% 15.8% 20.8% 25.3% 26.2% 1 0.5
(5) (19) (32) (42) (51) (53)
EF4 202 9.9% 10.9% 24.8% 28.7% 21.3% 4.5% 1 0.5
(20) (22) (50) (58) (43) (9)
EW1 201 0.5% 9.0% 16.9% 25.9% 31.8% 15.9% 2 1.0
(1) (18) (34) (52) (64) (32)
EW2 202 2.0% 5.0% 12.9% 17.8% 20.8% 41.6% 1 0.5
(4) (10) (26) (36) (42) (84)
EW3 202 4.5% 19.3% 35.2% 15.4% 20.3% 5.5% 1 0.5
(9) (39) (71) (31) (41) (11)
EW4 202 1.5% 10.9% 14.9% 21.8% 31.7% 19.3% 1 0.5
(3) (22) (30) (44) (64) (39)
EW5 202 7.4% 26.7% 25.7% 21.8% 15.8% 2.5% 1 0.5
(15) (54) (52) (44) (32) (5)
SF1 202 3.5% 16.5% 15.5% 28.5% 36% 3 1.5
(7) (33) (31) (57) (72)
SF2 202 5.0% 12.9% 22.8% 17.8% 41.6% 1 0.5
(10) (26) (46) (36) (84)
BP1 202 2.5% 11.4% 19.8% 17.3% 20.8% 28.2% 1 0.5
(5) (23) (40) (35) (42) (57)
BP2 202 5.5% 10.9% 21.3% 23.3% 39.1% 1 0.5
(11) (22) (43) (47) (79)
GH1 202 16.8% 55.9% 22.8% 3.5% 1.0% 1 0.5
(34) (113) (46) (75) (2)
GH2 202 11.9% 15.4% 32.2% 24.3% 16.3% 1 0.5
(24) (31) (65) (49) (33)
GH3 202 23.8% 22.3% 22.3% 24.8% 6.9% 1 0.5
(48) (45) (45) (50) (14)
GH4 202 6.4% 13.9% 44.1% 15.8% 19.8% 1 0.5
(13) (28) (89) (32) (40)
GH5 202 31.7% 20.3% 20.3% 23.8% 4.0% 1 0.5
(64) (41) (41) (48) (8)
CHG 202 4.5% 22.3% 51.5% 16.8% 5.0% ...... 7 ........ 0.5....
(9) (45) (104) (34) (10)
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Psychometric analyses
The data about the psychometric characteristics is given in Tables 3 and 4.
As Table 3 shows, means and standard deviations of the scales were in the 
range of 44-77 (SD 21-42) for epilepsy group and in the range of 66-88 (SD 
9-33) in the control group. In the epilepsy group mean and median scores were 
higher for physical function and lower for general health. Skewness, measuring 
the asymmetry of response distributions, was most marked for physical function 
in the epilepsy group and for role — physical in the control group. Most of the 
scales were negatively skewed, meaning that subjects more often gave 
responses representing positive health states. There were substantial ceiling 
effects for four domains — Physical functioning, Role -  physical, Role — 
emotional, Social functioning in both groups, in the epilepsy group in addition 
to these — for Bodily pain. Floor effects were significant in two domains in the 
epilepsy group: 31% and 32.5% of subjects had the minimum possible score in 
the Role — physical and Role — emotional domains respectively. The internal 
consistency coefficients, being above 0.70 for all dimensions, met the level 
acceptable for group comparisons. The internal consistency coefficients ranged 
from 0.75 to 0.92. Scaling assumptions were tested in two ways. Corrections 
between items and hypothesised scales were substantial within each scale and 
reached the level of >0,40 in all instances, supporting the reliability of the 
RAND-36 scales in both groups. In epilepsy group the lowest median item-total 
correlation was 0.53 for general health, the highest 0.84 for bodily pain. 
Discriminant validity was considered acceptable when these correlations 
exceeded all correlations between items and other scales. All the eight scales in 
both groups passed this level.
Table 3. RAND-36 subscale psychometric results.
RAND-36
subscales
Mean
(0-100)
Median Std Range Skewness
Kur-
tosis
Floor
(%)
Ceiling
(%)
The epilepsy group
Physical 76.56 85.00 24.26 100.00 -1.14 0.55 1.0 18.2
functioning
Role-physical 50.62 50.00 42.10 100.00 -0.01 -1.69 31.0 33.5
Role- 48.60 33.33 41.59 100.00 0.10 -1.62 32.5 32.5
emotional
Energy/ 47.64 50.00 22.14 100.00 0.01 -0.73 1.0 0.5
fatigue
Emotional 59.80 60.00 20.49 96.00 -0.27 -0.73 0 0.5
well-being
Social 69.40 75.00 27.68 100.00 -0.54 -0.78 1.5 28.1
functioning
Pain 67.69 70.00 28.67 100.00 -0.55 -0.73 2.5 26.1
General health 43.89 45.00 22.46 95.00 0.12 -0.92 2.0 0
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RAND-36
subscales
Mean
(0-100)
Median Std Range Skewness Kur-tosis
Floor Ceiling
(%) (%)
The control group
Physical 87.20 87.00 9.42 30.00 -0.15 -0.83 0 25.0
functioning
Role-physical 86.71 100.00 20.76 100.00 -2.36 6.70 3.0 59.0
Role- 69.13 66.00 33.11 100.00 -0.66 -0.75 8.5 45.0
emotional
Energy/ 65.54 64.00 12.36 76.00 -0.19 0.90 0 0.5
fatigue
Emotional 67.12 64.00 16.92 72.00 -0.05 -0.27 0 3.0
well-being
Social 87.82 88.00 11.50 62.00 -1.11 1.83 0 32.5
functioning
Pain 78.97 80.00 12.44 78.00 -1.94 5.72 0 3.5
General health 66.85 64.00 14.09 60.00 0.54 0.25 0 3.0
Table 4. Results of scaling success tests and reliability estimates.
Dimension Internal
consis­
tency3
Homo-
genityb
Item dis­
criminant 
validity0
Cron- 
bach's a
Relia­
bility
coefficients
The epilepsy group
Physical functioning 0.55-0.80 0.55 0.21-0.70 0.92 0.91
Role limitations (physical 0.67-0.76 0.61 0.34-0.63 0.86 0.86
problems)
Role limitations (emotional 0.58-0.67 0.56 0.31-0.60 0.79 0.78
problems)
Energy/fatigue 0.59-0.73 0.57 0.35-0.69 0.84 0.83
Emotional well-being 0.52-0.75 0.55 0.22-0.74 0.86 0.85
Social functioning 0.62 0.63 0.49-0.61 0.77 0.77
Pain 0.84 0.84 0.52-0.67 0.91 0.90
General health 0.54-0.79 0.53 0.31-0.64 0.85 0.83
The control group
Physical functioning 0.57-0.72 0.55 0.44-0.70 0.77 0.75
Role limitations (physical 0.42-0.69 0.41 0.35-0.61 0.76 0.78
problems)
Role limitations (emotional 0.58-0.76 0.52 0.55-0.72 0.80 0.80
problems) 
Energy/fatigue 0.56-0.68 0.55 0.40-0.65 0.76 0.75
Emotional well-being 0.68-0.73 0.60 0.57-0.70 0.88 0.88
Social functioning 0.61 0.59 0.42-0.60 0.79 0.78
Pain 0.53-0.76 0.48 0.48-0.69 0.82 0.81
General health 0.47-0.69 0.50 0.43-0.63 0.74 0.75
a Correlations, corrected for overlap, between items and hypothesised scales. 
b Average inter-item correlation 
c Correlations between items and other scales
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Validity
Validity of the RAND-36 was assessed using discriminant techniques. The 
RAND-36vs ability to distinguish between high and a low symptom load was 
determined assessing by seizure type and frequency. The descriptive statistics 
and features of score distribution for the RAND-36 scales are detailed in Tables
5 and 6. Variance between seizure types was statistically significant in five 
RAND-36 domains. The comparisons between groups were investigated for 
each domain using Tukey’s studentized range test at the 0.05 level. Patients 
who did not have generalised tonic-clonic seizures or multiple seizure types had 
significantly higher scores in the Role — physical and Social functioning. 
Those who had multiple seizure types had lower scores than those with only 
tonic-clonic seizure types or those with other types of seizures only in the Role 
— emotional. Those who experienced multiple seizure types scored signi­
ficantly lower in the Emotional well-being and Bodily pain domains compared 
to those who did not have generalised tonic-clonic seizures.
Variance between seizure frequency statuses was statistically significant in 
seven domains. The differences were significant between all the three groups in 
the Role — emotional domain. Between those who had not had seizures in the 
past year and those who had had seizures at least once a month or less often 
than once a month the differences were significant in the Role — physical, 
Energy/fatigue, and General health domains. Those experiencing seizures once 
or more in a month scored significantly worse in the Emotional well-being and 
Social functioning compared to those who had been seizure-free in the last year. 
In the Bodily pain domain the differences were significant between those 
having seizures once or more in a month compared to those who had had 
seizures less often than once a month or had not had them in the last year.
Discriminative power was examined by comparing RAND-36 score profiles 
of the healthy respondents and respondents with epilepsy. As shown in Fig. 1, 
the respondents with epilepsy scored significantly lower in all RAND-36 
domains than the controls (p<0.001), indicating that their perceived health status 
was poorer. The differences were most remarkable in Role -  physical, Role -  
emotional, Social functioning and General health domains.
12
Table 5. Descriptive statistics and features of score distributions for the RAND-36 Health Survey by seizure type.
Domain Tonic-clonic only (n=84) Tonic-clonic and others (n==61) Others only (n=58) p-value*
Mean Median Cl SEM Mean Median Cl SEM Mean Median Cl SEM
Physical functioning 74.5 87.5 68.7-80.4 2.9 74.2 75 67.4-79.0 2.9 83.0 90 77.7-88.4 2.7 0.06
Role-physical 48.5 25 39.1-57.9 4.7 43.9 25 32.5-55.2 5.7 60.8 62.5 51.2-70.3 4.8 0.05
Role-emotional 51.6 33.3 42.5-60.7 4.6 39.9 33.33 29.5-50.3 5.2 53.5 66.66 42.6-64.3 5.4 0.03
Energy/fatigue 46.0 45 40.9-51.2 2.6 45.2 50 39.7-50.6 2.7 52.6 55 47.2-57.9 2.7 0.1
Emotional well-being 60.8 64 56.4-65.1 2.2 55.2 56 49.5-60.9 2.8 63.2 64 58.3-68.2 2.5 0.02
Social functioning 67.7 75 61.6-73.9 3.1 62.5 62.5 55.4-69.6 3.6 79.1 87.5 72.8-85.4 3.1 0.006
Bodily pain 68.4 68.75 62.2-74.6 3.1 60.1 67.5 | 52.2-67.9 | 3.9 74.6 77.5 68.1-81.1 3.3 0.04
General health 42.1 40 37.4-46.9 2.4 43.9 40 37.6-50.1 3.1 46.5 45 40.9-52.0 2.8 0.4
Cl, 95% confidence interval; SEM, standard error of the mean.
* Variance between seizure types. Test of significance was Kruskal-Wallis one-way analysis of variance.
Table 6. Descriptive statistics and features of score distributions for the RAND-36 Health Survey by seizure frequency status in the last year.
Domain >1 seizure a month (n=53) <1 seizure a month (n=81) seizure free (n=69) p-value*
Mean Median Cl SEM Mean Median Cl SEM Mean Median Cl SEM
Physical functioning 73.0 75 67.3-78.7 2.8 74.3 85 68.5-80.2 2.9 81.9 90 76.3-87.5 2.8 0.07
Role-physical 33.5 25 23.4-43.6 5.0 49.4 50 40.3-58.5 4.6 65.2 100 55.1-75.4 5.1 0.0001
Role-emotional 27.0 30 17.7-36.4 4.7 49.0 33.33 39.9-58.1 4.6 64.7 100 55.0-74.4 4.9 0.0001
Energy/fatigue 45.1 50 39.7-50.5 2.7 43.2 40 38.2-48.2 2.5 54.8 60 49.5-60.1 2.6 0.004
Emotional well-being 55.1 56 49.6-60.6 2.7 58.4 60 53.8-63.0 2.3 65.0 72 60.3-69.8 2.4 0.02
Social functioning 59.2 62.5 51.6-66.8 3.8 69.1 75 63.0-75.3 3.1 77.5 87.5 71.5-83.5 3.0 0.001
Bodily pain 56.2 57.5 48.1-64.3 4.0 68.1 77.5 61.8-744 3.1 76.1 80 69.9-82.2 3.1 0.0006
General health 39.3 40 33.6-44.9 2.8 41.0 40 36.0-45.9 2.5 50.9 50 45.4-56.3 2.7 0.005
Cl, 95% confidence interval; SEM, standard error of the mean.
* Variance between seizure frequencies. Test of significance was Kruskal-Wallis one-way analysis of variance.
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Fig.l. Discriminative power of the RAND-36.
Comparison of mean scores for the RAND-36 health status measure: people with 
epilepsy and the control group.
* Test of significance was Kruskal-Wallis one-way analysis of variance.
Impact of epilepsy on quality of life
The results of the final models fitted to each RAND-36 domain scores, inclu­
ding the factors that remain significant after controlling for the others, are 
shown in Table 7. Each multifactor model is a main effect model (no significant 
interactions were found between the factors). Pairs of groups of factors 
significantly different were compared using Tukey HSD or Bonferroni’s 
procedures. Scores of the RAND-36 domains were first compared in terms of 
the clinical variables. Significant differences were found for seizure frequency 
in all domains, except the Physical functioning domain. Seizure free patients 
scored significantly higher than patients who had experienced seizures during 
the last year in the Role limitations — physical, Energy/fatigue, Bodily pain, 
and General health domains. The difference between those who had had sei­
zures once or more in a month compared to those having seizures less often than 
once a month or not having seizures during the last year was significant in Role 
limitations -  emotional, Emotional well-being, and Social functioning domains.
In the Role limitations — physical domain, after controlling for seizure 
frequency, age, stigmatisation, stigma severity, and age at onset of epilepsy, 
became significant. Younger people were less likely to score low in this do­
main, significant differences were between the 20-29 and 30-39 age groups 
compared to people who belonged to the age group of 60 years and over. Mean 
scores of this domain were significantly lower for those who were stigmatised, 
and for those who expressed very strong feelings of stigma (gave three “yes”
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answers on the stigma scale) compared to those who expressed less (one “yes” 
answer). Later age at onset was associated with lower scores, differences were 
significant between those for whom epilepsy had been diagnosed at the age of 
41-50 or more than 50 years compared to those for whom it had been diagnosed 
at an age under 20 years.
In the Role limitations — emotional domain, mean scores were significantly 
lower for those who were stigmatised, and for those who expressed very strong 
feelings of stigma (gave three “yes” answers on the stigma scale) compared to 
those who expressed themselves less strongly (one “yes” answer).
Table 7. Results of analysis of variance models.
Domains Factors Mean square ratio p-value
Physical functioning Stigmatization 4.78 0.03
Age at onset 3.65 0.001
Current age 4.39 0.001
Role limitations Seizure frequency 9.27 0.0001
(physical problems) Current age 3.54 0.02
Stigmatization 8.93 0.003
Stigma severity 4.16 0.02
Age at onset 3.15 0.01
Role limitations Seizure frequency 13.89 0.0001
(emotional problems) Stigmatization 7.91 0.005
Stigma severity 3.47 0.03
Energy/fatigue Seizure frequency 24.20 0.0001
Employment 3.26 0.02
Duration of disease ■ 3.27 0.02
Age at onset 2.66 0.03
Emotional well-being Seizure frequency 3.96 0.03
Stigmatization 4.27 0.04
Duration of disease 3.27 0.02
Social functioning Seizure frequency 11.88 0.0001
Stigmatization 6.98 0.01
Stigma severity 8.83 0.0007
Employment 23.85 0.0001
Seizure type 5.88 0.003
Age at onset 3.34 0.007
Bodily pain Seizure frequency 7.76 0.0006
Duration of disease 2.44 0.05
General health Seizure frequency 5.36 0.005
Age at onset 3.25 0.009
Stigmatization 4.69 0.03
Stigma severity 3.82 0.03
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In the Energy/fatigue domain, employment status, duration of epilepsy, and 
age at onset of epilepsy were significant. In this domain, mean scores were 
significantly lower for those currently unemployed compared to those who were 
in full-time or underemployed work, for those who had suffered from epilepsy 
two to five, or six to ten years compared to those who had suffered longer and 
for those whom epilepsy had been diagnosed at the age of 41-50 or more than 
50 years compared to those for whom it had been diagnosed at an age under 20 
years.
In the Emotional well-being domain, significantly lower were the scores of 
those who were stigmatised compared to those who were not and of those who 
had suffered from epilepsy two to five years compared to those who had 
suffered more than twenty years.
In the Social functioning domain, stigmatisation, stigma severity, employ­
ment status, seizure type, and age at onset of seizures became significant. Signi­
ficantly lower scores by those who were stigmatised, those who expressed very 
strong feelings of stigma (gave three “yes” answers) compared to those who felt 
it not so strongly (one “yes” answer), those who were currently unemployed 
compared to those who were in full-time employment or underemployed, those 
who experienced either tonic-clonic or multiple seizure types compared to those 
who had only other types of seizures, and those for whom epilepsy had been 
diagnosed at the age of 41-50 or more than 50 years compared to those for 
whom it had been diagnosed at an age under 20 years.
In the Bodily pain domain, lower scores were related to shorter time of 
duration of epilepsy (2-5 years) compared to longer periods (11-20 and more 
than 20 years).
In the General health domain, mean scores were significantly lower for those 
whose epilepsy had been diagnosed at the age of 41-50 or more than 50 years 
compared to those for whom it had been diagnosed at an age under 20 years. 
Those who were stigmatised also scored significantly lower compared to those 
who were not, and those who expressed very strong feelings of stigma (gave 
three “yes” answers) compared to those who did not (one “yes” answer).
In the Physical functioning domain, stigmatisation, age at onset, and current 
age were found to be significant. Mean scores of this domain were significantly 
lower for those who were stigmatised compared to those who were not and for 
those who were aged 60 years or more compared to those 20-29 years old. The 
overall pattern of variation in terms of age at onset was similar to that in the 
General health domain.
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Discussion
The RAND 36-Item Health Survey 1.0 is a generic self-completed multidimen­
sional questionnaire measuring health-related quality of life in larger popu­
lations and different subgroups e.g. patients. It is developed as a measure of 
health status or health outcome for use in cross-sectional and longitudinal 
studies [27]. Although the questionnaire has been quite widely used, it has been 
suggested that different ethnic or cultural groups may interpret same items of 
the questionnaire differently [13, 17]. Also different disease groups can score 
too close to the bottom or top of the score range, thus limiting the usefulness of 
a scale for comparing disease-burden profiles [30].
The preliminary study reported here concerned the translation, pilot-testing 
and psychometric evaluation of the Estonian RAND 36-Item Health Survey 1.0 
for evaluating the people with epilepsy. It was preliminary in that results pre­
sented were first of a series of applications of the questionnaire in Estonian 
studies. In general, the translation and pilot testing of the Estonian version 
demonstrated a satisfactory feasibility of the form and suggested that the 
response choices in the Estonian version were ordinal and comparable to the 
response choices in the U.S. version. We achieved a response rate of 78%. The 
results of the item descriptive statistics showed a high completeness of data 
(over 98.5% on the item level) and a good distribution across response choices 
on the scale levels. The application of the RAND-36 showed up very well 
regarding satisfactory psychometric results in terms of scale characteristics with 
reliability coefficients above 0.70. For the epilepsy group both floor and ceiling 
effects were low for mental health, vitality and general health. Floor effects in 
the epilepsy sample were negligible for six scales, ceiling effects for three -  
mental health, vitality and general health. The construct validity was supported 
by the findings that those with frequent seizures did poorly compared to those 
with infrequent seizures or currently seizure-free. A finding, which was expec­
ted and in accordance with other studies [3, 11, 23, 28, 32]. Although the diffe­
rences between seizure types were not significant in all the RAND-36 domains, 
there was a clear tendency to higher significance of scoring lower when having 
generalised tonic-clonic seizures. Patients who experienced both generalised 
tonic-clonic and other types of seizures did poorly when compared to those who 
did not experience them. That was also expectable [3, 11, 23]. Discriminant 
validity was highly acceptable. People with epilepsy had significantly lower 
scores than the controls in all domains. The RAND-36 is currently being 
applied in further validation studies along with other instruments. In Estonia, it 
is, together with additional condition-specific measures, included in trials eva­
luating the health status of people with stroke, Parkinson’s disease, migraine, 
and after head trauma. Results from our study are encouraging and the follo­
wing research will show the sensitivity of the instrument to change among 
patients with other particular illnesses. We hope that our work of validating
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questionnaire with clinical assessment will contribute to the growing capacity of 
Estonian as well as general research into the RAND-36 health profile.
Our study focused on adults living in the community. The clinical characte­
ristics of the present study were similar to most other series of prevalence cases 
of epilepsy [15, 25, 26]. Most of the study respondents had generalised seizures 
with or without other seizure types, the average duration of the disease was 11 
years and patients were predominantly on carbamazepine monotherapy. Accor­
ding to this study, the levels of stigma among people with epilepsy were also 
high (52%) in spite of the fact that 40% of the study’s respondents had less than 
one seizure a month and 34% had been seizure-free in the last year.
Though the mental health of the study respondents was not much worse than 
that of the control group, their social functioning was significantly lower and 
limitations due to emotional problems more expressed. Previously, the results of 
the European study had brought attention to the fact that it was unclear why 
respondents with epilepsy scored relatively badly on the domain concerned with 
physical function [3]. Although current seizure activity remained the most 
important predictor, there was a concomitant importance of socio-demographic 
variables (current age and employment status) to the quality of life. Older 
people and people who were currently unemployed were more likely to score 
lower. The other substantial disease characteristics in explaining the variation in 
the scores of several domains after controlling for seizure status were age at 
onset of epilepsy, duration of disease, and seizure type. Age at onset became 
significant in the case of Physical functioning, Role limitations -  physical, 
Energy/fatigue, Social functioning, and General health. In all those domains, 
later age at onset was associated with lower scores. Dominian et al. [14] have 
reported an association between depression and older age at onset, Jacoby et al. 
[23] considered older age at onset to be implicated in feelings of depression and 
stigma. Duration of disease was significant in case of Energy/fatigue, Emotional 
well-being and Bodily pain. Here, a shorter time of duration of epilepsy was 
related to lower scores. Seizure type became significant in relation to Social 
functioning — those who experienced either tonic-clonic or multiple seizure 
types scored significantly lower compared to those who had only other types of 
seizures.
To increase the clinical significance of these tests, it is essential to perform 
repetitive trials. This will be one of the subjects of further investigation. As the 
RAND-36 was not designed to measure limitations or restrictions specifically 
associated with epilepsy, a disease-specific instrument may be more sensitive in 
evaluating variations in patient perception [22, 37].
We consider the strong sides of our study to be that epilepsy diagnosis was 
based on a clinical assessment and that a profound translation and psychomet- 
rical testing phase preceded the inclusion of the RAND-36 questionnaire in the 
research. Although we are aware of the limitations to the generalisability of the 
study in interpreting the results due to it being a relatively small and somewhat 
biased sample size.
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The RAND-36 is a reliable and valid descriptive health status measure for 
epilepsy population that enables to get valuable additional information con­
cerning the quality of the everyday-life of the people with epilepsy. The 
questionnaire has been criticised for its ceiling and floor effect [22, 41]. In our 
study, we found high ceiling effects associated with most of the domains. 
Jenkinson et al. have mentioned that the instrument has its limitations - for 
instance contains no variable on sleep [24]. However, we would conclude that it 
gives a good survey of the general health status of the people and enables an 
adequate health assessment comparison between the groups of patients with 
disease of varying severity.
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Abstract
Background: The Quality-of-Life in Epilepsy Inventory (QOLIE-31) was 
developed in effort to assess health-related quality of life (QOL) in patients with 
epilepsy.
Objectives: To test the acceptability, validity, and reliability of the Estonian 
version of the QOLIE-31 and to describe, by it, how QOL is affected by 
patients’ and epilepsy characteristics.
Research Design: Postal survey by using a booklet containing the QOLIE-31 
and several other items concerned with lifestyles and illness.
Subjects: 203 patients with epilepsy aged 20-70.
Measures;: The 7 domains within the QOLIE-31 questionnaire.
Results: The form was translated with accompanying translation quality 
ratings and pilot tested. All sub-scales passed tests for item-internal consistency 
and item-discriminant validity. Correlations between items and hypothesised 
scales exceeded 0.40 in all instances, except one. The QOLIE-3l’s ability to 
distinguish between high and low symptom load was determined assessing by 
seizure type and frequency.
Conclusions: QOL was the poorest for patients with frequent seizures and 
for those with multiple seizures types. Although current seizure activity
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remained the most important predictor, there was a concomitant importance of 
socio-demographic variables (education, marital status and employment) and 
characteristics connected with the disease (seizure type, type of AED therapy, 
AED side effects, age at onset, and duration of epilepsy). Also, stigmatisation 
and stigma severity turned out to be very important. The results of the QOLIE- 
31 were compared with the same data obtained in other countries. The values of 
the domains were generally lower than in developed countries and similar to 
those given in another Easten European country.
Introduction
Epilepsy is a diagnosis that enfolds a group of disorders in which seizures recur. 
Because different seizures manifest themselves differently, they also vary in the 
degree to which they present a risk to physical safety, their predictability, their 
responsiveness to treatment and their potential to interfere peoples’ everyday- 
life [1]. At the same time, epilepsy is one of the most common neurological 
conditions, with an age-adjusted incidence of between 20 and 70 per 100,000 
and an estimated prevalence of 0.4 to 1% [1-5]. According to the present 
available data, originating from Tartu, the estimated prevalence ratio of active 
epilepsy is 5.3 per 1,000. This means, in Estonia, with a population of approxi­
mately 1.4 million people, epilepsy roughly affects 7950 adults with 
approximately 530 new cases yearly [6, 7].
As there is often a poor correlation between the patient’s and the physician’s 
assessments [8], many researchers agree on the importance of a comprehensive 
view within epilepsy-care [9-11] and quality-of-life measures are assuming 
greater importance in medical practice [12]. A diverse consortium of epilepsy 
and health services researchers (The QOLIE Development Group) initiated 
development of a broader, but epilepsy-specific instrument by expanding on the 
RAND 36-Item Health Survey [13] and ESI-55 [14] concept of a self-report 
measure of health-related quality of life (HRQOL). The QOLIE-31 has been 
validated extensively to assure that the identified domains relate to different 
issues. It is a 31-item questionnaire that addresses 7 domains of HRQOL in 
subscales that can be compiled into a summary score reflecting experiences in 
the previous month [15-17]. To be effective, an instrument must be practical for 
the specific setting, measure what it purports to measure (valid), and be 
consistent from one administration to the next (reliable) [12]. But, measures 
need also to be psychometrically tested in a specific cultural context to assure 
their psychometric soundness [18-20].
The purpose of the present paper was to test the acceptability, validity, and 
reliability of the Estonian version of the QOLIE-31 questionnaire and to 
describe the QOL of the Estonian people with epilepsy by using it.
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Methods
Clinical information, if needed, was abstracted from medical notes and during 
the personal re-examination of subjects. Abstracted information used in the 
study related to the etiology of epilepsy, classification of seizure type and 
current antiepileptic drug (AED) therapy. To evaluate the impact of epilepsy on 
employment status and perceived stigma, the patients were sent a questionnaire 
by mail. The questionnaire employed a combination of open questions together 
with a previously translated and validated stigma scale (The Stigma of Epilepsy 
Scale) (Cronbach’s alpha = 0.71) [21]. The questionnaire covered the following 
issues: (1) Demographic characteristics — information was obtained about 
subjects’ sex, age, marital and employment status, and educational level. (2) 
Seizure frequency — patients were asked whether they had had seizures once or 
more in a month, less often than once a month, or not at all in the past year. (3) 
History of the epilepsy — patients were asked about age at first attack. (4) AED 
treatment and side effects — patients were asked about the AED they were 
taking and about the experienced side effects during the past month. (5) 
Perceived stigma was measured with a three-item scale developed originally for 
stroke [22], adapted for epilepsy and already used in other QOL studies [23, 
24]. Respondents with epilepsy had to state whether they (a) felt that other 
people were uncomfortable with them, (b) treated them as inferior, or (c) 
preferred to avoid them. Each of the three items required a yes/no response. An 
individual’s score was the sum of the “yes” responses. (6) Epilepsy-specific 
data about QOL that was collected using the QOLIE-31 questionnaire — 
respondents were asked to complete an epilepsy-specific measure, the QOLIE- 
31 [25], which contained 7 multi-item scales: Seizure worry (SW) — 5 items, 
Overall quality of life (OQL) — 2 items, Emotional well-being (EWB) — 
items, Energy/fatigue (E/F) — 4 items, Cognitive functioning (COG) —
6 items, Medication effects (ME) — 3 items, Social functioning (SF) — 
5 items. A QOLIE-31 overall score was obtained using a weighted average of 
the multi-item scale scores. The QOLIE-31 also included a single item that 
assessed overall health. During the scoring procedure, first, the raw precoded 
numeric values of items were converted to 0-100 point scores, with higher 
converted scores always reflecting better QOL. Next, the subtotal scores for 
each scale were summed and divided by the number of items that the 
respondent answered within each scale. The QOLIE-31 overall score was 
calculated by summing the product of each scale score times its weight and 
summing over all scales.
Patients were divided into 3 groups by seizure type (as having only tonic- 
clonic, only other types, or both tonic-clonic and other types) and frequency.
For the use of the QOLIE-31 questionnaire, written permission was asked 
and received from the RAND Office of Contract and Grant Services in Santa 
Monica, California, USA, in October 1997.
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Translation
As recommended [26], the translation procedure included translation into 
Estonian, assessment of item comprehension, back-translation into English, and 
development of a consensual version. The items and responses of the original 
American QOLIE-31 questionnaire were first translated into Estonian by 2 
independent native Estonian speakers with excellent knowledge of English. The 
translators then met to discuss until agreement was reached on item wording 
according to content correspondence. Subsequently the common version was 
evaluated by an other native Estonian speaker in terms of conceptual 
equivalence, linguistic performance and clarity. The agreed upon Estonian form 
was then backtranslated into English and rated. If modifications were necessary, 
the reformulation in Estonian version was performed. The final version was 
tested in a pilot study.
Piloting
The translated Estonian versions of the QOLIE-31 questionnaire was given for 
self-assessment to 15 epilepsy patients who visited their neurologist at the 
University’s Outpatients’ Clinic. During individual interviews, each item and 
response choice was carefully discussed as to its meaning and connotation with 
the responders. As a result the wording of 4 questions of the QOLIE-31 was 
altered slightly. Then the questionnaires were mailed by post to 15 epilepsy 
patients. The goal of this administration was to detect problems with the forms 
in terms of missing data, inconsistent answers and ease of administration. No 
respondent found the questionnaires either difficult or too personal.
A question, concerning problems with driving for patients on AED treat­
ment, was excluded during the scoring procedure from the QOLIE-31 ques­
tionnaire for those who did not have a driving-license because it did not directly 
assess the Social function domain in these people. The reason was, as in our 
society, it is quite common for older people, especially for women, not to have a 
driving licence or use a car. From 30 patients in the pilot-study, 22 had never 
had a driving licence. From 15 questionnaires mailed to patients, 9 of those who 
had reported not having a driving-license had left the question unfilled, 4 
reported having had no trouble with it and 2 marked they had had some trouble.
Subjects
Our results are based on data gained from a sample of 203 patients, in the 20-70 
age group. The research took place in 1997-98. The QOL data was collected 
from respondents with epilepsy living in 2 towns of Estonia — Tartu and 
Viljandi. Tartu, with a population of 100 977 [27] is the country’s second
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largest city. Southern Estonia revolves around Tartu which is the intellectual 
and educational centre of Estonia. Viljandi County, with a population of 62 782 
[27], is located in south-central Estonia. The administrative centre of the county 
is the town of Viljandi, which is situated 81 kilometres from Tartu. In Tartu, the 
study followed an epidemiological survey of epilepsy. The patients for the pre­
sent study were selected at random from the preliminary lists of the epi­
demiological study. The epidemiological survey included persons who were 
residents of Tartu and were aged 20 and over, and had before or within the 
course of 01.01.1991-01.01.1996 had at least 2 unprovoked epileptic seizures, at 
least 1 of them within the previous 5 years. Data collection for the epidemio­
logical study consisted of data registration from a multi-source medical register 
review and data registration from a personal case re-examination. Case records 
of patients treated in the University Hospital, Outpatients’ Clinics, physicians 
offices, emergency rooms, the electroencephalograpic laboratory with a diag­
nosis of epilepsy, convulsions, syncope, amnestic attacks, abnormal involuntary 
movements were reviewed and invitations for re-examination were sent to the 
suitable persons. During the last 2 years, all the patients were re-examined at 
least once by a neurologist to specify the type of their seizures. In Viljandi, 
primary information about people with epilepsy was gathered through the local 
epilepsy support group, and clinical information was abstracted from medical 
notes held in the County Hospital and Outpatients’ Clinic register. To evaluate 
the accuracy of diagnoses, the problematic cases were investigated by one of the 
authors and re-examined if necessary. The present study excluded the Russian- 
speaking people because there were not any sufficiently well translated ques­
tionnaires available for them. All patients gave their consent to participate in the 
research and the project was approved by the Ethics Committee of the Uni­
versity of Tartu.
Response to the study
Questionnaires were sent to identified individuals by post, with a covering letter 
from the study conducters, explaining the purpose of the study. To those who 
did not respond to the initial questionnaire a reminder was sent about 3 to 6 
weeks later. Questionnaires to be completed individually were mailed to 290 
patients, of whom 225 replied — a response rate of 78%. From all the 
questionnaires returned, 22 appeared to be unusable, the rest were included in 
the study.
Statistical analysis
The data were analysed using statistical analysis package SPSS Professional 
Statistics™ 7.5 [28]. Test of significance was one-way analysis of variance
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(ANOVA). Attention is drawn to results which differences were significant at 
the 5% level or less (p<0.05). The questionnaire was evaluated using the data 
completeness at an individual item and scale level, correlations between items 
and hypothesised scales, correlations between items and other scales, average 
inter-item correlation, intemal-consistency reliability (Cronbach’s alpha [29]) 
and score distributions (floor and ceiling effects, skewness and kurtosis). 95% 
confidence intervals (Cl) were computed to define the range of variation around 
the mean.
Construct validity was assessed in connection with seizure frequency and 
seizure type following hypotheses that patients with frequent seizures and 
patients with tonic-clonic or multiple seizure types would have poorer health 
status. To test for such comparisons between groups, Tukey’s studentized range 
test was used for each variable.
Results 
Characteristics of respondents
The main characteristics of respondents are given in Table 1. The median age 
of the study epilepsy sample was 41 (25th and 75th percentiles 29 and 57) 
years. Median age of the onset of epilepsy was 26.9 years, and the median 
duration of epilepsy was 11.3 years (25th and 75th percentiles 5.8 and 22.4). 
Patients were divided into five groups by duration of the disease and into six 
groups by age at onset of their epilepsy. Eighty-eight point seven percentage 
were receiving AED treatment. From those, 83.9% were receiving 
monotherapy. From those on monotherapy, the majority (74.8%) were receiving 
carbamazepine. The most commonly experienced side effects were non­
specific: memory problems (31%), tiredness (25%), sleepiness (20%), headache 
(20%) and nervousness (20%). From those experiencing any of the symptoms 
associated with the AED treatment, the majority (73.9%) reported having three 
or more. A third of subjects (33%) reported no side effects. Fifty-two point four 
percentage felt stigmatised by their epilepsy. From those, 24.7% answered 
“yes” to all three items, 27.8% to two and 47.5% to one item showing the 
severity of the stigmatisation.
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Table 1. Characteristics of respondents.
Parameter Study respondents %
Age (median) 41 years
Sex (M/F) 99/104 48.8/51.2
Marital status
married/cohabiting 83 40.9
single 84 41.4
divorced 21 10.3
widowed 15 7.4
Employment status
full-time 67 33.0
underemployed 65 31.9
unemployed 22 11.0
retired or receiving disablement pension 49 24.1
Education
less than primary (lower than 8th level) 22 10.8
primary (8th or 9th level) 68 33.5
high school (1 1th or 12th level) 93 45.8
university 20 9.9
Duration of epilepsy (median) 11.3 years
until 1 year 11 5.4
2-5 years 45 22.2
6-10 years 46 22.7
11 -20 years 44 21.7
over 20 years 57 28.1
Age at onset
under 10 years 20 9.9
11-20 years old ■ 68 33.5
21 -30 years old 38 18.7
31 -40 years old 36 17.7
41 -50 years old 15 7.4
over 50 years old 26 12.8
Seizure type
tonic-clonic only 84 41.4
tonic-clonic and others 61 30.0
others only 58 28.6
Seizure frequency status in the last year
seizure free 69 34.0
<1 seizure a month 81 39.9
>1 seizure a month 53 26.1
Medication
free from medication 23 11.3
on AED treatment 180 88.7
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Data completeness
Missing value rates for the items of the QOLIE-31 were low and did not exceed 
2% for any item. The total number of omitted items per questionnaire was 
6.5%. Ninety-four percentage completed all 31 items.
Psychometric analyses
As Table 2 shows, means and standard deviations of the scales were in the 
range of 48-64 (SD 18-26). The mean and median scores were higher for 
Medication effects and lower for Energy/fatigue. Skewness that measures the 
asymmetry of response distributions was most marked for Seizure worry. There 
were substantial ceiling effects for 2 domains — Energy/fatigue and Social 
functioning. Floor effects were significant in 2 domains: 3.45% and 1.97% of 
subjects had the minimum possible score in the Seizure worry and Medication 
effects’ domains, respectively. Reliability was assessed through internal consis­
tency. The internal consistency coefficients, being above 0.70 for all dimen­
sions, met the level acceptable for group comparisons. The internal consistency 
coefficients ranged from 0.71 to 0.88. Scaling assumptions were tested in two 
ways. Correlations between items and hypothesized scales, which assess the 
extent to which an item is related to the remainder of its scale, were substantial 
within each scale and reached the level of >0.40 in all instances, except within 
one — the Medication effects domain (0.38-0.50), supporting the reliability of 
the QOLIE-31 scales. The lowest median item-total correlation was 0.42 for 
Medication effects, the highest 0.62 for Overall quality of life. Discriminant 
validity was considered acceptable when these correlations exeeded all 
correlations between items and other scales. All the 7 scales passed this level. 
The data about the psychometric characteristics is given in Tables 2 and 3.
Table 2. QOLIE-31 subscale psychometric results.
QOLIE-31
subscales
Mean
(0-100) Median SD
Range Skewness Kurtosis
Floor
(%)
Ceiling
(%)
Seizure worry 54.67 60 26.26 95 -0.43 -0.97 3.45 0.49
Overall 
quality of life
49.18 50 17.59 95 0.31 0.12 0.49 0.49
Emotional
well-being
60.14 60 19.95 100 -0.30 -0.75 0.49 0.49
Energy/
fatigue
48.40 50 20.17 85 -0.11 -0.70 0.49 4.43
Cognitive
functioning
59.41 61.95 23.75 92.50 -0.32 -0.85 0.49 0.99
Medication
effects
63.64 63.90 27.70 188.90 0.11 1.05 1.97 0.49
Social
functioning
63.54 65 25.08 95 -0.29 -0.83 0.49 11.33
Table 3. Results o f scaling success tests and reliability estimates.
Dimension Internalconsistency®
Homo­
geneityb
Item discri­
minant 
validity0
Cron- 
bach's a
Reliability
coefficients
Seizure worry 0.59-0.81 0.56 0.21-0.57 0.86 0.86
Overall quality of life 0.62 0.62 0.28-0.67 0.77 0.77
Emotional well-being 0.59-0.75 0.55 0.23-0.73 0.85 0.86
Energy/fatigue 0.53-0.67 0.50 0.19-0.69 0.79 0.80
Cognitive functioning 0.62-0.75 0.55 0.28-0.59 0.88 0.88
Medication effects 0.38-0.50 0.43 0.20-0.48 0.72 0.71
Social functioning 0.51-0.65 0.47 0.30-0.64 0.77 0.78
“Correlations, corrected for overlap, between items and hypothesised scales. 
bAverage inter-item correlation 
Correlations between items and other scales
Validity
Validity of both scales was assessed using discriminant techniques. The 
QOLBE-31’s ability to distinguish between high and a low symptom load was 
determined assessing by seizure type and frequency.
The descriptive statistics and features of score distribution for the QOLIE-31 
scales are detailed in Tables 4 and 5. Variance between seizure types was 
statistically significant in 4 QOLIE-31 domains. The comparisons between 
groups were investigated for each domain using Tukey’s studentized range test 
at the 0.05 level.
Patients who did not have generalised tonic-clonic seizures or multiple 
seizure types had significantly higher scores in the Overall quality of life and 
Social functioning domains. Those who had multiple seizure types had lower 
scores than those with only tonic-clonic seizure types or those with other types 
of seizures only in the Seizure worry and Medication effects. Those who expe­
rienced multiple seizure types scored significantly lower in the Seizure worry, 
Medication effects and Social functioning domains compared to those who did 
not have generalised tonic-clonic seizures. (Fig. 1) The overall score of the 
QOLIE-31 was significantly different between all the 3 groups of seizure types.
Variance between seizure frequency statuses was statistically significant in 
all 7 domains. The differences were significant between all the 3 groups in the 
Seizure worry, Medication effects and Social functioning domain. Between 
those who had not had seizures in the past year and those who had had seizures 
at least once a month or less often than once a month, there were significant 
differences in the Overall quality of life, Emotional well-being, Energy/fatigue, 
Cognitive function domains and between the values of the overall score of the 
questionnaire. (Fig. 2)
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Table 4. Descriptive statistics and features of score distributions for the QOLIE-31 by seizure type.
Domain
Tonic-clonic only (n=84) Tonic-clonic and others (n=61) Others only (n=58)
p-value*Mean Median Cl SEM Mean Median Cl SEM Mean Median Cl SEM
Seizure worry 56.27 60.8 50.8-61.7 2.8 47.83 48.3 40.9-54.8 3.5 59.52 65.7 52.8-66.3 3.4 0.04
Overall quality of life 47.89 50.0 44.2-51.6 1.8 46.27 45.0 41.4-51.2 2.5 54.09 50.0 49.9-58.3 2.1 0.03
Emotional well-being 60.91 62.0 56.7-65.1 2.1 56.85 52.0 51.2-62.5 2.8 62.48 68.0 57.6-67.3 2.4 0.27
Energy/fatigue 46.19 45.0 41.5-50.8 2.3 47.54 45.0 42.4-52.7 2.6 52.50 55.0 47.7-57.3 2.4 0.17
Cognitive functions 60.54 66.1 54.9-66.1 2.8 55.43 56.1 49.5-61.3 2.9 61.96 62.6 56.4-67.5 2.8 0.28
Medication effects 65.04 66.7 59.3-70.8 2.9 58.43 61.1 52.8-66.2 3.4 67.10 62.5 57.6-71.4 3.5 0.05
Social functioning 63.51 65.6 57.9-69.1 2.8 57.68 57.5 51.0-64.4 3.4 69.75 68.8 64.2-75.3 2.8 0.03
Overall 57.50 58.0 53.4-61.6 2.1 53.40 51.3 48.4-58.4 2.5 61.40 59.6 57.1-65.7 2.1 0.05
Cl, 95% confidence interval; SEM, standard error of the mean.
* Variance between seizure types. Test of significance was Kruskal-Wallis one-way analysis of variance.
Table 5. Descriptive statistics and features of score distributions for the QOLIE-31 by seizure frequency status in the last year.
Domain >1 seizure a month (n=53)
<1 seizure a month (n=81) seizure free (n=69)
p-value*Mean Median Cl SEM Mean Median Cl SEM Mean Median Cl SEM
Seizure worry 44.76 48.0 37.2-52.3 3.7 53.95 62.7 48.5-59.4 2.8 63.12 70.0 57.2-69.0 3.0 0.0005
Overall quality of life 46.79 50.0 43.4-50.1 1.7 45.15 45.0 41.2-49.1 2.0 55.73 55.0 51.2-60.3 2.3 0.0005
Emotional well-being 57.28 56.0 51.9-62.7 2.7 57.09 60.0 52.6-61.6 2.3 65.91 72.0 61.4-70.4 2.3 0.01
Energy/fatigue 46.51 45.0 41.2-51.8 2.7 44.51 45.0 40.1-48.9 2.2 54.42 55.0 49.6-59.3 2.4 0.008
Cognitive functions 53.10 57.0 47.5-58.7 2.8 56.85 61.1 51.7-62.0 2.6 67.27 73.6 61.3-73.3 3.0 0.002
Medication effects 54.98 55.6 47.4-62.5 3.8 59.57 58.3 54.0-65.2 2.8 75.08 77.8 69.6-82.5 3.2 0.0001
Social functioning 53.36 56.3 47.1-59.6 3.1 61.24 62.5 56.1-66.4 2.6 74.07 82.5 68.1-80.1 3.0 0.0001
Overall 51.50 50.9 47.0-56.0 2.3 54.50 54.4 50.7-58.4 1.9 65.20 69.3 60.7-69.8 2.3 0.0001
Cl, 95% confidence interval; SEM, standard error of the mean.
* Variance between seizure frequencies. Test of significance was Kruskal-Wallis one-way analysis of variance.
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Fig. 1. Comparison of mean scores for the QOLIE-31 by seizure type.
* Test of significance was Kruskal-Wallis one-way analysis of variance.
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Fig. 2. Comparison of mean scores for the QOLIE-31 by seizure frequency. 
* Test of significance was Kruskal-Wallis one-way analysis of variance.
Impact of epilepsy on QOL
Scores of the QOLIE-31 domains were first compared in terms of the clinical 
variables. Significant differences were found for seizure frequency in all 
domains. The results of the final models after controlling for seizure status are 
shown in Table 6. Each multifactor model is a main effect model (no 
significant interactions were found between the factors). Pairs of groups of 
factors significantly different were compared using Tukey HSD or Bonferroni's 
procedures.
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In the Seizure worry domain, seizure type, education, type of AED therapy, 
stigmatisation and stigma severity remained significant. Significantly lower 
scores were obtained by those who experienced either tonic-clonic or multiple 
seizure types compared to those who had only other types of seizures, those 
who had high school or university education compared to those who had 
primary or less than primary education, those who were on polytherapy 
compared to those on monotherapy, those who were stigmatised, and those who 
expressed very strong feelings of stigma (gave three “yes” answers) compared 
to those who did not (one “yes” answer).
In the Overall quality of life domain, seizure type, stigmatisation, age at 
onset, marital status, employment, type of AED therapy and AED side effects 
remained significant. Significantly lower scores were obtained by those who 
experienced either tonic-clonic or multiple seizure types compared to those who 
had only other types of seizures, those who expressed very strong feelings of 
stigma (gave three “yes” answers) compared to those who did not (one “yes” 
answer), those for whom epilepsy had been diagnosed at the age of 41-50 or 
above 50 compared to those for whom it had been diagnosed at an age under 20, 
those who were married or cohabiting compared to those who were single, those 
who were currently unemployed compared to those who were in full-time 
employment or underemployed, those who were on polytherapy compared to 
those on monotherapy, and those who stated having experienced side effects of 
the AEDs.
In the Emotional well-being domain, duration of epilepsy, employment, and 
AED side effects remained significant. Significantly lower scores were obtained 
by those who had suffered from epilepsy for 2 to 5 years compared to those who 
had suffered more than 20 years, those who were currently unemployed 
compared to those who were in full-time employment or underemployed, and 
those who stated having experienced side effects of the AEDs.
In the Energy/fatigue domain, age at onset, employment, and AED side 
effects remained significant. In this domain, scores were significantly lower for 
those whose epilepsy had been diagnosed at the age of 41-50 or over 50 
compared to those for whom it had been diagnosed at an age under 20 years, for 
those who were currently unemployed compared to those who were in full-time 
employment or underemployed, and for those who stated having experienced 
side effects of the AEDs.
In the Cognitive functions domain, age at onset, education, type of AED 
therapy, AED side effects, and stigmatisation remained significant. 
Significantly lower scores were obtained by those for whom epilepsy had been 
diagnosed at the age of 41-50 or over 50 compared to those for whom it had 
been diagnosed at an age under 20 years, those who had had primary or less 
than primary education compared to those who had high school or university 
education, those who were on polytherapy compared to those on monotherapy, 
those who stated having experienced side effects of the AEDs and those who 
were stigmatised.
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In the Medication effects domain, AED side effects, stigmatisation, and 
stigma severity remained significant. Significantly lower scores were obtained 
by those who stated having experienced side effects of the AEDs, those who 
were stigmatised, and those who expressed very strong feelings of stigma (gave 
three “yes” answers) compared to those who did not (one “yes” answer).
In the Social functioning domain, marital status, employment, AED side 
effects, stigmatisation, and stigma severity remained significant. Significantly 
lower scores were obtained by those who were single, divorced or widowed 
compared to those who were married, for those who were currently unemployed 
or retired compared to those who were in full-time employment or 
underemployed, those who stated having experienced side effects of the AEDs, 
those who were stigmatised, and those who expressed very strong feelings of 
stigma (gave three “yes” answers) compared to those who did not (one “yes” 
answer).
In the Overall score, stigmatisation, stigma severity, age at onset, AED side 
effects, and type of AED therapy remained significant. Significantly lower 
scores were obtained by those who were stigmatised, those who expressed very 
strong feelings of stigma (gave three “yes” answers) compared to those who did 
not (one “yes” answer), those for whom epilepsy had been diagnosed at the age 
of 41-50 or over 50 compared to those for whom it had been diagnosed at an 
age under 20 years, those who stated having experienced side effects of the 
AEDs, and those who were on polytherapy compared to those on monotherapy.
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Table 6. Results of the QOLIE-31 using analysis of variance models.
Domains Factors Mean square ratio p-value
Seizure worry Seizure frequency 25.46 0.0001
Seizure type 4.26 0.03
Education 2.45 0.04
Type of AED therapy 3.89 0.005
Stigmatisation 5.73 0.001
Stigma severity 5.68 0.02
Overall quality of life Seizure frequency 15.47 0.0001
Seizure type 12.86 0.004
Stigmatisation 8.35 0.007
Age at onset 7.32 0.008
Marital status 4.12 0.01
Employment 3.68 0.03
Type of AED therapy 3.53 0.03
AED side effects 2.75 0.04
Emotional well-being Seizure frequency 6.36 0.001
Duration of epilepsy 4.25 0.003
Employment 3.78 0.04
AED side effects 2.74 0.05
Energy/fatigue Seizure frequency 7.36 0.0007
Age at onset 4.71 0.004
Employment 4.24 0.02
AED side effects 2.52 0.05
Cognitive function Seizure frequency 9.36 0.0003
Age at onset 4.71 0.006
Education 4.42 0.009
Type of AED therapy 3.59 0.01
AED side effects 2.82 0.04
Stigmatisation 2.63 0.04
Medication effects Seizure frequency 6.47 0.003
AED side effects 3.92 0.007
Stigmatisation 3.54 0.03
Stigma severity 2.94 0.05
Social functioning Seizure frequency 15.63 0.0001
Marital status 4.27 0.006
Employment 5.76 0.005
AED side effects 3.38 0.03
Stigmatisation 3.41 0.03
Stigma severity 3.35 0.05
Overall Seizure frequency 11.24 0.0001
Stigmatisation 4.67 0.03
Stigma severity 4.83 0.01
Age at onset 3.74 0.01
AED side effects 3.95 0.05
Type of AED therapy 3.48 0.05
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Conclusions
The Estonian version of the QOLIE-31 showed psychometric properties 
comparable to those of the American version. The construct validity of the 
questionnaire was supported by the findings based on the values of the overall 
score that those with frequent seizures did poorly compared with those who 
experienced infrequent seizures or were currently seizure free and that those 
who had multiple seizure types had the lowest value, followed by those who 
experienced generalised tonic-clonic seizures and those with other types only. 
These expected findings were in accordance with other studies [23, 24, 30-32].
The most important predictor in assessing the QOL was seizure frequency. 
The other substantial disease characteristics after controlling for seizure status 
were seizure type, type of AED therapy, AED side effects, age at onset, and 
duration of epilepsy. Seizure type became significant in the case of Seizure 
worry and Overall quality of life. In both cases, people having generalised 
tonic-clonic seizures, either only or together with some other type of seizure, 
scored lower. Type of AED therapy became significant in relation to Seizure 
worry, Overall quality of life, Cognitive functions and the overall score. In all 
these cases, people receiving polytherapy had lower scores compared to these 
on monotherapy. People who stated experiencing AED side effects got lower 
values of the domains in Overall quality of life, Emotional well-being, 
Energy/fatigue, Cognitive function, Medication effects and in the overall score 
compared to those who reported no side-effects. Age at onset became 
significant in the case of Overall quality of life, Energy/fatigue, Cognitive 
function and in the case of overall score. In all those cases differences were 
significant between 2 groups of patients: lower scores were obtained by those 
for whom epilepsy had been diagnosed at the age of 41-50 or over 50 compared 
to those for whom it had been diagnosed at an age under 20 years. Duration of 
epilepsy remained significant only in the case of Emotional well-being where 
significantly lower scores were obtained by those who had suffered from 
epilepsy 2 to 5 years compared to those who had suffered more than 20 years. 
The other substantial socio-demographic variables included education, 
stigmatisation, stigma severity, marital status and employment. As the QOLIE- 
31 questionnaire is a relatively new measure, there is not much data about its 
use in the QOL studies. The averages for the Estonian patients of all domains 
were compared to the available data from USA [15], Spain [33] and Hungary
[34]. (Table 7) The SDs did not show a significant difference between the 
groups. The overall scores of the scale were highest for the USA. and Spain, 
followed by Estonia and Hungary. The values of the domains of the Estonian 
QOLIE-31 were significantly lower compared to 3 other countries in the 
Overall quality of life domain. In the Energy/fatigue domain, the average 
differed significantly only from the data from the USA and Spain. To surprise, 
in the Medication effects domain the average value of the Estonian epilepsy 
group was significantly higher compared to the same data from the USA and
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Hungary- That can be explained, at least partly, by the fact that the people with 
epilepsy from Tartu were during the epidemiological study consulted by a 
neurologist in terms of their treatment problems. The authors of the Hungarian 
study [34] have explained their higher value in this domain compared to the 
USA by the different mental health expectations, the difference in the expected 
efficacy of treatment, the confidence in doctors and by the different 
circumstances and opportunities open to people from developed countries and 
from Eastern European countries. As well could it be the result of a general lack 
of knowledge and indifference, as due to the complicated political status, an 
individual's health and well-being was not valued for a long period. The 
averages of the domains of the Estonian QOLIE-31 were most similar to those 
of the Hungarian epilepsy group. Also, there was no statistically significant 
difference in the value of the overall score. The averages were generally lower 
(the negative judgement) compared to the American and Spanish data but they 
changed in parallel with it.
Table 7. Comparison of the mean scores of the QOLIE-31 domains of the respondents 
from USA, Spain, Hungary and Estonia.
__________ Averages (SD) of the QOLIE-31 domains__________
Domains USA Spain Hungary Estonia 
________________________ (n=304) (n=252) (n=170) (n=203)
Seizure worry 58.29 (25.76) 51.47 (29.73) 53.95 (28.53) 54.67 (26.26)
Overall quality of life 67.17 (18.38)* 63.80 (16.95)* 55.45 (19.32)* 49.18 (17.59)
Emotional well-being 67.20 (19.28)* 61.78 (19.13) 58.28 (18.48) 60.14 (19.95)
Energy/fatigue 55.30 (21.10)* 60.89 (20.27)* 49.68 (17.68) 48.40 (20.17)
Cognitive function 59.96 (22.76) 60.32 (23.80) 59.26 (20.23) 59.41 (23.75)
Medication effects 55.34 (30.52)* 60.30 (29.10) 57.39 (31.13)* 63.64 (27.70)
Social functioning 67.25 (26.88) 66.44 (27.96) 56.88 (23.60)* 63.54 (25.08)
Overall score 62.87 (16.31)* 61.77 (17.33)* 56.45 (16.50) 57.38 (18.50)
* The means different from the corresponding results of the Estonian epilepsy group at
0.05 significance level (t-test).
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Teadustegevus
Peamiseks uurimisvaldkonnaks on epilepsiahaigete elukvaliteet. Osalemine käi­
masolevates uuringuprojektides: autonoomne närvisüsteem neuroloogiliste hai­
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